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Abstract
Abstract
The antibody response to native antigens derived from Treponema pallidum (Nichols strain) was 
investigated by western blotting. In early primary disease the responses were most frequently to the 
major immunodominant antigen, TpN47, and the flagellar proteins. Strong responses to several 
other lipoproteins, especially TpN44.5, TpN17 and TpN15, were observed in all other disease 
stages. Generally, this confirmed the importance of TpN47, TpN44.5, TpN17, and TpN15 as 
diagnostlcally significant antigen.
Western blot analysis using recombinant proteins showed the four major lipoproteins, TpN47, 
TpN44.5, TpN17, and TpN15, to be important disease specific antigens, with TpN47 particularly 
reactive in early primary infections. TpN24-28 was found to be disease specific but only reactive 
with relatively few strongly positive sera, and so of relatively little diagnostic significance. Further 
analysis of the other recombinant proteins by enzyme immunoassay confirmed them as important 
diagnostic antigens, but no single recombinant protein was capable of detecting all cases of 
serologically confirmed syphilis. However, an enzyme immunoassay using a solid phase coated 
with a combination of all four major lipoproteins proved highly specific and showed improved 
sensitivity over a commercially available enzyme immunoassay based on native antigens.
Synthetic peptide epitope mapping studies of the four major lipoproteins showed that the antigenic 
sequences within these proteins were not simple linear epitopes. The complicated picture of several 
reactive regions across the proteins, each containing multiple epitopes, was typical of the type of 
responses seen when a substantial part of the antibody response is directed towards 
conformational epitopes.
Further analysis of the epitopes present within the four major lipoproteins using phage display 
isolated several long protein sequences which represented high affinity antibody binding motifs. The 
size of the sequences suggests that the retention by the solid phase is due either to conformational 
epitopes, or to a mixture of epitope types producing high affinity binding through multipoint 
attachment. The sequences identified have potential as antigens for use in diagnostic tests.
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Chapter 1
Clinical disease
Syphilis is a systemic contagious disease of man cause by the spirochaete Treponema pallidum 
subsp. pallidum. It is a chronic disease characterised by multiple clinical stages, normally called 
primary, secondary and tertiary, interspersed by long periods of latent asymptomatic infection. The 
disease is usually sexually transmitted in adults. Less commonly, it can also be acquired by blood 
transfusion with blood from an infectious individual, needle sharing by intravenous drug users, and 
tattooing. Transplacental transmission to the fetus resulting in congenital syphilis remains a global 
problem, except in Northern Europe and the USA.
Due to the inability to cultivate the organism in vitro, serological diagnosis has become an important 
tool for both the diagnosis of infection at all stages of the disease, and the monitoring of treatment. 
The different manifestations of the disease offer unique challenges for sérodiagnostic procedures, 
not fully countered by existing tests. This means there is considerable scope for improvements to 
sérodiagnostic procedures to be gained by identification of diagnostically significant antigens. For 
antigens to be diagnostically significant they must be reactive at all stages of the disease. The 
following descriptions of the different manifestations of syphilis are taken from a selection of 
sources and are included for background information and to place the later discussions in context 
(Fitzgerald, 1981; Lukehart and Holmes, 1994; Tramont, 1995; Mindel et al., 1989; Lossick and 
KraUs, 1991; Larsen et al., 1990; Hutchinson and Hook, 1990; Thompson et al., 1990; Thin, 1990; 
Spâriing, 1990).
Untreated syphilis
T.pallidum can penetrate abraded skin or intact mucous membranes and spreads throughout the 
body via the bloodstream and lymphatics. 2 to 6 weeks later, depending on the size of the inoculum, 
a primary lesion develops at the site of contact and heals in a further 2 to 6 weeks. In a proportion 
of patients a secondary stage appears 6 weeks after the primary lesion has healed. In some 
patients the time between the primary lesion healing and the onset of the secondary stage can be 
prolonged to several months, in others these stages may overlap. In about 20% of cases infectious 
episodes occur during the following year. In the rest, the latent asymptomatic period follows which 
may persist for life in at least 60% of individuals. In 30 - 40% a third late destructive stage develops
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involving the skin, mucous membranes, and bones. A more serious form may develop in some 
individuals also involving the CNS, aorta, and other internal organs.
The course of untreated syphilis has been documented in the Oslo study from 1890 to 1951. One 
thousand nine hundred and seventy-eight patients with early syphilis were left untreated. Gestland 
(1955) reanalysed the data from 1404 of the patients who were Norwegian residents of Oslo. 
Secondary syphilis relapse occurred in 25% of patients. Gummas (see below) were observed in 
14.4% of males and 16.7% of females. Late neurosyphilis developed in 9.4% of males and 5.0% of 
females. Cardiovascular lesions were observed in 13.6% of males and 7.6% of females. A total of 
23% of patients died as a direct result of syphilis. Serious late syphilitic complications were twice as 
common in males than females. There are several criticisms of this study. The study was 
terminated before all the patients had died and post-mortem examinations were not performed on 
all of the deceased. This means that late complications would have been underestimated. It is 
thought that some of the patients were probably suffering from non-venereal syphilis which was 
prevalent in Norway at the time. Also, some of the patients suffered reinfections, so that the study is 
not the course of one infection. Therefore, the study is more of historical interest rather than an 
estimate of the likely outcome of untreated disease.
Primary syphilis
After infection the organisms quickly spread throughout the body, but preferentially multiply at the 
site of entry, producing a small papule which rapidly ulcerates (Magnuson et al., 1956). The ulcer, 
or chancre, is usually round or oval, and painless. It is not usually secondarily infected, which is a 
feature of all open syphilitic lesions. The chancre usually develops about 3 weeks after infection, 
although the incubation period between infection and development of the lesion can range from 10 
to 90 days. The chancre may spontaneously heal after 2 to 8 weeks, although it may still be present 
during the secondary stage. Affected lymph nodes may be tender and contain numerous 
treponemes. Serous fluid from the chancre also contains large numbers of treponemes and is 
highly infectious.
Secondary syphilis
About 6 weeks after the primary chancre has disappeared the symptoms of secondary syphilis 
appear. By this stage of the disease, the organism has invaded every organ of the body and is
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present in virtually all body fluids. This is demonstrated by the generalised and diverse nature of the 
symptoms seen, which include fever, headache, sore throat, arthralgias and anorexia. Headache, 
especially at night, is due to a low grade meningitis shown by pathological changes to the CSF. The 
most characteristic symptoms seen are a generalised rash, mucous patches and condylomata lata. 
Condylomata lata are probably the result of confluent moist papules covered by a white mucoid 
exudate. Mucous patches are painless greyish-white erosions forming circles and arcs, or ‘snail- 
track* ulcers. Both of these ulcerative lesions are highly infectious, containing numerous 
treponemes. The rash usually covers the trunk and limbs, but appearance on the face, soles of the 
feet and palms of the hands is highly indicative of syphilis. It is usually accompanied by a 
generalised, painless, lymphadenopathy. More rarely symptoms include alopecia, laryngitis and 
hepatitis. All these lesions disappear spontaneously within 2 to 6 weeks and leave no evidence of 
infection behind. Infectious episodes can recur especially over the first year after disappearance of 
secondary symptoms.
Latent syphilis
If left untreated, the cutaneous lesions of secondary syphilis disappear and a period of latency 
follows. Latent syphilis is, by definition, an asymptomatic period with positive syphilis serology. For 
epidemiological purposes, latent disease of less than 2 years duration is termed early latent 
syphilis, otherwise it is classified as late latent syphilis. During the period of early latency the 
disease may relapse several times with the reappearance of symptoms of earlier disease. The 
patient remains infectious throughout this period and women continue to give birth to congenitally 
infected infants. Approximately 60% of patients remain latent for the rest of their lives with only 
weakly positive syphilis serology as the only indication of infection. Autopsy studies indicate that a 
proportion of these patients have subclinical infections, particularly of the cardiovascular system. 
The remaining 40% of patients will eventually develop clinical tertiary syphilis.
Tertiary syphilis
Benign and severe syphilitic lesions may develop 10 to 20 years after the initial infection. These 
lesions include, the formation of gummas in late benign syphilis, neurosyphilis, and cardiovascular 
syphilis.
18
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Late benign syphilis
A proliferative or destructive inflammatory process called gumma formation provides the 
pathogenesis of late benign syphilis, Gummas are commonly observed in the skin and bones, but 
may also appear in the mucosa, viscera, muscles and eyes. The gumma is a chronic 
granulomatous lesion which is an intense inflammatory response to a few treponemes which 
impairs the function of the structure involved. It starts as a painless nodule which breaks down into 
one or several punched-out ulcers. Like lesions at other stages of the disease it is free from 
secondary infection. It heals slowly from the centre with distinctive pigmentation and a paper-thin 
scar. This pigmentation and scarring are quite characteristic and a useful aid to diagnosis. The 
most common sites involved are, the face, legs, buttocks, upper trunk, and scalp. Gummatous 
bone lesions can involve the tibia, fibula, palate, pharynx, and the nasal septum. They tend to be 
destructive, causing perforation of the hard palate and nasal septum leading to a saddle shaped 
nose. They also lead to a chronic hoarseness due to destruction of the epiglottis and larynx. The 
most serious lesion is the gummatous infiltration of the tongue which leads to a general swelling 
and a smooth red surface. Penicillin treatment has no effect on the progression of syphilitic glossitis 
at this late stage. The restricted blood supply eventually produces leucoplakia, necrotic white 
patches on the back of the tongue, which often become malignant
Neurosyphilis
The cerebrospinal fluid is invaded by treponemes in the primary and secondary stages of the 
disease, which is reflected in changes to the cerebrospinal fluid. Asymptomatic neurosyphilis is the 
most common form of neurosyphilis and is defined as the absence of neurological symptoms with 
pathological changes to the cerebrospinal fluid. Changes may include positive syphilis serology, 
raised cell counts and protein levels. In patients with asymptomatic neurosyphilis the disease 
seldom progresses to neurosyphilis.
Symptomatic neurosyphilis can present at a variety of time intervals. Syphilitic meningitis may occur 
rapidly, while meningovascular syphilis can take a few years to present, and parenchymatous 
neurosyphilis is only seen several decades after the initial infection. In symptomatic neurosyphilis 
the lesions can appear anywhere in the central nervous system.
Syphilitic meningitis may develop within a year of infection. The symptoms resemble a viral 
meningitis which includes fever, stiff neck, and lymphocytosis. The more severe conditions of acute
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syphilitic hydrocephalus, focal cerebral involvement, and cranial nerve palsy may appear in some 
patients.
Meningovascular syphilis is due to pathological changes in the medium and larger arteries of the 
brain and spinal cord. The vessel walls are gradually destroyed which induces thrombus formation, 
and causes narrowing of the vessel and eventual closure, resulting in a large cerebrovascular 
accident. The involvement of the spinal cord is a rare condition and manifests as weakness of the 
legs, which sometimes progresses to paralysis.
Parenchymatous neurosyphilis may be manifested as dementia paralytica or tabes dorsalis. 
Invasion of the cerebrum by T.pallidum causes meningoencephalitis and will result in a dementia 
paralytica after several decades, and finally in death. This condition may resemble almost any 
psychiatric or neurological disorder. Frequently symptoms include memory loss, diminishing 
intellectual functions, personality changes and dementia. Tabes dorsalis is very rare since the 
introduction of penicillin treatment.
Cardiovascular syphilis
In untreated syphilis cardiovascular symptoms develop after a period of 30 years. With modem 
antisyphilitic treatment very few patients ever have active infection for such a long period of time, so 
cardiovascular syphilis is rare. The cardiovascular system is not involved in the early stages of 
syphilis, so adequate treatment of the disease prevents syphilitic heart disease. Three major 
cardiovascular syndromes may occur, aortic aneurysm, aortic valve incompetence, and coronary 
ostia! stenosis. The syphilitic aneurysm is the most common manifestation. The clinical symptoms 
are minor, consisting of mild chest pain and tambouric heart sounds. Aortic valve disease causes 
aortic regurgitation and a prominent second heart sound. The result may be enlargement and 
dilation of the left ventricle. Syphilitic disease of the coronary arteries results in narrowing of the 
vessels causing angina and sudden death due to extensive infarction.
Congenital syphilis
Congenital syphilis has always proved difficult to diagnose due to the clinical presentation. 
Diagnosis is often reliant on serological evidence, however serological testing is compromised by 
the presence of passively acquired maternal IgG antibodies In the foetal circulation. For this reason,
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testing for the presence of treponemal specific foetal IgM antibodies has been adopted. Clearly, IgM 
responses must be considered when identifying diagnostically significant antigens.
The infection is usually transmitted to the fetus by transplacental passage of T.pallidum from an 
infected mother. An infant can also be infected at the time of delivery by contact with a genital 
lesion. The risk of congenital infection is directly related to the disease stage of the maternal 
infection (Wendel, 1988). The highest risk of transmission is during the primary and secondary 
stages, and as the disease progresses to the later latent stages the risk diminishes. The risk of fetal 
infection also increases as the pregnancy advances. Two characteristic syndromes can be 
identified, early and late congenital syphilis. Early congenital syphilis refers to those clinical 
manifestations that appear within the first 2 years of life. Those features that occur after 2 years and 
usually manifest near puberty constitute late syphilis.
Early congenital syphilis
A primary stage does not occur because the organisms directly infect the foetal circulation. The 
symptoms of congenital syphilis are similar to those found in secondary syphilis except the 
involvement is more systemic and the disease progression more rapid. The clinical manifestations 
of early congenital syphilis are a result of active infection and inflammation (Dorfman and Glaser, 
1990; Sanchez et at, 1983) Symptoms may be present at birth or delayed for several months if the 
infant remains untreated. Infants with congenital syphilis may have low birth weights, 
hepatosplenomegaly and generalised lymphadenopathy (Ingall et at, 1990). Commonly, a 
haemolytic anaemia with thrombocytopaenia is present (Whitaker et at, 1965). The reduction in 
platelet numbers is believed to be due to diminished survival mediated by circulating immune 
complexes. Rhinitis or 'snuffles' used to be common, but occurs less frequently today. The 
discharge is watery and contains a large number of spirochaetes, but becomes thick and purulent if 
left untreated. The infection can lead to involvement of the nasal cartilage resulting in perforation of 
the nasal septum and development of the saddle nose deformity (Schulz et at, 1990). Involvement 
of the throat and upper airway may lead to hoarseness and laryngitis. The rash of congenital 
syphilis is initially oval and red, but then turns coppery brown with distinctive blisters containing 
numerous treponemes. The lesion is most prominent on the palms and soles of the feet. Mucous 
patches and condylomata lata may also occur. Skeletal lesions are commonly seen, which tend to 
be multiple and systemic, affecting the lower limbs most frequently (Cremin and Fisher, 1970).
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Neurosyphilis is also quite common with features comparable to adult neurosyphilis. Acute syphilitic 
meningitis occurs, and if untreated can lead to chronic meningovascular syphilis which presents 
towards the end of the first year of life. A secondary nephrotic syndrome may develop which is due 
to deposition of immune complexes in the kidneys.
Late congenital syphilis
The clinical manifestations of late congenital syphilis are malformations that represent scars 
induced by the initial lesions of early congenital syphilis or reactions to persistent inflammation 
(Fiumara and Lesser, 1970; Rathbun, 1983). Infection of the tooth bud during late gestation causes 
a characteristic malformation known as Hutchinson's teeth. The upper central incisors are small, 
widely spaced, peg-shaped and notched with discoloured enamel (Ingall et al., 1990). More 
diagnostic are malformations of the molars consisting of many small cusps instead of the usual 
four. They also show defective enamel and are prone to decay. Bone deformities are common, 
usually involving the skull and long bones. These include frontal bossing or squaring of the skull and 
bowing of the tibia. Involvement of the nasal septum may lead to bone destruction and result in a 
saddle nose deformity (Fiumara and Lesser, 1970). Linear scars or rhagades radiating from 
mucocutaneous junctions are the result of mucous patches and condylomata lata involving these 
areas. The eyes and ears may be affected resulting in interstitial keratitis and neural deafness due 
to cochlear degeneration. Interstitial keratitis, Hutchinson's teeth, and eighth nerve deafness 
comprise Hutchinson’s triad which is specific for congenital syphilis (Ingall et al., 1990). 
Neurosyphilis, dementia paralytica and tabes dorsalis may be found after puberty in untreated 
cases.
Congenital syphilis is effectively prevented by routine prenatal screening and penicillin treatment of 
infected women and their sexual partners. The development of the characteristic malformations can 
be prevented by treatment during pregnancy or within the first three months of life.
HIV co-infection
The course of syphilis is characterised by the failure of the immune system to completely eliminate 
the treponemes. This chronic infection and associated inflammatory reaction are responsible for 
many of the lesions seen. Clearly any factors which facilitate the persistence of the organisms may 
alter the course of the disease. HIV infection results in an immunosuppression and has been shown
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to alter the natural course of syphilis (Johns et al., 1987). However, the exact mechanism by which 
this happens is not understood. Confusing clinical symptoms and abnormal serological findings 
have been described (Radolf and Kaplan, 1988). Many authors have reported rapid progression to 
the late stages of syphilis and neurologic involvement even after treatment of primary or secondary 
syphilis (Dawson et ai, 1988; Musher, 1991; Kase et ai, 1988; Femandez-Guerrero et ai, 1988). 
Neurosyphilis seldom appears in early syphilis in normal non HIV infected patients. Johns et ai 
reported four cases of neurosyphilis in HIV seropositive patients with active syphilis. One patient 
developed meningovascular syphilis within four months of infection, whereas in the non 
immunocompromised individual it usually develops 5 to 10 years after the initial infection. The effect 
of maternal HIV infection on the likelihood of congenital syphilis developing is not fully understood. 
The immune dysfunction is likely to allow greater proliferation of the treponemes and a higher rate 
of infection. Infants bom to HIV infected mothers with untreated early syphilis are more likely to 
show symptoms of congenital syphilis than those bom to HIV seronegative mothers with early 
syphilis (Sânchez et ai, 1990). This suggests that the disease is perhaps more severe which is a 
similar picture to that seen with HIV infected adults. Concurrent HIV and syphilis infections raise 
new considerations related to diagnosis, treatment, and the progression of the disease. The 
atypically weak or non-existent reactivity in standard serological tests, and the absence of obvious 
symptoms in some cases has profound implications for the detection of infection. The changes in 
the immune response present in this group of patients have implications for both, the level of 
sensitivity required from sérodiagnostic tests, and potential changes to the antigens that the 
antibody response is directed towards. This makes this an important group of patients to consider 
when developing and evaluating new serological tests.
Treatment
Penicillin treatment was introduced in 1944 and remains the treatment of choice. Penicillin inhibits 
bacterial cell wall construction and therefore only destroys actively growing bacteria. The replication 
time of T.pallidum is about 30 hours (Cumberland and Turner, 1949). Generally, treatment regimes 
aim to produce a high penicillin concentration and maintain it over a prolonged period of time. The 
regimes are extended for advanced disease to allow the drug to permeate all body tissues and 
completely eliminate the organisms. There are a wide variety of different treatment regimes 
described, all producing similar results, suggesting a fair degree of latitude is permissible. Effective
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treatment is achieved if the concentration of penicillin in the serum is maintained above 0.03 U/mL 
for 8 to 10 days, and the troughs in the concentration should not exceed 15 hours (Mohr et al., 
1976). The World Health Organisation recommend treatment with 1.2 MU of procaine penicillin G 
daily for 10 days for early syphilis, and an increase in the duration of the programme to 15-20 days 
for late syphilis. This regime was used successfully in the mass treatment campaign against non- 
venereal syphilis. An alternative treatment that is effective at most stages of syphilis is a single 
injection of the long-acting benzathine penicillin (2.4MU). However, it is unsuitable for treating 
neurosyphilis as it does not reach the CSF (Polnikom et al., 1980). Failure to reach therapeutic 
levels in the CSF also preclude its use for the treatment of congenital syphilis and HIV seropositive 
patients. This regime is most suitable where the patient can only attend the clinic once and is 
unable or unlikely to continue the treatment elsewhere. In the event of penicillin allergy, 
tetracycline/doxycycline and erythromycin or its newer relatives are the alternative drugs. All 
treponemal infections are unaffected by sulphonamides, rifampicin, and quinolones at clinical 
doses.
Syphilis responds well to antibiotic therapy and is easily cured in most cases. The monitoring of 
treatment and confirmation of cure can not be accomplished by conventional methods because the 
organism can not be cultivated. However, serological tests have been used for this function, due to 
the finding that the cardiolipin response detected by nontreponemal test (see below) diminishes on 
successful treatment. Conversely, specific anti-treponemal antibodies remain present for life in 
many cases, which make all currently available treponemal tests (see below) unsuitable for 
treatment monitoring. The identification of diagnostically significant antigens that become non 
reactive after treatment would be of considerable benefit to the field of syphilis serology.
Non-venereal treponematoses
Other spirochaetes of the genus Treponema cause a group of chronic granulomatous diseases 
which include yaws, non venereal endemic syphilis or bejel, and pinta. In sequence, the causative 
organisms are; T.pallidum subsp. pertenue, T.pallidum subsp. endemicum, and T.carateum. These 
organisms are morphologically indistinguishable from T.pallidum subsp. pallidum, and share 
common antigens resulting in a degree of crossimmunity. The differences between the various 
subspecies are discussed more fully later. No laboratory test has yet been devised that can 
distinguish these organisms from each other, or from T.pallidum subsp. pallidum. The identification
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of antigens capable of making this distinction would be very useful but, in view of the extensive DNA 
homology (see below) shown by these organisms, this is extremely unlikely. They are primarily 
categorised as separate organisms due to differences in the clinical pictures produced. The 
diseases, and hence the organisms, are distinguished by the clinical appearance and anatomical 
site of the lesions, the mode of transmission, the age and geographical location of the individual.
Yaws is transmitted by direct contact with an infectious lesion or by fingers contaminated with lesion 
exudate. Yaws transmission is enhanced by crowded environments with poor sanitation and 
personal hygiene (Engelkens et al., 1991a). The disease is usually acquired in childhood between 
the ages of 5 and 15. There is no racial or sex difference between those who become infected and 
in endemic areas more than 80% of the population are infected (Benenson, 1990a). Climatic 
conditions affect the type of yaws lesion and its transmission. In warm humid areas the lesion 
proliferates and contains many treponemes, whereas in dry, arid regions the lesions tend to be 
small or absent, after the primary lesion disappears.
Endemic syphilis is also transmitted by non-venereal contact among children. In contrast to yaws, 
transmission of infection by contaminated drinking vessels may be more common than by direct 
contact with infectious lesions (Benenson, 1990b; Engelkens et al., 1991b). The disease tends to 
be familial with spread of infection from children to adults rather than to the general community 
Endemic syphilis lesions are virtually indistinguishable from early yaws and the two diseases may 
occur at different times in the same population but not in the same person.
Several variants of endemic syphilis are recognised by their geographical location showing different 
disease expression. Sibbens of Scotland, radesyge of Norway, and skerjevo of Yugoslavia are now 
extinct, while Njovera or dichuchwa of Africa is still found in small pockets (Antal and Causse, 
1985). Bejel of the Eastern Mediterranean is the only variant still prevalent. It is found in semi- 
nomadic people living in the Saharan regions of Africa. Improved living standards, better medical 
care, and mass penicillin treatment campaigns have greatly reduced its prevalence (Meheus and 
Antal, 1992)
Pinta is restricted to the western hemisphere and is found only in remote parts of Southern Mexico 
and small regions of Columbia, Peru, Ecuador, and Venezuela (Benenson, 1990c). Treatment 
programmes have greatly reduced the prevalence of pinta.
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Laboratory diagnosis
T.pallidum can not be routinely cultured in vitro (Fieldsteel et al., 1981., Norris, 1982.) or stained 
with simple laboratory stains (Swisher, 1987), therefore serological methods have formed the basis 
for the identification of syphilis infection. Many tests have been developed over the years, but most 
have arisen as modifications of previous tests in an attempt to rectify deficiencies. These tests 
generally use crude antigen preparations and there is a poor understanding of the underlying 
principles of some of these tests, particularly the cardiolipin response. An historical perspective of 
the sequence of diagnostic test evolution gives a useful insight into the type of problems 
encountered and how they were overcome. As current tests are derived from these historical 
methods; many of the problems described still exist today.
History of syphilis testing
Troponoma pallidum subop. pallidum was first associated with syphilis by Sohaudin and Hoffman in 
1905 using a modified Giemsa stain to examine lesion material. In 1909 Coles described the use of 
dark field microscopy to identify the organism. This method remains in use today for the 
examination of the exudate from lesions present in early syphilis. Many serological methods exist 
and can be categorised into two types; nontreponemal tests and treponemal tests.
Nontreponemal tests
In 1906, Wassermann adapted the complement fixation test to detect antibodies present during 
syphilis using an antigen derived from the liver of newborn infants who had died of congenital 
syphilis. This test was thought to be specific but Landsteiner showed that extracts of beef heart 
worked equally well. These complement fixation tests required complicated reagents and were quite 
time consuming to perform. A major advance was made in 1922 when Khan developed a 
macroscopically read flocculation test that did not require complement and took only a few hours to 
perform. Many derivations of the Khan flocculation test were developed but they all suffered from 
the same limitations. The antigens used were crude preparations which were poorly standardised, 
therefore results were difficult to compare between different testing occasions and different 
laboratories. This was solved in 1941 when Pangbom isolated from beef heart the active antigenic 
component, cardiolipin. Cardiolipin, in combination with cholesterol and lecithin, produces a specific 
antigen for the detection of antibodies of the so-called reagin" type found in active syphilis. This
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antigen had major advantages over the previous crude extracts. It could be standardised both 
chemically and serologically, thus ensuring reproducibility of results between test runs and between 
different laboratories. These purified antigens allowed new microflocculation tests to be developed 
such as the Venereal Disease Research Laboratory (VDRL) test (Harris et al., 1946). These tests 
yielded reproducible results, could be performed rapidly, and gave acceptable levels of sensitivity 
and specificity. The VDRL could only be performed on serum specimens because of the need to 
heat the sample before testing. To overcome this, a modification was developed where EDTA and 
choline chloride were added to stabilise the antigen and improve its reactivity. The resulting 
unheated serum reagin (USR) test (Portnoy etal., 1961), did not need the sample to be heated and 
could use plasma as well. The rapid plasma reagin (RPR) teardrop card test (Portnoy et al., 1957, 
1961) was developed as a field test using charcoal particles to improve visualisation of the reaction. 
The test was performed on plasma from blood obtained by finger prick on a card rocked by hand. A 
slight modification was developed, more suitable for mass screening in a laboratory setting 
(Falcone et al., 1964). This test is known as the RPR 18mm circle card test and is slightly more 
sensitive than the field test version. An automated version of the RPR was developed (McGrew et 
al., 1968) which was particularly applicable to situations where large numbers of specimens have to 
be tested, like blood transfusion centres and public health laboratories. It used a continuous flow 
analyser to mix the reactants and the results were deposited on to a paper strip for interpretation. A 
final modification to the RPR test, this time involving the antigen and not the protocol, produced the 
toluidine red un heated serum test (TRUST) (Pettit et al., 1983). The charcoal used to visualise the 
reaction was replaced by toluidine red particles. The VDRL, USR, TRUST, and RPR tests, are all 
still in use today, however the RPR, in all of its guises, is probably the most popular test
Treponemal tests
Nontreponemal tests were found to suffer from nonspecific or false-positive reactions (see below), 
so a search for a specific serological test for syphilis was undertaken using antigens derived from 
the treponeme itself. The first attempt was the T.pallidum immobilisation (TPI) test which used dark 
field microscopy to look for the ability of a serum specimen, in the presence of complement, to 
immobilise live treponemes. The test has faded from use because it was extremely complicated to 
perform and required a supply of live T.pallidum. Much simpler and less expensive procedures have 
made it redundant. The Reiter treponeme, T.phagedenis, can be easily cultivated in vitro and was
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thought to be a substitute for T.pallidum with identical antigenic specificity. Complement fixation 
tests using Reiter treponeme antigen were developed but a problem of significant false positive 
reactions and the inherent complexities of the procedure heralded their demise. The first significant 
development in treponemal serology was the fluorescent treponemal antibody (FTA) test (Deacon 
et al., 1957). This detected specific treponemal antibodies using killed T.pallidum (Nichols strain) 
fixed to a glass slide and a fluorescently labelled anti-human immunoglobulin reagent to visualise 
the bound antibodies from the specimen. The test was found to suffer from false positive reactions 
and so a method using an increased specimen dilution of 1:200 was developed, the FTA-200 
(Deacon et al., 1960). However, although highly specific, the lower specimen concentration used 
niade this test insensitive. The problem was solved by the inclusion of an absorbing specimen 
diluent containing an extract prepared by sonicating cultures of T.phagedenis (Hunter et al., 1964). 
The diluent removed cross reacting antibodies thereby improving both the sensitivity and specificity 
of the original test. The modified method came to be known as the FTA absorption (FTA-ABS) test 
and is used today as a confirmatory test for syphilis. The FTA-ABS test, although specific, was not 
suitable for testing large numbers of specimens because of its complexity and low throughput. So, a 
quick and inexpensive treponemal test suitable for mass screening was still sought.
Rathlev (1965, 1967) was the first to successfully apply haemagglutination techniques to the 
serodiagnosis of syphilis. In the test, tanned sheep red blood cells coated with sonicated T.pallidum 
would agglutinate in the presence of treponemal antibodies in a patient’s serum. Modifications to 
the basic procedure followed that were designed to improve the sensitivity and specificity of the test. 
A new reaction medium improved the reactivity and the inclusion of an absorbing diluent, similar to 
the one used in the FTA-ABS test, reduced the number of false positive reactions (Tomizawa and 
Kasamatsu, 1966, 1969). This final form of the test is known as the T.paliidum haemagglutination 
assay (TPHA). The test was originally performed in a tube format and so used relatively large 
volumes of reagents. A version was developed in a microplate format that used much smaller 
quantities of reagents, the microhaemagglutination assay for antibodies to T.pallidum (MHA-TP). 
The TPHA and the MHA-TP tests are both widely used today as treponemal screening tests. 
Various commercial versions of the tests have been developed each with its own features. The 
main variation, in some tests, has been the replacement of sheep red blood cells by avian red blood 
cells to increase the sedimentation rate and hence reduce the assay time. This principle is used in
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the PK-T.pallidum (PK-TP) test, an automated version principally for blood donor screening on the 
Olympus PK7100 analyser.
Commonly used diagnostic tests
Over the years there have been many tests for syphilis developed, but as can be seen from the 
review above many are simply modifications of the core principle. Many of these tests are still in 
widespread use today. Even though each has its limitations, testing strategies have been adopted 
to minimise their deficiencies. This means that these tests tend to persist even though better 
methods are available using more modem techniques.
Direct microscopic examination
Syphilis can be diagnosed by direct visualisation of the organism by dark field microscopy. The 
technique is most applicable during primary and secondary syphilis, and relapsing episodes when 
mucocutaneous lesions are present containing numerous treponemes. T.pallidum can be identified 
in serous fluid taken from a lesion by their characteristic morphology and motility. However, 
T.pallidum subsp. pallidum can not be distinguished by visualisation from T.pallidum subsp. 
pertenue, T.pallidum subsp. endemicum, and T.carateum. Commensal spirochaetes are found as 
part of the normal flora of the genital and rectal mucosal surfaces, and are present in the mouth. 
T.refringens and T.denticola can be easily confused with T.pallidum (Creighton, 1990). Therefore, 
dark field microscopy may not provide reliable diagnosis in the case of non-penile lesions. Dark field 
microscopy may also be performed on aspirates taken from enlarged lymph nodes in cases where 
external lesions are absent. If non-pathogenic treponemes can be ruled out, the demonstration of 
organisms by dark field microscopy is diagnostic of syphilis. The sensitivity of dark field examination 
approaches 80%. Problems associated with dark field microscopy are that it must be performed 
immediately as it requires live organisms so the specimens can not be transported. This means that 
the test can only be performed in clinics with appropriately trained staff and the necessary 
equipment. Additionally, there is the risk involved in examining potentially infectious specimens, 
possibly containing HIV. A method that could identify T.pallidum in dry or fixed slides would offer 
considerable advantages. The specimens could be transported to a specialist laboratory for 
examination and much of the infection risk could be eliminated.
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The direct fluorescent antibody (DFA-TP) test is an enhanced direct detection method that uses 
fluorescently labelled antibodies to distinguish non-pathogenic treponemes from pathogenic 
treponemes in fixed smears. As the test uses fixed specimens, and does not require the organisms 
to be motile, therefore it is not as reliant on specimen condition as dark field microscopy. The 
original test used fluorescently labelled Immunoglobulin G (IgG) prepared from either human sera 
or immunised rabbits (Kellogg and Mothershed, 1969), but this proved to still give specificity 
problems. Improvements in specificity were achieved by using a fluorescently labelled monoclonal 
antibody specific for TpN47, the pathogen specific immunodominant antigen of T.pallidum (Ito et al., 
1992). This test was found to be 100% specific and sensitive, correctly identifying 30 specimens 
with syphilis from 31 specimens without. In contrast, dark field microscopy gave a sensitivity of 97% 
and a specificity of 77% (Hook et al., 1985). This suggests that the DFA-TP test is slightly more 
sensitive than dark field, but considerably more specific. However, in another study consisting of 
twice the number of patients, the two tests gave relatively similar sensitivities, and both gave 
specificities of 100%. Dark field showed a slightly better sensitivity than DFA-TP, 79% compared to 
73% (Romanwski et al., 1987). This second study shows the two tests to be fairly comparable in 
terms of sensitivity but DFA-TP is potentially more specific. Considering the practical advantages of 
the DFA-TP test over dark field microscopy it may become the method of choice for examining 
lesion material. The test has been adapted to detect T.pallidum In tissue sections (Ito et al., 1991), 
so a combination of the DFA-TP test and histological staining can be used to examine biopsy and 
autopsy material.
In the absence of in vitro culture, these direct detection methods are the only way to confirm the 
diagnosis of syphilis. However, they are only viable during the stages of the disease when lesions 
containing treponemes are present It is for this reason that the use of these methods persists in 
specialised clinics. During the stages of syphilis when lesions are absent serological tests form the 
main diagnostic tool.
Nontreponemal tests
Four nontreponemal tests are in widespread use; the VDRL test, the USR test, the TRUST, and the 
RPR test. These tests are similar in format and based on a common antigen which is composed of 
an alcoholic solution containing cardiolipin, cholesterol, and sufficient purified lecithin to produce 
standardised reactivity and enable émulsification. They differ in minor features only, specimen type,
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the matrix used to visualise the reaction, and the method of reading the result. The VDRL can not 
be performed on plasma as the specimen has to be heat inactivated before testing, but the other 
tests can be performed on serum or plasma. The VDRL and the USR must be read microscopically 
as they do not contain anything to help visualise the flocculation of the antigen preparation. In 
contrast, the RPR and the TRUST tests contain coloured particles which become trapped in the 
matrix as the antigen flocculates. The RPR test uses particles of carbon, whereas the TRUST uses 
toluidine red dye particles. The inclusion of visible particles allows the tests to be read 
macroscopically. All four tests are performed on plastic coated cards or glass slides onto which 
rings have been printed. Standardised amounts of undiluted serum and antigen suspension are 
mixed together and spread out within the ring. The card is then mechanically or manually rotated 
under humid conditions. When serum contains anti-cardiolipin antibodies, flocculation occurs which 
can be seen by the trapped carbon particles in the aggregates or read microscopically.
The test results are read immediately after rotation and scored as reactive or non-reactive. False 
negative results, in specimens with high antibody titres, can occur due to the excess antibody 
preventing agglutination. This is known as the prozone phenomenon. This can be overcome by 
testing the specimen at a range of dilutions. Semi-quantitative testing by serially diluting the serum 
can be used to monitor the change in titre as a result of treatment. The result is expressed as the 
reciprocal of the highest reactive dilution.
These nontreponemal tests measure IgM and IgG antibodies to lipoidal material released from 
damaged host cells as well as lipoprotein-like material (Matthews et al., 1979) and possibly 
cardiolipin released from the treponemes. The anti-lipoidal antibodies are produced not only as a 
result of treponemal disease, but also in other diseases where tissue damage occurs (Catteral, 
1972). Acute false positive reactions have been associated with many types of viral infections, 
malaria, immunizations, and pregnancy (Grossman and Peery, 1969; Jaffe and Musher, 1990; Salo 
et al., 1967; Sparling, 1971). Chronic false positive reactions have been associated with systemic 
lupus erythrematosus, malignancy, narcotic addiction, leprosy, and old age (Jaffe and Musher, 
1990; Tuffanelli, 1966). Therefore, a reactive nontreponemal test does not confirm T.pallidum 
infection.
These tests are used as screening tests because they are widely available, inexpensive and 
convenient to perform. Their disadvantages are a lack of sensitivity in early primary infections and in
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late syphilis, and the potential to give false negatives due to a prozone phenomenon. Their main 
advantage, and one of the reasons their use persists, is that they become non reactive after 
successful treatment. Therefore, they are useful tools for monitoring the progress of treatment 
regimens. Positive results are usually confirmed by retesting with a treponemal test.
Treponemal tests
Due to nonspecific and false-positive results found with nontreponemal tests many different 
treponemal tests have been developed over the years. They are based around specific antigens 
associated with treponemes and detect antibodies formed by the host to T.pallidum infection. The 
FTA-ABS test is an indirect fluorescent antibody technique. The patient’s serum is diluted in an 
adsorbing diluent, the main component of which is an extract from cultures of the non-pathogenic 
Reiter treponeme. This diluent is designed to remove group treponemal antibodies produced in 
some individuals in response to non-pathogenic treponemes. The diluted serum is dispensed on to 
a microscope slide to which T.pallidum have been fixed. If anti-treponemal antibodies are present 
they bind to the immobilised T.pallidum. FITC labelled anti-human IgG is added and binds to the 
patient’s antibodies resulting in FITC bound to treponemes, which can be visualised by fluorescent 
microscopy. Most laboratories use commercial kits for performing FTA-ABS tests and studies have 
shown large discrepancies between the performance of different kits (Beebe and Noun, 1984; 
Chronas at a/., 1992). A modification of the FTA-ABS test is the FTA-ABS double staining test 
which employs a tetramethlyrhodamine isothiocyanate labelled anti-human IgG and a counterstain 
of FITC-labelled anti-Tpallidum conjugate. The counterstain was developed to eliminate the need 
to locate the treponemes by dark field. Counterstaining the organisms ensures that a non-reactive 
result is due to absence of antibodies and not absence of treponemes. These tests are complex 
systems requiring careful balancing of reagents, experienced operators and accurate setup of 
equipment to achieve consistent results. The specificity is not absolute, it ranges from 92% to 99% 
(Hunter at a/., 1986) and has a false positive rate of around 1% in normal individuals (Luger, 1988). 
These tests are used exclusively to confirm a positive nontreponemal or haemagglutination test.
Haemagglutination tests offer a relatively simple quick procedure to detect specific treponemal 
antibodies. The MHA-TP is probably the most widely used test. The basic principle of all the 
haemagglutination tests is similar. Formalised, tanned sheep or avian red blood cells are coated 
with antigens derived from sonicated T.pallidum (Nichols strain). The suspension of coated
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erythrocytes is mixed with serum diluted in an adsorbing diluent containing Reiter antigen and other 
adsorbents. The Reiter antigen is used to remove group specific treponemal antibodies and thereby 
reduce the incidence of false positive reactions. If anti-treponemal antibodies are present in the 
specimen they bind to the sensitised erythrocytes and cause agglutination. A reactive result is seen 
by the formation of a smooth mat of cells on the bottom of the well. This is contrasted by a negative 
reaction where the cells settle to form a small round button in the bottom of the well. Specimens are 
tested in parallel with uncoated control cells to control against false reactions caused by anti­
species antibodies. The test is recorded as reactive only if the coated cells are reactive and the 
uncoated cells are non-reactive. The haemagglutination assays detect T.pallidum specific IgM and 
IgG antibodies. However, despite the complicated adsorbing diluents false reactions still occur in a 
small number of specimens. The haemagglutination tests are suitable for testing large numbers of 
samples because they are easy to set up and simple to read. They can be used for screening or 
confirmation of a positive nontreponemal test. The test can be performed quantitatively by testing 
dilutions of the specimen, but no relationship has been identified between titre and the stage of the 
disease or its progression. The test remains positive even after treatment, sometimes for life, so it 
is not suitable for monitoring treatment. Positive haemagglutination test results are usually 
confirmed using a fluorescent antibody test.
Other tests
Enzyme immunoassay, western blotting, and more recently DNA based methods, have had a major 
impact on the field of infectious disease diagnosis. However, their adoption for the diagnosis of 
syphilis has been slow and the older tests are still in widespread use. These tests offer distinct 
advantages over the commonly used cardiolipin tests and haemagglutination assays, and are likely 
to eventually become more widely adopted.
Enzyme immunoassays
Enzyme immunoassays have been used to great effect for the serodiagnosis of infectious diseases 
and have provided numerous benefits in many areas. A large number of different assay designs 
exist and a full description of them all is outside the scope of this thesis. Briefly however, the 
indirect enzyme immunoassay is based on a solid-phase coated with a source of antigen. The solid- 
phase can be the inside surface of a test tube, microplate well, or the outside of a bead. The diluted 
specimen is incubated with the solid-phase to allow any specific antibodies to bind. Unbound
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material is removed by sequential washes in a buffer containing detergent. The bound antibodies 
are detected by incubating the solid-phase with a dilution of an enzyme labelled anti­
immunoglobulin antibody. Again, unbound material is removed by sequential washes. The bound 
enzyme is detected by the addition of a substrate which is converted from a colourless state to a 
coloured one in the presence of the enzyme. The enzyme reaction is stopped by destroying or 
inhibiting the enzyme and the coloured product measured spectrophotometrically. So, the quantity 
of specific antibody in the original specimen is proportional to the amount of coloured product 
produced in the enzyme reaction. Since the first report of enzyme immunoassay being used for the 
serodiagnosis of syphilis (Veldkamp and Visser, 1975), several other tests have been reported 
which used sonicated T.pallidum (Nichols strain) as the solid-phase antigen (Pope et al., 1982; 
Farshy et al., 1984; Hunter et al., 1982; Farshy et al., 1985; Codd et al., 1988). Enzyme 
immunoassays that use components of the nonpathogenic Reiter treponeme (Pedersen et al.,
1982) and modified cardiolipin antigen (Pedersen et al., 1987; White and Fuller, 1989) as antigen 
sources have also been reported. All the authors report respectable sensitivity and specificity 
figures for these tests, which are no worse than established tests. Additionally, these tests offer 
practical advantages, in terms of specimen processing and result reporting, compared to the widely 
used nontreponemal and treponemal tests. On this basis alone, these tests offer benefits over 
existing serological tests for syphilis. The disadvantages of this type of method are their complexity 
and the specialised equipment needed to perform them. They are best suited to processing large 
numbers of specimens rather than single tests. As the reagents require careful balancing to get 
optimal performance and the assay requires quality control to maintain consistent performance, 
these methods are best suited to large specialised laboratories. Most laboratories do not have the 
facilities to develop and maintain their own in-house methods so most enzyme immunoassays used 
are commercial kits. In-house assays tend to be less well standardised resulting in variable 
performance and are not extensively characterised, or approved by regulatory authorities. 
Commercial kits come and go, but several have been around for many years and so have 
established performance data.
The Syphilis Bio-EnzaBead test is an indirect immunoassay format with the solid phase consisting 
of ferrous metal beads coated with sonicated T.pallidum. The sequential steps of the procedure are 
performed by transferring the beads to fresh wells using a magnetic transfer device. It has been
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evaluated by several groups (Stevens etal., 1985; Moyer etal., 1987; Burdash etal., 1987; Larsen 
et al., 1987), but only the last group distinguished the specimens on the basis of disease stage. 
They found an overall sensitivity of 94.7% and FTA-ABS gave 98.1%. The sensitivity with FTA-ABS 
positive primary and secondary syphilis was 100% and in early latent and late latent syphilis it was 
96.4% and 84.6%, respectively. Another widely evaluated commercial test is the Captia® Syphilis-G 
test, an indirect immunoassay in a microplate format with wells coated with sonicated T.pallidum 
antigen. Young et al. (1989) reported an overall sensitivity of 98.4% and a specificity of 99.3%, while 
Lefevre et al. (1990) found an overall sensitivity of 98.3%.
Enzyme immunoassay has been used to detect IgM antibodies, which are of particular significance 
in early infection and congenital syphilis. The only other way to detect IgM antibodies is the FTA- 
ABS 19S IgM test which is extremely difficult to perform reliably and is not available in kit form. All 
IgM tests require the separation of IgM from IgG to remove competition from disease specific IgG 
antibodies, the presence of which could cause false negative reactions and the removal of 
rheumatoid factor which can cause false positive reactions. Many enzyme immunoassays have 
been developed that detect specific IgM using an anti-IgM reagent and an adsorbing diluent to 
remove the IgG and the rheumatoid factor. This strategy is only of limited success due to the 
difficulties encountered in ensuring that the adsorption step is complete.
A more successful format is the IgM-capture principle. The solid phase is coated with an anti-IgM 
antibody which captures a sample of the IgM present in the specimen. Disease specific IgM is 
detected using T.pallidum antigen labelled with a monoclonal antibody conjugated to an enzyme. 
After unbound material has been removed by sequential washes, the bound enzyme is detected by 
the addition of a substrate. The advantage of this format is that it is a much simpler procedure as 
there is no need for a separation stage and there is no interference from rheumatoid factor. The 
disadvantages are that it requires careful balancing of the reagents and the use of high 
concentrations of antigen to achieve the performance. This makes the test complicated to develop 
and maintain, and costly to produce. Again, it is probably best suited to large laboratories with 
resources to maintain and control the test, however most laboratories use commercial kits. A kit 
that has been widely evaluated is the Captia® Syphilis-M test. Several evaluations have been 
performed with reasonable agreement between the studies, although the numbers of specimens 
tested was low (Lefevre et al., 1990; Ijsselmuiden et al., 1989b). The sensitivity was found to be
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highest in early primary syphilis at around 90% and decreased with disease progression. Both 
studies found the test to be positive in all cases of congenital syphilis that were examined. Another 
study that evaluated it specifically in relation to congenital syphilis (Stoll et al., 1993) found it more 
sensitive than FTA-ABS 19S at detecting probable cases.
Western blotting
Western blotting has been used widely for infectious disease diagnosis. The high sensitivity and 
specificity it offers make it an ideal confirmatory test. It has been particularly effective for the 
confirmation of human immunodeficiency virus infection. The test is performed by first 
electrophoretically separating an extracted sample of the organism on an SDS polyacrylamide gel. 
The gel is removed from the apparatus and a sheet of nitrocellulose is laid on top. The protein 
bands are electrophoretically transferred to the membrane, which is cut into separate longitudinal 
strips for testing against individual specimens. A strip is incubated with diluted patient’s serum and 
any specific antibodies bind to the proteins immobilised on the membrane. The strip is washed 
several times to remove unbound material before being incubated with an anti-human 
immunoglobulin antibody conjugated to an enzyme. The conjugate will bind to any antibodies 
attached to the proteins on the membrane. After a series of washes to remove unbound conjugate, 
the remaining material is detected using an enzyme substrate which produces an insoluble 
coloured product. The coloured product precipitates within the membrane causing the reactive 
proteins to be seen as dark lines on the membrane.
The first report of the use of western blotting for the diagnosis of syphilis was in 1985 (Hensel et al.,
1985). The problem with western blotting is that the result is not in a quantitative form, so the 
interpretation can be subjective and relies on the correct identification of key protein bands. Until 
1993 when the nomenclature was standardised (Norris et al., 1993), individual researchers referred 
to proteins by their own designations, so it was difficult to develop a consensus definition of which 
reactive bands constituted a positive result. However, all reports support its value as a confirmatory 
test. Dettori et al. (1989) found reactivity to the 15kDa protein in 97% of 110 confirmed cases of 
syphilis. The cases that were negative were two seronegative early primary infections and a case of 
late latent treated syphilis. This shows the high sensitivity of the test as these cases are extremely 
difficult cases to detect by conventional means. The specificity was shown by the absence of 
antibodies in 47 patients with false positive syphilis tests and 121 normal blood donors. In another
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study the criteria for a positive blot were that at least 3 of the 4 antigens, 47, 44.5, 17 and 15kDa, 
should be reactive (Byrne et al., 1992). They found an overall sensitivity of 91.7% and a specificity 
of 100% in clinical defined specimens. The test was very sensitive in early primary infection, 
detecting 37 of 40 cases (93%). This may have been due to the use of a conjugate specific for both 
IgG and IgM antibodies. Generally, there is a consensus that the significant proteins are those 
identified by these researchers, but the exact number of the bands that have to be reactive to 
qualify as a positive blot remains a contentious issue.
Western blotting has also been applied to detecting IgM antibodies, particularly in congenital 
syphilis. The test is more complicated than that described above; it requires the serum to be 
fractionated to remove IgG antibodies, eliminate rheumatoid factor interference, and uses a specific 
anti-IgM conjugate. As with the standard western blot, there is no consensus as to the reactive 
bands required to qualify as a positive blot. Dobson et al. (1988) examined 5 symptomatic 
congenital syphilis cases and found reactivity with the 47kDa and 37kDa proteins. Similar 
asymptomatic cases were only reactive with the 47kDa band. The importance of the 47kDa protein 
has been further demonstrated by Sânchez et al. (1989) who fractionated sera from infants with 
congenital syphilis by high performance liquid chromatography. In all cases, they showed that the 
IgM reactivity was directed towards the 47kDa antigen. Several groups agree that the significant 
proteins include the 15.5, 17, 44.5 and 47kDa proteins, but other treponemal proteins also appear 
to be reactive (Lewis et al., 1990; Sânchez et al., 1989). Lewis et al. (1990) found IgM reactivity 
most frequently to the 47 and 37kDa proteins and less often to the 42, 34,5, 31 and 24kDa proteins. 
The criterion used was that there should be 5 distinct bands which must include the 47, 17 and 
15kDa bands. They found 23 of 25 symptomatic infants with congenital syphilis gave positive blots 
using these criteria. The test was less sensitive in asymptomatic cases, but they concluded that it 
still offered superior sensitivity and specificity to the FTA-ABS 19S IgM test.
Polymerase chain reaction
The polymerase chain reaction (PCR) was invented in 1987 by Kary Mullis working in the Human 
Genetics Department at the Cetus Corporation (Mullis and Faloona, 1987). The discovery of Taq 
polymerase (Saiki et al., 1988), a thermostable DNA polymerase isolated from Thermus aquaticus, 
turned PCR into a simple procedure. It is an in vitro technique for the enzymatic synthesis of 
specific DNA sequences using two synthetic oligonucleotide primers that hybridise to opposite
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strands of a DNA template and flank the region of interest in the target DNA. All the components of 
the reaction are assembled in a single tube and subjected to a repetitive series of heating and 
codling cycles. The reaction is heated to over 90°C to denature the template, then cooled to allow 
the primers to anneal, and then heated to 72°C to allow extension of the annealed primers by Taq 
polymerase. This thermal cycle is repeated many times. As the primer extension products from one 
cycle can act as a template in the next, the number of target DNA copies doubles at every cycle. 
This results in an exponential accumulation of the DNA fragment corresponding to the sequence 
between the two primers. Therefore, 20 cycles of PCR produces around a million-fold increase in 
the amount of target DNA present. The amplified DNA is usually analysed by agarose gel 
electrophoresis to identify if the diagnostic fragment is present.
PCR has been utilised effectively to aid in the diagnosis of a variety of Infectious diseases, 
especially sexually transmitted diseases. It has had a significant impact on the diagnosis and 
management of HIV infection, and methods for the detection of Chlamydia trachomatis have 
become commercially available and FDA approved. The use of PCR in the field of syphilis is less 
well advanced. Most researchers have concentrated on its use in areas where conventional 
serological tests are ineffective, i.e. early infection, congenital syphilis, and neurosyphilis. They have 
tended to use sequences from within the lipoproteins of T.paliidum as targets for amplification 
because most had been cloned and their sequences were readily available in databases. Burstain 
et al. (1991) used as their target a 658 base pair segment of the tpnAl gene, which codes for the 
immunodominant TpN47 lipoprotein. They found that T.pallidum DNA could be amplified from 
paraffin-embedded tissue. The sensitivity of the test was determined using suspensions of 
organisms and was shown to be consistently positive with as few as 10 organisms.
The method was further evaluated for the diagnosis of congenital infection using samples of 
amniotic fluid, neonatal sera, and neonatal CSF (Grimprel at a/., 1991). The test detected all seven 
amniotic fluid specimens that were positive in the rabbit infectivity test, but was less sensitive with 
neonatal sera and neonatal CSF. It detected 3 out of 5 neonatal CSF, and 4 out of 6 neonatal sera 
that were positive by rabbit infectivity test.
The superior sensitivity with amniotic fluid may be because it is known to contain large numbers of 
treponemes. Hay et ai. (1992) used primers derived from the sequences of two proteins, TpN44.5
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(TmpA) and 4D. A positive result required both sequences to be amplified. They found a sensitivity 
of detection equivalent to 65 organisms in nonclinical specimens and tests using CSF specimens 
had an overall sensitivity of 58% in patients with a history of syphilis. However, 3% of patients with 
no known history of syphilis were also positive, which is a surprisingly high false positive rate. 
Noordhoek et al. (1991) used a nested PCR technique to amplify a 617bp fragment of the 39kDa 
basic membrane protein and showed the method to be extremely specific in an animal model 
(Wicher et al., 1992). It was capable of detecting the isolated DNA from a single treponeme, but 
was less sensitive when used on CSF, detecting the equivalent of 100 organisms/mL. The method 
was evaluated using archived CSF specimens from neurosyphilis cases and detected 5 of 7 cases 
with symptomatic neurosyphilis and 2 of 16 patients with asymptomatic neurosyphilis. DNA could be 
detected in the CSF of patients long after intravenous penicillin treatment and so is probably of 
limited value in determining the efficacy of treatment.
This drawback highlights a major problem of using the presence of amplified DNA as a marker of 
infection. PCR will amplify the DNA from residual dead organisms present after successful 
treatment just as well as it does the DNA from live organisms causing active infection. This has 
been overcome in other infectious diseases by using a reverse transcriptase PCR (RT-PCR) 
method. RT-PCR uses RNA as the initial template from which a DNA copy is made, then a specific 
fragment is amplified as in a standard PCR. For amplification to occur disease specific RNA must 
be present and as RNA is quickly degraded live organisms must be present. Centurion-Lara et al. 
(1997) developed a RT-PCR method that targeted a 366bp region of the 16s rRNA of T.pallidum. It 
detected a single organism by Southern analysis when whole organisms were diluted, and 10'2 to 
10"3 organisms when RNA equivalents were used to make cDNA. The test was demonstrated to 
detect 10'2 T.pallidum RNA equivalents in cerebrospinal fluid. They showed that 20 different isolates 
of T.pallidum from cerebrospinal fluid, aqueous humor, blood, and chancres, were detectable using 
the test. The test was shown to be more sensitive than a TpN47 DNA PCR method used for 
comparison. However, it needs to be evaluated on clinical specimens before it can be determined if 
it provides improved diagnosis of early disease, congenital infection, and neurosyphilis. It also 
remains to be seen if it provides new information on some of the anomalous results seen in treated 
neurosyphilis cases.
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The use of PCR in early primary infection has been investigated using an animal model. T.pallidum 
DNA was amplified from whole blood, serous fluid and punch biopsies of skin lesions in 
experimentally infected rabbits (Wicher et al., 1992). Of the 10 rabbits infected, nine were found to 
be positive by PCR eight days post infection. The rabbit that was negative by PCR failed to develop 
orchitis, suggesting the original infection failed. All specimen types were found to be equally 
effective, apart from serum where false negative results were obtained in all cases. These 
researchers thought that the treponemes may have been trapped during the clotting process. 
These results contradict the findings of others who reported reactive PCRs in 66% of neonatal 
serum specimens positive in the rabbit infectivity test (Grimprel et al., 1991).
Generally, experimenters have found PCR to be highly specific and extremely sensitive, but prone 
to problems associated with specimen inhibition of the reaction and false positives due to laboratory 
contamination. PCR could be extremely valuable in diagnosing infection in situations were 
conventional serological methods have limitations, i.e. early primary syphilis, congenital infection 
and neurosyphilis. However, PCR remains confined to the research laboratory due to the 
specialised equipment required and uncertainties over the interpretation of results.
Sérodiagnostic efficacy
The serological diagnosis of syphilis is traditionally based on identifying positive sera with a 
screening test, followed by retesting using a confirmatory method. This has the effect of increasing 
the predictive value of a positive result. In populations where the incidence of positives is low, even 
tests of high specificity have low positive predictive values. This is because the few false positive 
reactions that do occur are greater than the number of true positives detected. Using a second 
method to test the positives from the first has the effect of increasing the incidence of positives in 
the second test population. So, even if the second method has the same specificity as the first it will 
increase the predictive value of a positive result Also, it is unlikely that a specimen will be falsely 
reactive in two different methods. However, the sensitivity of the confirmatory test must not be lower 
than the screening method or there would be a danger of false negatives by failing to confirm true 
positives. So, due to the low incidence of positives in the population, testing using a combination of 
methods is standard practice in syphilis serology.
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Screening
There are three main screening strategies commonly employed, a cardiolipin antigen test or a 
treponemal test, such as the MHA-TP, used alone, or a combination screen using both together. 
Cardiolipin antigen tests continue to be used as screening tests because of their speed, simplicity 
and low costs. They all detect non-treponemal anti-cardiolipin antibodies that are released in 
response to the infection and become positive 7 to 10 days after the appearance of the primary 
chancre. The sensitivity ranges from 60% to 87% in primary infection and reaches 100% in 
secondary syphilis. There is a reduction in reactivity in the later stages of the disease, with about 
30% of cases of late latent syphilis being non-reactive (Luger, 1988), and they become negative 
after successful treatment. Cardiolipin tests suffer from what is known as biological false positives, 
patients with a repeatedly reactive test but no history of syphilis, in about 0.3 to 0.9% of specimens. 
They are also prone to false negative results due to the prozone effect caused by high 
concentrations of antibodies. A prozone effect is thought to occur in about 1% of cases of 
secondary syphilis, although some reports suggest this is an underestimate of the problem 
(Spangler et al. 1964). To overcome this problem sera must be tested at a series of dilutions, which 
greatly increases the testing required. For these reasons, it is not advisable to test solely with a 
cardiolipin test, although in areas of high prevalence or limited resources it may still be considered a 
viable option.
Screening with a single haemagglutination test is effective for all stages of syphilis, except in early 
infection where the sensitivity is considered to be lower than that of a cardiolipin test. 
Haemagglutination assays are very sensitive and specific methods for the detection of T.pallidum 
antibodies. False reactions are rare, only 0.07% of specimens give a false positive result and 
0.008% a false negative result (Luger, 1988). One long term study that looked at serodiagnosis 
over a 20 year period (Anderson et al., 1989) found the sensitivity of cardiolipin tests to be 70% 
compared to 75% for haemagglutination tests in untreated primary syphilis. Another study (Young et 
al., 1992) found the sensitivity of cardiolipin tests and haemagglutination to be 73% and 71%, 
respectively. So, on balance the two tests are fairly similar in performance in early infection. This 
has been taken by some authors to suggest that haemagglutination may be used as a sole 
screening method (Diggory, 1983). Generally, this is only considered viable for situations where 
early infections are not suspected.
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The most common screening strategy employed is a combination of cardiolipin test and 
haemagglutination assay. When used together, these two tests provide a better screen than either 
of them used alone. Young et al. (1992) found the sensitivity of a combination of cardiolipin test and 
haemagglutination assay to be 84%, compared to 73% and 71% when used separately. This testing 
strategy offers excellent performance that cannot be surpassed, but it requires considerably more 
work than does a single test and it is not suited to automation.
Enzyme immunoassay is a method ideally suited to automation and the testing of large numbers of 
specimens. It is a sensitive and specific method capable of matching the performance of other 
treponemal tests and is suitable as a direct replacement for treponemal haemagglutination tests. 
The effectiveness of a method as a single screening test relies on its ability to detect early 
infections. Evaluation of a commercially available enzyme immunoassay (Captia® Syphilis-G) 
showed that it had a greater sensitivity in early infection than any other test, 82% compared to 76% 
for dark field microscopy, 73% for VDRL, 71% for TPHA, and 80% for FTA-ABS (Young et al., 
1992). A combination of VDRL and TPHA gave a slightly higher sensitivity of 84% that was not 
statistically significant. The authors concluded that the assay was a suitable replacement for the 
combination screening strategy. Considering the automation and direct data transfer advantages 
that enzyme immunoassay methods have to offer, they are an attractive proposition for laboratories 
requiring a high specimen throughput. Enzyme immunoassay may be used in either of two ways, as 
a single method screen, or as a replacement for a haemagglutination test in a combination screen. 
The excellent sensitivity and specificity shown by this test are why it was used for comparative 
purposes in the study reported here.
Confirmation
FTA-ABS is the most widely used confirmatory test. It has a reputation for being very sensitive and 
highly specific, but this reputation is a result of the dual testing strategy employed increasing the 
predictive value of a positive result. The specificity varies from 91% to 99% (Hunter et al., 1986) 
and the sensitivity from 83% to 89% depending on whether borderline results are included or 
excluded (Larsen et al., 1986). The prevalence of false reactions is around 1% in normal 
individuals, but may be much higher in hospitalised patients. This means that if the FTA-ABS test 
was used for screening it would give an unacceptable number of false reactions. The relatively poor 
specificity of FTA-ABS test has led some authors to suggest the use of enzyme immunoassay as
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an alternative confirmatory test. Several commercially available enzyme immunoassays have been 
recommended as confirmatory tests (Lefevre etal., 1990; Moyer etal., 1987; Burdash etal., 1987). 
The nature of enzyme immunoassay methods and the potential for automation makes them more 
suited to screening than confirmation. Western blotting has been investigated as an alternative 
confirmatory test (Dettori et al., 1989; Byrne et al., 1992). Most investigators find it a highly specific 
method, well suited to use as a confirmatory test. However, more work needs to be done to define 
the exact criteria that constitute a positive result. The identification of the diagnostically significant 
antigens of T.pallidum is crucial to this requirement.
Much of the discussion over the advantages and disadvantages of one testing strategy over another 
centres on their sensitivity in early infections. It must be remembered that all infectious diseases 
have a window between Infection and the development of a detectable antibody response. No 
testing strategy will detect all early infections, but as many as 15% of cases of primary syphilis were 
found to be serologically non reactive at presentation (Anderson et al., 1989). There is clearly a 
need for tests with greater sensitivity than the existing strategies can deliver. The route most likely 
to succeed is through the use of recombinant protein to allow only the diagnostically significant 
antigens to be present in the test This would have the effect of improving the specific activity of the 
antigen preparations thereby increasing test sensitivity. The crude antigens used in existing 
serological tests contain large amounts of non specific material and common antigens, which 
contribute to high number of false reactions suffered by all serological tests for syphilis. 
Recombinant proteins may help reduce the rate of false reactions by improving the specificity of 
antigens used. This is the starting point for the work reported in this study.
The organism 
Taxonomy
The Treponema genus covers a variety of bacteria, some only very distantly related, whose shared 
classification is mainly based on their morphology and the periplasmic location of their flagella. They 
cause a range of diseases in humans and animals, including venereal syphilis, endemic syphilis, 
yaws, pinta, and spirochaetosis of rabbits. Treponema pallidum subsp. pallidum (venereal syphilis), 
Treponema pallidum subsp. endemicum (endemic syphilis). Treponema pallidum subsp pertenue 
(yaws), Treponema carateum (pinta), and Treponema paraluiscuniculi (spirochaetosis of rabbits)
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are virtually identical in terms of morphology, protein composition, and where tested, DNA 
homology (Fieldsteel, 1983; Maio and Fieldsteel, 1978, 1980; Maio etal., 1978). They are classified 
as separate organisms on the basis of their different patterns of infection in humans and laboratory 
animals (Turner and Hollander, 1957). Treponema carateum and Treponema paraluiscuniculi are 
not classified as subspecies of T.pallidum due to lack of genetic information (Smibert, 1984). 
Treponema pallidum subsp. pallidum, endemicum and pertenue show greater than 95% DNA 
homology (Fieldsteel, 1983.; Maio and Fieldsteel, 1978, 1980), but less than 5% homology with 
Treponema phagedenis, Treponema refringens and Serpulina hyodysenteriae (Maio and Fieldsteel, 
1978; Maio etal, 1978).
Pulsed-field gel electrophoresis studies have shown the T.pallidum genome to be a circular 
chromosome of approximately 1000 kbp, making it one of the smallest prokaryotic genomes (Saint 
Girons etal., 1992; Walker etal., 1991). Recently, the complete genome sequence was determined 
and shown to be 1,138,006 base pairs containing 1041 predicted coding sequences (Fraser et al., 
1998). Analysis of the sequence has shown systems for DNA replication, transcription, translation, 
and repair are intact, but catabolic and biosynthetic activities are minimised. The number of 
identifiable transporters is small, and no phosphoenolpyruvate: phosphotransferase carbohydrate 
transporters were found. Potential virulence factors identified included a family of 12 potential 
membrane proteins and several putative haemolysins.
Growth
Neither the human pathogenic treponemes or Treponema paraluiscuniculi are cultivable solely in 
vitro, but the other treponemal species can be quite easily cultured in liquid media under anaerobic 
or microaerobic conditions. T.pallidum is propagated by intratesticular infection of rabbits for 
research and diagnostic purposes. Fieldsteel et al. (1981, 1982) achieved limited in vitro culture, 
also confirmed in other laboratories (Norris and Edmondson, 1986, 1987), by co-cultivation with 
SflEp cottontail rabbit epithelial cells in a special culture medium under microaerophilic conditions. 
They achieved approximately 100-fold increase in cell numbers, but subculture and long term in 
vitro growth were not successful. The fastidious nature and slow growth, both in vivo and in vitro, 
suggest the organism may have metabolic limitations or requirements for unidentified host 
products.
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Morphology
T.pallidum is a corkscrew shaped organism with rigid, uniform, tightly wound, deep spirals. It is 6 to 
20 pm long, 0.10 to 0.18 pm wide, with a spiral wavelength of 1.0 to 1.5 pm, and an amplitude of 
0.5 to 0.7 pm. It is highly motile and moves with a characteristic motion, a deliberate backward and 
forward movement with rotation about the longitudinal axis. When attached to a heavier obstacle it 
bends and contorts, but springs back to shape on release. The basic structure resembles that of 
Gram-negative eubacteria in the presence of an outer membrane (Sell and Norris, 1983; Penn et 
al., 1985). The outer membrane consists of a fragile lipid bilayer that is highly sensitive to detergent 
solubilisation and lacks lipopolysaccaride. It has been shown to have a low protein to lipid ratio and 
freeze-fracture studies show very few intramembranous particles compared to other similar bacteria 
(Walker et al., 1991), The cytoplasmic membrane forms a complex with a thin peptidoglycan layer 
and, along with the outer membrane, encloses a periplasmic space. The periplasmic space 
contains structures known as endofagella or periplasmic flagella. Between 2 and 4 flagella originate 
from each end of the cell and run along the longitudinal axis towards each other, overlapping in the 
middle. They are about 17nm wide and extend over more than half the length of the organism (3 to 
10 pm). They are helical in shape and retain this shape when released from the cell, indicating the 
spiral shape of the organism is at least partly due to the flagella structure. The flagella consist of an 
inner core, approximately 12nm in diameter, surrounded by an outer protein sheath. Treponemes 
contain unique structures located within the cytoplasm, known as cytoplasmic filaments. These 
ribbon like structures, with no known function, are about 7nm wide and run the length of the 
organism just underneath the cytoplasmic membrane, parallel with the flagella (Masuda and 
Kawata, 1989).
Major polypeptides of T.pallidum.
The key to understanding the pathogenesis and physiology of T.pallidum is the identification of 
functional elements within the organism. As the organism cannot be cultured in vitro, only limited 
amounts of material have been available for study which has limited the type of experimental 
procedures that can be used. The purification of the structural components of T.pallidum has been 
an important step in the identification of proteins associated with the outer membrane, cytoplasmic 
membrane, flagella, and other structures. This has been particularly effective in characterising the 
structure and composition of the periplasmic flagella. The isolation of specific membrane
45
Chapter 1
components has proved to be more problematic due to the highly labile nature of the outer 
membrane and the inability to differentiate outer membrane components from cytoplasmic ones. 
The advent of molecular biology techniques has allowed a large number of treponemal proteins to 
be cloned and expressed in E.coli. A complete list of all cloned proteins and plasmid constructs has 
been compiled by the Treponema pallidum Polypeptide Research Group (Norris et al., 1993). 
However, their function and phenotypic effect have been difficult to determine because deletion 
mutants can not be constructed due to the inability to culture the organism in vitro. Sequence 
homology with proteins of known function from other bacteria has been used to ascribe a putative 
function to some treponemal proteins. So, although a large number of T.pallidum proteins have 
been identified, their structural significance and functions remain unknown in many cases. 
Generally, these proteins were isolated from cDNA libraries by an immunoscreening method using 
hyperimmunised anti-Tpallidum antiserum, therefore they are antigenic by definition. These 
proteins represent a range of potentially diagnostically significant antigens of T.pallidum for 
evaluation and consideration.
Nomenclature
At one time different laboratories had their own designations for T.pallidum polypeptides, which 
made exchange of data and comparisons between laboratories difficult. Norris et al. (1987) 
compared SDS-PAGE patterns of T.pallidum from different laboratories and showed this method to 
be inadequate to definitively identify the polypeptides. A method using 2DGE in combination with 
monoclonal antibodies yielded adequate differentiation and was used as the basis of the current 
nomenclature (Norris et al. 1993). The system consists of the prefix TpN followed by the relative 
molecular mass of the protein based on consensus SDS-PAGE results. The corresponding gene is 
indicated by lower case italics. So, the 17kDa protein, TpN 17 is coded for by the gene designated 
tpn17.
Flagellar proteins
The periplasmic flagellum is the best characterised structure of T.pallidum (Charon et al., 1992), 
probably because they are readily isolated by differential centrifugation. The flagella of T.pallidum 
consist of multiple proteins arranged into an outer sheath and a central core (Penn et al., 1985;
1 Radolf et al., 1986; Cockayne et al., 1987; Blanco et al., 1988). This contrasts with other bacteria 
where the flagella are constructed of multiple repeats of a single polypeptide subunit (Namba et al.,
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1989). The flagellar proteins are highly immunogenic which has facilitated their identification and 
characterisation by electrophoretic and immunoblotting techniques. Six flagella-associated proteins 
have been identified, cloned, and sequenced, TpN37a, TpN34.5, TpN33, TpN30, TpN29, and 
TpN27.5. TpN37a has been designated FlaA, and TpN34.5, TpN33, and TpN30 have been 
designated FlaB1, FlaB2, and FlaB3, respectively, on the basis of DNA sequences and antigenic 
similarities.
FlaA
The FlaA gene was cloned and sequenced (Isaacs et al., 1989), and found to code for a protein of 
37kDa. The promoter region contains -35 and -10 sequences that show consensus with those 
sequences known to be recognised by a70 transcriptional factors (Isaacs et al., 1990). The mature 
protein sequence is preceded by a hydrophobic signal peptide and a consensus signal peptidase I 
cleavage sequence. This suggests that the signal peptide is cleaved off the protein translation 
product and FlaA is transported across the cytoplasmic membrane. FlaA appears only to be present 
in certain spirochaetes and is highly conserved in the sequences studied (Parales and Greenberg, 
1991, 1993). It shows no sequence homology with conventional bacterial flagellins. FlaA is thought 
to be secreted into the periplasmic space and overlaid on to the growing flagellar core to form the 
outer sheath of the flagella. This association with the outer sheath has been identified using 
monoclonal antibodies which lose reactivity after removal of the outer sheath of the flagella 
(Cockayne et al., 1987).
FlaB
FlaB1 and FlaB3 were cloned as a single DNA fragment and are closely associated (Champion et 
al., 1990). FlaB3 is only 281 base pairs down stream of FlaB1 and lacks a promoter sequence. 
FlaB1 is preceded by a consensus a28 promoter sequence, so it is possible that the two genes are 
expressed as a polycistronic mRNA. F/aB2 was cloned and sequenced separately and was found to 
be expressed from a separate consensus a28 promoter sequence (Pallesen and Hindersson, 1989). 
FlaB1, FlaB2, and FlaB3 are similar sized proteins and exhibit a high degree of homology with each 
other. The FlaB proteins show a high degree of homology to flagellins of other bacteria, particularly 
in the N-terminal region. As described with other bacteria (Namba et al., 1989), the FlaB proteins 
are thought to be secreted with an intact N-terminal sequence and transported through the flagellar
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base unit and core to be added to the end of the flagella. However, the exact relationship between 
the individual proteins is unknown. v .
Other flagellins
TpN29 and TpN27 are two proteins of unknown structural or functional significance which are 
detected in some flagellar preparations (Norris et al., 1988). They have not been cloned and do not 
appear to be degradation products of other flagellins because monoclonal antibodies directed 
against FlaA and FlaB proteins do not react with them. The recent availability of the full genome 
sequence may facilitate the cloning of these proteins and allow putative functions to be assigned.
Membrane associated proteins
The ability of T.pallidum to evade the immune system, and the fastidious nature of its growth 
requirements, suggest that the membrane structure may be of importance due to its metabolic 
involvement and immunogenic properties. The membrane associated proteins that have been 
isolated represent prime candidates for diagnostically significant antigens. The surface of 
T.pallidum has long been thought to be relatively inert, behaving as if it lacked proteins and antigens 
(Penn etal., 1985). The application of conventional cell fractionation techniques that had been used 
successfully on other Gram-negative organisms, failed to produce significant information. As a 
result phase partitioning experiments with the anionic detergent, Triton X-114 (Bordier, 1981), were 
employed. The solubilisation of the membrane recovered nearly all the major antigens of T.pallidum 
in the detergent enriched fraction (Radolf and Norgard, 1988; Cunningham et al., 1988), indicating 
their hydrophobic nature. A large number of these proteins were shown to be lipidated and strongly 
antigenic in humans and animals. So far, eight major antigenic lipoproteins of T.pallidum have been 
cloned, sequenced, and characterised.
The strong antigenicity of these lipoproteins was in contradiction to the inertness of the outer 
membrane. This suggested that these lipoproteins were not surface exposed and this inference 
was further reinforced by freeze-fracture electronmicrography studies. These studies showed that 
the fracture faces contained approximately 100-fold fewer intramembranous particles (IMP) than 
other similar organisms (Walker et al., 1989, 1991). These IMPs were designated treponemal rare 
outer membrane proteins, or TROMPS.
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The exact location of the major lipoproteins of T.pallidum was difficult to establish due to the 
intrinsic instability of the outer membrane resulting in periplasmic associated proteins becoming 
surface exposed. The major immunodominant antigen, TpN47, was located to the cytoplasmic 
membrane using immunoelectron microscopy of ultra-thin cryosections (Cox et al., 1992). Using a 
novel immunofluorescence technique in which treponemes are encapsulated in porous gel beads, 
four of the major antigens, TpN47, TpN34, TpN 17 and TpN 15, were shown to be associated with 
the cytoplasmic membrane (Cox et al., 1995). A method was developed without the use of 
detergents that produced a pure outer membrane preparation (Blanco etal., 1994). This was shown 
by the absence of the abundant lipoprotein TpN47 and the previously characterised cytoplasmic 4D 
protein (see below) from isolates prepared by the method. Analysis of these outer membrane 
fractions showed the presence of six protein species of 17kDa, 28 KPa, 45 kPa, 65 kPa, and two 
31kDa proteins with distinct isoelectric points. The proteins of 17kPa and 45kPa were shown to be 
the lipoproteins, TpN 17 and TpN44.5, by their physical properties and reactivity with specific 
monoclonal antibodies. Over 90% of these lipoproteins remained associated with the cytoplasmic 
membrane but their presence also in the outer membrane fraction was not thought to be 
contamination in view of the absence of the normally abundant TpN47. The remaining 31kPa, 
28kDa, and 65kOa proteins were considered true outer membrane proteins and designated 
Trompl, Tromp2 and Tromp3, respectively.
Lipoproteins
Using phase partitioning with detergents to study the T.pallidum membrane structure resulted in a 
large number of proteins being identified. Many of these proteins were found to be lipidated and 
highly immunogenic. Eight major lipoproteins have been identified and represent candidates for 
evaluation as diagnostically significant antigens. They have been cloned by several groups from 
genomic libraries and sequenced Table 1 summarises the lipoproteins and the groups responsible 
for their identification and characterisation.
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Table 1. Lipoproteins of T.pallidum
Protein
designation
Mr Deduced
MW
N-terminal sequence References
TpN47
(47K) 47,000 46,740 MKVKYALLSAGALQLLWG i  CG
Chamberlain etal., 
1989; Hsu etal., 1989; 
Weigel etal., 1992
TpN44.5
(TmpA) 42,000 42,000 MNAHTLVYSGVALACAAMLGS I  CA
Hansen etal., 1985; 
Schouls etal., 1989; 
Yelton etal., 1991
TpN39
(38K) 38,000 36,194 MKENSCTACSRRLALFVGAAVLWG I  CS Bailey ef a/., 1989
TpN35
(TmpC) 35,500 35,600 VREKWVRAFAAVFCAMLLIG 1 CS
Hubbard etal., 1991; 
Schouls etal., 1991
TpN29-35 
(34K, TpD)
30.000 -
38.000 22,087 MKRVSLLGSAAIFALVFSA 4 CG
Schouls etal., 1989; 
Swancutt etal., 1986, 
1989, and 1990
TpN24-28 
. (TpE)
24.000 -
30.000 ND
Bailey etal., 1989; van 
Embden etal., 1983
TpN17
(Tpp17) 17,000 14,438 MKGSVRALCAFLGVGALGSAL 4 CV
Akins etal., 1993; 
Chamberlain et al., 
1989
TpN15
(Tpp15) 15,000 13,967 MVKRGRFALCLAVLLGA 4 CS
Purcell etal., 1989, 
and 1990
Alternative designations are shown in brackets. The relative molecular weights are based on SDS-PAGE. The deduced 
molecular weights are for the mature polypeptides, without lipid attachments, based on DMA sequence data. The table is 
modified from Norris et al. (1993).
All the lipoproteins have a hydrophobic signal sequence of between 17 and 21 amino acids followed 
by a consensus signal peptidase II recognition site. The consensus recognition sites are a leucine, 
valine or serine residue separated from a cysteine by 2 or 3 hydrophobic amino acids. The signal 
sequence is bound by the enzyme, the lipid added to the cysteine residue through an amide linkage 
and the formation of a diacylglyceryl thioester bond, and then the signal sequence is cleaved (de 
Vrije et al., 1990). The importance of the cysteine residue has been shown by mutation to a serine 
residue resulting in non-lipidated protein being produced (Schouls et al., 1991). The sequences, 
apart from the signal sequence, are hydrophilic which suggests that the partitioning to the detergent 
phase is due to their lipid content and not the amino acid composition. The lipoproteins are highly 
immunogenic and thought to be located in association with the cytoplasmic membrane. None of
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these proteins show significant homology with other bacterial or eukaryotic sequences in 
databases, and so have no putative functions assigned to them.
Other membrane associated proteins 
TpN39b (basic membrane protein)
This positively charged, hydrophobic protein was cloned and sequenced by Dallas et al. (1987). The 
deduced N-terminal amino acid sequence contains a signal peptide and signal peptidase I cleavage 
site.
TpN34 (TmpB)
TmpB was cloned along with the lipoprotein TmpA (TpN44.5) by Hansen et al. (1985). The open 
reading frame of TmpB overlaps the 3’ end of the TmpA encoding region by one base pair. The two 
proteins are expressed as a polycistronic mRNA from a single RNA transcriptional initiation site.
Treponemal rare outer membrane proteins
Trompl
The amino acid sequence of the 31kDa protein from outer membrane fractions was determined and 
used to clone the encoding structural gene, which was designated trompl (Blanco et al., 1995). The 
recombinant protein was used to generate antisera which showed both proteins originally identified 
were Trompl The N-terminal region of the protein consists of a hydrophobic sequence and a 
putative signal peptidase I cleavage site. The protein was predicted to contain 14 membrane 
spanning beta pleated sheet segments, highly analogous to Gram-negative outer membrane 
proteins. Native Trompl was demonstrated to have porin activity in the black lipid bilayer assay 
which suggests it may be an quter-membrane spanning protein. The controlled expression of 
recombinant Trompl in E.coli showed it to be localised to the outer membrane fraction and porin 
activity of recombinant Trompl was demonstrated using the black lipid bilayer assay (Blanco et al., 
1996). The work of Blanco and colleagues suggests that Trompl is a surface-exposed protein with 
porin like properties. However, no evidence for either outer membrane location or surface exposure 
of native Trompl within motile or intact treponemas has been presented. The trompl gene has 
been found to be part of an ABC transport operon with significant sequence homology to a family of 
Gram-negative periplasmic substrate-binding proteins (Hardham etal., 1997).
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The apparent discrepancies between the studies of Blanco and colleagues and this sequence data 
prompted work to resolve the differences. Akins etal. (1997) showed that Trompl was probably a 
substrate-binding protein anchored to the cytoplasmic membrane by an uncleaved signal sequence. 
They could not show porin activity and suggested the previous reactivity seen in the black lipid 
bilayer, assay may have been due to the presence of detergent or other contaminants. The 
differences in the predicted secondary structure were attributed to atypical processing events due to 
the recombinant Trompl being fused to the E.coli OmpT leader sequence. Trompl produced in an 
in wfro-coupled transcription-translation reaction, lacking signal peptidase I activity, resulted in a 
protein of the same size as native Trompl This is inconsistent with cleavage of the N-terminal 
signal sequence. However, recently Blanco et al. (1999) have shown, using mass spectrometry,
that purified native Trompl is processed and does not contain an uncleaved signal sequence as
*  ■.
previously reported (Akins et al., 1997). So, true outer membrane proteins remain to be conclusively 
identified.
Trompl
Amino acid sequences were used to amplify and clone the structural gene coding for the 28kDa 
outer membrane protein, now designated Tromp2 (Champion et al., 1997). The deduced amino 
acid sequence showed a 24 amino acid N-terminal hydrophobic signal sequence and a signal 
peptidase I cleavage site. Protein modeling suggests a structure of 9 membrane spanning beta 
pleated sheet segments. In contrast to Trompl Tromp2 does not seem to be toxic to E.coli and 
even maximum expression levels result in the protein being localised to the outer membrane. 
Evaluation in the black lipid bilayer assay shows only occasional channel formation even at high 
levels of membrane insertion. Thus, whether Tromp2 has porin activity is not clear.
Trompl
The 65kDa protein identified in outer membrane preparations has been tentatively designated 
Tromp3. It occurs in smaller, more variable amounts than the other outer membrane proteins which 
suggests that it may be differentially expressed. The small quantities of protein available have 
prevented amino acid sequencing and cloning.
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Other proteins 
TpN19 (4D)
The 4D antigen was one of the first T.pallidum proteins to be cloned in E.coli (van Embden et al.,
1983). The native molecule has a molecular weight of around 190kDa and is composed of ten 
19kDa subunits which form a ring-like structure about 6nm in diameter (Fehniger et al., 1986). It 
can be purified as a separate entity on sucrose density gradients and is thought to be located within 
the cytoplasm. The function of the 4D antigen is unknown and no homologous sequences have 
been identified.
TpN60 (GroEL)
TpN60 is a polypeptide of approximately 60kDa and a major component of T.pallidum. The native 
molecule is a ring-like structure with a molecular weight of around 800,000. It was shown to 
immunologically crossreact with similar proteins from other bacteria (Hindersson et al., 1984). 
Cloning (Hindersson et al., 1987) and sequence analysis show that it is homologous to the GroEL 
heat shock protein of E.coli (Houston et al., 1990).
Antibody responses in syphilis
The study of the proteins of T.pallidum by conventional purification and functional analysis 
techniques has been hampered by the inability to culture the organism in vitro. So, the focus of 
many research groups has been to examine and catalogue the important proteins and polypeptides 
using antibodies from immunised animals and human syphilitic patients. As a result, the antibody 
response during syphilis has been extensively investigated by many groups of researchers using a 
variety of approaches, including crossed Immunoelectrophoresis, SDS-polyacrylamide gel 
electrophoresis and western blotting, radioimmunoprecipitation, and two dimensional 
electrophoresis. A large body of information exists which is difficult to interpret due to the 
inconsistent identification of proteins between groups. This may be due to differences in the 
methods used to separate the organisms from rabbit tissue, differences due to the electrophoresis 
format used, and different or ill-defined molecular weight markers. Although the SDS-PAGE 
patterns of T.pallidum reported by different laboratories were shown to be quite similar (Penn et al.,
1986), considerable uncertainty existed with regard to the identity and molecular weights of 
polypeptides described by different researchers. A collaborative study compared the results of 
different groups, their methods, and used monoclonal antibodies to identify and define various
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proteins of T.pallidum (Norris and Edmondson, 1987). A set of consensus molecular weights for the 
proteins of T.pallidum were obtained, which formed the basis for the nomenclature system 
described by the Treponema pallidum Polypeptide Research Group (Norris et ai., 1993). This 
provides a means of reinterpreting existing information from participating laboratories in relation to 
current nomenclature, where suitable molecular weights were assigned. However, a large number 
of papers remain impossible to interpret due to the lack of established standards or a means of 
comparing the results to those of the participating laboratories. The experimental work described in 
the results section of this thesis also plays an important role in providing an identity to the proteins 
cited in the studies discussed below.
The antibody response has been studied using two strategies, experimental infection of laboratory 
animals, and the analysis of serum specimens from patients with different stages of syphilis 
infection. The experimental infection of rabbits allows the progress of the infection to be monitored 
much more closely than is possible using human serum specimens. Hanff et al. (1983) 
experimentally infected rabbits and monitored the appearance of reactivity to the various proteins 
over several months. By the 9th day post infection, they found weak reactivity to proteins that were 
probably TpN60, the GroEL homologue or common antigen, TpN47, and several flagellar proteins, 
TpN37, TpN33 and TpN30. The next proteins to become reactive were two low molecular weight 
species, probably TpN17 and TpN15. As the infection progressed so the reactivity of all proteins 
increased proportionately until by 1 month post infection there was reactivity to more than 21 distinct 
polypeptides. Lukehart et al. (1986) conducted a similar study, but also measured the IgM as well 
as the IgG responses. The initial IgM responses were to proteins which were probably TpN47, 
TpN44.5, and TpN37, followed by reactivity to TpN17 and TpN15 a few days later. The IgG 
response developed after the IgM response and was initially directed towards TpN37, followed by 
reactivity to TpN47.
Although not in full agreement, these studies show broadly similar findings which have also been 
demonstrated by others (Alderete and Baseman, 1981; Wicher et al., 1991). The course of syphilis 
in man has been studied using serum specimens from patients at different stages of syphilis, so 
accurate time course experiments are impossible. The information is restricted to the broad 
categories into which the disease can be clinically subdivided, early primary infection, secondary or
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early latent syphilis, latent syphilis, and the later destructive stages like neurosyphilis or 
cardiovascular syphilis.
Van Eijk and van Embden (1982) found different immunoglobulin subclasses to be present at 
different stages of the disease. In early primary infection there are IgM, IgG, and IgA responses to a 
protein, probably TpN47, and IgM only to what was probably TpN17, with IgA to probable TpN15. In 
secondary syphilis the IgA response disappeared and the IgM reactivity was the same as in early 
infection but with the addition of reactivity towards TpN37. IgG reactivity was seen to TpN47, 
TpN44.5, TpN37, TpN17, and TpN15. In latent syphilis and neurosyphilis they found only IgG 
reactivity, with the same reaction pattern as in secondary syphilis. This study identified surprisingly 
few proteins compared to other studies, particularly the IgG responses in secondary syphilis where 
one might expect upwards of 20 distinct polypeptides to be Identified.
Hanff et al. (1982) showed that serum IgG from uninfected individuals reacted weakly with three 
polypeptides, probably TpN47, TpN33 and TpN30. They found IgM antibodies in patients with 
primary infection and IgG antibodies in all patients with syphilis. In early primary infections the 
reactivity was to proteins that were probably TpN47, TpN33, TpN30 and TpN15. Antibody to 
TpN44.5 and TpN17 were markers for non primary infection. In secondary and early latent syphilis 
reactivity to a large number of protein bands were identified which reduced in number and intensity 
as the disease progressed to the later stages. In the later stages of the disease, strong reactivity 
remained to TpN47, TpN44.5, TpN17, and TpN15.
Another comprehensive study by Baker-Zander et al. (1985) showed similar results, except that 
they found IgM reactivity in secondary and early latent cases. Sera from early primary infections 
varied in reaction pattern, but were consistently strongly reactive with TpN47 and sera from 
secondary and early latent syphilis were uniformly reactive with 22 separate polypeptide antigens. 
Similar reactivities have been demonstrated by other researchers using radioimmunoprecipitation 
rather than western blotting (Moskophidis and Muller, 1984).
The work discussed above is by no means a complete review of all the available literature. The 
studies are some of the more comprehensive investigations of the antibody response where the 
proteins can be identified with some confidence, although a certain amount of intuition is still 
required. There are many other studies that simply confirm these findings and others that remain
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uninterpretable in terms of current nomenclature. The rabbit infection experiments show a clearer 
consensus of the profile of immunogenic proteins and the time course of the appearance of 
detectable antibodies of different classes than do the human studies. This is probably because the 
patient specimens used tend to be a diverse population, categorized on clinical judgment, which 
leads to a more variable picture. However, although there is not complete agreement on the 
proteins antigenic at each stage of the disease, there are general findings from which conclusions 
can be drawn. The earliest responses, both IgG and IgM, are to TpN47 and the flagellar proteins. 
This is followed by the development of significant IgG reactivity to TpN44.5, TpN17 and TpN15. By 
the time secondary syphilis develops there are antibody responses to a large number of proteins in 
addition to those recognised in the earlier stages. The number and intensity of the responses 
decrease in latent and the later destructive stages of the disease, but reactivity to TpN47, TpN44.5, 
TpN17, TpN15, and several flagellar proteins remains. Several studies have shown reactivity to 
some of the flagellar proteins and TpN47 in the serum of a few normal individuals with no history of 
syphilis (Hanff et al., 1982; Baker-Zander et al., 1985). This is of potential concern as TpN47 is 
widely considered a pathogen-specific immunodominant antigen and important for the development 
of immunodiagnostic tests.
Sera from the experimental infection of rabbits, and human sera from infected individuals have 
been used to examine the cross reactivity between T.pallidum subsp. pallidum and other 
treponemes. Much effort has been expended in trying to distinguish between the different 
pathogenic treponemes for diagnostic and epidemiological purposes. The antibody response to 
infection with T.pallidum subsp pertenue, the causative agent of yaws, is indistinguishable from that 
seen in syphilis (Baker-Zander and Lukehart, 1983; Thornburg and Baseman, 1983). Fohn et al. 
(1988) found patients suffering from pinta, caused by T.carateum, also showed the same antibody 
reaction pattern as those with syphilis The cross reactivity with non-pathogenic treponemes has 
long been of interest because of their cultivable nature and they have been used as sources of 
antigens for serological tests. T.phagedenis biotype Reiter, T.refringens strain Noguchi, and 
T.vincentii have all been shown to contain numerous proteins that cross react with antibodies to the 
proteins of T.pallidum subsp. pallidum, which indicates the conserved antigenic determinants of 
treponemes (Lukehart et al., 1982; Wicher et al., 1986). Lukehart et al. (1982) identified three 
pathogen specific proteins of T.pallidum using syphilitic rabbit serum that had been extensively
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adsorbed with Reiter treponemes. The proteins identified were 48kDa, 14kDa, and 12kDa, which 
probably correspond to TpN47, TpN17 and TpN15.
In conclusion, the antigens most likely to be diagnostically significant are those proteins most 
frequently cited, TpN47, TpN44.5, TpN17 and TpN15. These proteins have all been cloned and 
sequenced by several groups of researchers, but few have been extensively evaluated as 
diagnostic reagents.
Diagnostic recombinant proteins
Established treponemal serological tests for syphilis are mainly based on antigens derived from 
sonicated T.pallidum. The cloning of T.pallidum proteins allowed them to be expressed and purified 
In large quantities. An obvious application of the technology was as a source of specific antigens to 
replace in vivo cultivated organisms in serological tests. Considering how many T.pallidum proteins 
have been cloned, very few have been evaluated as diagnostic antigens. TpN35 (Schouls et al., 
1991), or TmpC, and TpN29-35 (Hindersson et al., 1986), or TpD, have been evaluated to a limited 
extent, making it impossible to assess their importance as diagnostic antigens. Three proteins that 
have been evaluated extensively are TpN19 (4D antigen), TpN38, a putative fibronectin-binding 
adhesin, and TpN44.5, a membrane associated lipoprotein.
Recombinant TpN19, previously called the 40 antigen, was evaluated by indirect enzyme 
immunoassay using an anti-IgG conjugate (Radolf et al., 1986). Using stored specimens, the 
antigen was found to be negative with 172 VDRL negative sera and 20 specimens from patients 
with a biological false positive response. The sensitivities were 81% in early primary syphilis, 100% 
in secondary/early latent disease, but dropped to 57% in cases of neurosyphilis and cardiovascular 
syphilis. Using fresh sera from dark field positive patients with untreated primary infection the 
sensitivity was 83%, compared to FTA-ABS and VDRL which were both slightly better at 88%. Just 
like all other serological tests for syphilis, sera from patients with yaws and pinta were all positive.
Recombinant TpN38 was evaluated using a radioimmunoassay (Rogers et al., 1986). It detected 71 
out of 81 untreated and treated cases which were not defined by disease stage. This translated to a 
sensitivity of 87.7% and a specificity of 95.4% which compared unfavourably with FTA-ABS, which 
detected all the positives. The sensitivity was examined further using 50 untreated primary cases. 
Only 38 were positive, giving a sensitivity of 76% compared to FTA-ABS which gave 86%. Of the 42
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biological false positives tested four were falsely positive, compared to none by FTA-ABS. In 
summary, this antigen appears to lack sensitivity compared to established tests and shows false 
reactions.
TpN44,5 (TmpA) and TpN36 (TmpB) were cloned together and found to be expressed from 
overlapping open reading frames. They were both evaluated as diagnostic antigens by Schouls et 
al. (1989) using an enzyme immunoassay format. TpN36 was found to be non reactive with a high 
proportion of the specimens tested and so was considered unsuitable for use as a single diagnostic 
antigen. TpN44.5 was evaluated much more extensively. It detected 21 out of 24 untreated primary 
syphilis cases giving a sensitivity of 87.5%. All the specimens that were positive by FTA-ABS were 
also positive in the recombinant assay. It was positive with all secondary (25) and latent (19) 
specimens tested, which were also all positive by VDRL and FTA-ABS. It was tested against 
specimens from patients with treated syphilis, 30 VDRL positive cases and 30 VDRL negative 
cases, and found to detect 25 and 10, respectively. In a second study (Ijsselmuiden et al., 1989a) 
the assay detected 42 out of 55, or 76%, of untreated primary infections. Again, reactivity was 
almost universal in secondary and early latent cases, detecting 100% and 98% of cases, 
respectively. The lower sensitivity in this study in early infections was probably due to the inclusion 
of a number of specimens from dark field positive, FTA-ABS negative cases. Overall, the use of 
TpN44.5 as a single antigen produced results fairly similar to that expected from established 
treponemal tests, perhaps showing slightly less sensitivity in early primary infections. This test was 
licensed to Eurodiagnostics (Apeldoom, Netherlands), but never became commercially available 
nor was its performance reported in peer reviewed journals.
TpN47 has been thought to be the immunodominant antigen of T.pallidum and reactivity to it 
features prominently in the immune response to syphilis. So, it is puzzling as to why the literature 
contains so few publications of the use of TpN47 as an antigen in an immunoassay, and none by 
the group that originally cloned the protein. The use of TpN47 for the study, diagnosis and 
production of vaccines for syphilis was covered in a patent assigned to the University of Texas (WO 
8802403). As it is such a key protein in the immune response the patent rights were probably 
licensed for development of a commercial test. ADI Diagnostics (Ontario, Canada) produced an 
enzyme immunoassay which used non-acylated TpN47 as the solid-phase antigen which had little 
impact in the marketplace and there seems to be a lack of peer reviewed articles describing its
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performance. The company’s own product literature shows the sensitivity to be slightly lower in all 
stages of the disease than MHA-TP. This alone would probably mean the test would be of limited 
appeal to diagnostic laboratories.
Generally, the most surprising aspect is that although many proteins of T.pallidum have been 
cloned and the sequences are readily available in databases, very few have been evaluated as 
potential diagnostic antigens. From the work described above it can be seen that the use of single 
antigenic proteins has failed to yield the sensitivity required to produce superior performance to 
existing testing strategies. A combination of several antigenic proteins may be required to detect 
sufficient antibody specificities to provide adequate serodiagnosis at all stages of the disease, and 
hence attain the sensitivity required to replace existing tests.
Research objectives
Syphilis is a multi-stage disease with complicated antibody responses, where serological tests have 
to be effective over a wide range of disease presentations. The diagnostic tests currently in 
common use have limitations in terms of both sensitivity and specificity, which manifests as poor 
sensitivity in early primary infections and a high rate of false positive and negative reactions. This 
can mainly be attributed to the crude antigen preparations used in all existing sérodiagnostic tests. 
There is an obvious requirement for more specific and sensitive sérodiagnostic tests. There are 
also particular stages of the disease or complications where the deficiencies of the existing 
serological tests are more profound. In cases of HIV co-infection the antibody response is often 
undetectable by existing tests, and in congenital syphilis maternal antibody interferes, making the 
detection of foetal IgM an important diagnostic tool. These diagnostic applications are not supported 
by existing nontreponemal tests and haemagglutination assays. The diagnosis of neurosyphilis 
requires the detection of the organism in CSF, which is not easily achieved by microscopy, but is an 
application ideally suited to the use of PCR. Syphilis diagnosis still relies heavily on microscopy 
techniques and serological methods based on crude antigen preparations. The application of the 
techniques of modern molecular biology offers the opportunity to improve the accuracy of syphilis 
diagnosis. The use of recombinant proteins and enzyme immunoassay technology would improve 
the specificity and sensitivity of serological methods, immunoblotting could make confirmatory
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testing truly specific, and PCR technology could successfully detect the presence of live organisms
V
in body fluids. ,
However, this study is solely concerned with improved sérodiagnostic methods. The most obvious 
route to improved serological methods is through the use of recombinant proteins as antigens. This 
is a strategy that has had a major impact on sensitivity and specificity of sérodiagnostic procedures 
in many areas of infectious disease diagnosis. Considering the difficulties and expense of producing 
antigens in animals, it is surprising that recombinant protein antigens have not been utilised 
previously. Many of the proteins of T.pallidum have been cloned and sequenced. Generally, these 
proteins were isolated from cDNA libraries using immunoscreening methods, so most of them are 
antigenic to a greater or lesser extent. These represent a range of potential antigens for use in 
serological tests. However, the exact antigens that are diagnostically significant in syphilis is an 
area of controversy. Very few of the documented proteins have been evaluated as diagnostic 
reagents, and at the beginning of this project no tests using recombinant proteins were 
commercially available.
The initial objectives of this study were to confirm the diagnostically significant antigens of 
T.pallidum, by a combination of assessment of the literature and experimental work. Once 
identified, these antigens would become the targets for a series of experiments designed to clone, 
express and purify the recombinant proteins in order to provide material for evaluation. The 
antigenicity of each protein would be examined using sensitive immunoblotting techniques before 
being used for the development of an enzyme immunoassay method.
Although recombinant proteins are easier to produce and purer than native antigen, they still suffer 
some problems. Some recombinant proteins are difficult to express and purify, resulting in 
contamination with residual E.coli proteins. This can cause specificity problems due to 
crossreaction with antibodies to E.coli protein naturally occurring in the patient's serum. These 
problems are magnified when the immunoassay requires multiple recombinant proteins to express 
the antigenicity required for adequate diagnosis. These problems can be overcome by control of the 
purification scheme, but another solution is the use of synthetic peptide antigens which, due to the 
manufacturing process, offer the advantage of high levels of purity and are relatively inexpensive. In 
order to design suitable peptides it is essential to identify the sequences within the antigens 
responsible for their antigenicity. This is the subject of the second phase of the study reported here.
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The objective was to identify the epitopes within the protein to which the antibody response was 
directed, by using a series of overlapping peptides complementary to the protein sequence. This 
phase would be supported using a complementary technique, known as phage display, to gain 
additional information on the types of epitopes present within the antigens. If short antigenically- 
significant sequences could be identified, then synthetic peptides could be constructed to express 
the antigenicity. If multiple sequences were identified these could be joined to make a compound 
synthetic peptide antigen for use in serological tests. An alternative possibility would be to express 
the antigenic sequences as an artificial recombinant protein.
To summarise the key objectives:
e Identify the diagnostically significant antigens of T.pallidum.
• Produce recombinant versions of these antigens.
• Test the antigenicity of the recombinant antigens in the different stages of syphilis.
• Use the recombinant antigens to develop an enzyme immunoassay.
• Identify the sequences within each protein responsible from their antigenicity.
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General DNA manipulation methods 
Culture media
LB broth Amount/litre
Tryptone 10g
Yeast extract 5g
NaCI 10g
Sterilise by autoclaving. LB agar was prepared by adding 1.5% (w/v) agar before autoclaving. LB 
top agar was prepared by adding 0.7% (w/v) agar before autoclaving.
NZY broth Amount/litre
Casein hydrolysate 10g
Yeast extract 5g
NaCI 5g
MgS04.7H20  2g
Sterilise by autoclaving. NZY agar was prepared by adding 1.5% (w/v) agar before autoclaving. NZY 
top agar was prepared by adding 0.7% (w/v) agar before autoclaving.
x10 M9 salts Amount/litre
NazHPCUJHzO 128g
KH2 PO4  30g
NaCI 5g
NH4CI 10g
Dissolve in water to a final volume of 1 litre and sterilise by autoclaving.
M9/+Thl minimal medium Amount/litre
16.8g of agarose was added to 1L of water and autoclaved. It was cooled to 50°C and the following
components added, mixed and dispensed into petri dishes.
x10M9 salts 100mL
20% glucose* 20mL
1M MgS04** 2mL
1M CaCI2** 0.1mL
10mg/mL thiamine* 1 m l
* 0.2pm filter sterilise
** autoclave separately
Bacterial strains (E.coli,)
XL-1blue
recA^, endAI, gyrA96 f/?/-1, hsdRM, supE44, relA1, lac-, F[proAB, /ac^ZAMIS TnlO(tef)]
XL-1 blue cells carry the F’ episome encoding pili that allows infection by filamentous M13 phage or 
phagemid vectors. The F’ episome can be maintained by growth in the presence of tetracycline. It 
contains the /acfZAM15 mutation which provides a-complementation of the p-galactosidase gene. 
This allows blue/white colour selection of recombinant colonies when supplemented with X-gal and 
lSbpropyl-p-D-thiogalactopyranoside (IPTG). The F’ episome encoded /acq produces 10-fold more 
lac repressor than is found in most host strains. This ensures stringent repression of any effects 
from cloned inserts. XL-1 blue cells are restriction negative (hsdR17), recombination (recA1) and
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endonuclease deficient (endA1). These mutations prevent the cleavage of cloned DNA, enhance 
insert stability and improve plasmid minipreps, respectively. XL-1 blue was used for all routine 
cloning experiments. The strain was maintained by growth on LB agar containing 12.5pg/mL 
tetracycline.
TG1
supE, hsdA5, thi, A(lac-proAB), F[traD36, proAB+ lacP /acZAM15]
TG1 cells carry the F' episome which allows infection by filamentous M13 phage and phagemids. 
The F’ episome is maintained by growth on M9/+Thi minimal medium. Single colonies can be 
picked and grown up in LB broth with no practical loss of the F’ episome, however repeated 
passage must be avoided. This strain was used to grow and amplify the fUSE2 expression library.
SOLR™
e14-(mcrA), A(mcrCB-hsdSMR-mrr) 171, sbcC, recB, reed, umuC.:Tn5(kanr), uvrC, lac, gyrA96, 
relA, f/w-1, endA*], XR, F\proAB, /ac/^ ZAMIS] Su- (nonsuppressing)
SOLR cells are provided with the SurfZAP vector kit When SOLR host cells containing the 
amplified phagemid library are infected with M13 helper phage, the phagemid is replicated as single 
stranded DNA and is packaged into M13 particles. SOLR cells are a supO strain and so allow the 
replication of phagemid DNA, but not the expression of the helper phage proteins. Therefore, the 
helper phage genome is not replicated but is lost from the SOLR cells as the library is amplified. 
SOLR cells are cultured on LB agar containing SOpg/mL kanamycin.
BL21(DE3)
F-, orripT, hsdSB (rB-mB-), gal, dcm, (DE3)
In pET vectors, target genes are cloned under the control of strong bacteriophage T7 transcription 
and translation signals. Expression is induced by providing a source of T7 RNA polymerase in the 
host cell. Constructs are transferred into an expression host containing a chromosomal copy of the 
T7 RNA polymerase gene under lacUVS control, expression is induced by the addition of IPTG. 
BL21(DE3) carries a chromosomal copy of T7 RNA polymerase gene under the control of the 
lacUV5 promoter. This makes it suitable for the production of protein from genes cloned in pET 
vectors.
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MC1061
araD139, A(ara, leu)7697, A(lac)%7A, galil, galK, hsdR2, strA, mcrA, mrcBI
This is a recA+ strain that shows high electroporation efficiency and was used to produce the
fUSE2 expression library.
Ligation
Ligation of restriction fragments was achieved using a Stratagene ligation kit according to the 
manufacturer’s recommendations. Wherever possible forced directional cloning or 
dephosphorylated vectors were used. For blunt-end ligation dephosphorylated vectors were used 
and ten-fold more T4 DNA ligase was used in the reaction.
Restriction digestion
All restriction enzymes were used in accordance with the manufacturer’s recommendations. 
Generally, material was digested with an excess of around 10-fold (i.e. 5U of enzyme per 1pg of 
DNA for 2 hours at the recommended temperature).
Phenot/chloroform purification
An equal volume of phenol:chloroform:isoamyl alcohol (Sigma, 25:24:1) was added to the nucleic 
acid sample in an eppendorf tube. The contents were mixed vigorously until an emulsion formed. 
The tube was centrifuged in a MSB microfuge at 13000rpm for 2 mins to separate the organic and 
aqueous phases. The top aqueous phase was transferred to a fresh tube. An equal volume of water 
was added to the organic phase and mixed vigorously. The phases were partitioned by 
centrifugation as described above. The top aqueous phase was removed and added to the aqueous 
phase from the first extraction. The phenol/chloroform extraction was repeated until no protein was 
visible at the solvent interface. An equal volume of chloroform was added to the nucleic acid sample 
and mixed vigorously until an emulsion formed, then centrifuged in a MSB microfuge at 13000rpm 
for 2 mins to separate the organic and aqueous phases. The top aqueous phase was transferred to 
a fresh tube and the lower organic phase and interface discarded. The DNA was recovered by 
precipitation with ethanol.
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Ethanol precipitation
A 1/10 volume of 3M sodium acetate, pH5.3 was added to the nucleic acid and mixed. Exactly two 
volumes of ice-cold ethanol was added and mixed. The tube was stored on ice for two hours to 
allow the DNA to precipitate. The DNA was pelleted by centrifuging at 13000rpm in a MSB 
microfuge in a cold room. The supernatant was carefully aspirated and the tube half filled with 70% 
ethanol. The tube was spun at 13000rpm for 2 mins and the 70% ethanol aspirated. The tube was 
store open on the bench at room temperature until all fluid had evaporated. The DNA pellet was 
dissolved in an appropriate quantity of purified water.
Preparation of competent cells
A single E.coli colony was inoculated into 50mL of LB agar and agitated at 37°C until an 
absorbance of 0.5 at 600nm was reached. The culture was cooled on ice for 10 mins and spun at 
2000g for 10 mins. The cell pellet was drained thoroughly then resuspended in a volume of RF1 
that was 1/3 of the original culture volume. The cells were incubated for 15 mins on ice then 
pelleted as described above. The cell pellet was resuspended in a volume of RF2 that was 1/12.5 of 
the original culture volume. The cells were incubated on ice for 15 mins, then aliquoted in 1OOpL 
amounts in microfuge tubes and snap frozen. Competent cells were stored ready to use at -80°C 
for up to 4 weeks.
RF1 Amount/litre Final concentration
RbCI 12g 100mM
MnCl2.4H20  9.9g 50mM
1M Potassium acetate, pH7.5 30mL 30mM
CaCI2.2H20 1.5g 10mM
Glycerol 150g 15% (w/v)
Adjust to pH5.8 with 0.2M acetic acid and 0.2pm sterile filter.
RF2 Amount/litre Final concentration
0.5M MOPS (pH6.8) 20mL 10mM
RbCI 1.2g 10mM
CaCi2.2H20  11g 75mM
Glycerol 150g 15% (w/v)
Adjust to pH6.8 with NaOH and 0.2pm sterile filter.
Transformation
Cells were transformed with a maximum of O.ông of ligation reaction per pL of competent cells. The 
cells were thawed on ice and the ligation reaction added to the tube. The competent cell/ligation 
mixture was incubated on ice for 30 mins, then heat shocked at 42°C for 2 mins before returning to 
the ice for a further 5 mins. 500pL of warm LB broth was added and the culture incubated for 1 hour
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at 37°C. The cells were plated on to LB agar plates containing the appropriate antibiotic for the 
vector being transformed using a sterile glass spreader. The plates were incubated overnight at 
37°C in a warm air oven.
Agarose gel electrophoresis
Horizontal agarose gel electrophoresis was used to analyse and purify DNA fragments. The 
agarose concentration used depended on the size of fragments to be resolved. Concentrations of 
0.7 and 2.5% were used. Agarose was dissolved in x1 TBE or TAB buffer by heating in a 
microwave, allowed to cool before ethidium bromide was added to O.ôpg/mL. The agarose was set 
in the electrophoresis tank tray and submerged in x1 TAB or TBE as appropriate. DNA was diluted 
in x6 Loading buffer, added to the well in the agarose gel in a horizontal submarine electrophoresis 
apparatus (Bio-Rad). The gel was run at no more than 5V/cm until the tracking dye reached the end 
of the gel. The DNA was visualised under UV illumination.
x6 Loading buffer Amount/Litre
Bromophenol blue 2.5g
Glycerol 300mL
Dissolved in purified water and made up to 1 L.
x10 TBE buffer Amount/Litre
Tris base ' 54g
Boric acid 27.5g
0.5M EDTA, pHB.O 20mL
Dissolved in purified water and made up to 1 L
x50 TAB buffer Amount/Litre
Tris base 242g
Glacial acetic acid 57.1 mL
0.5M EDTA, pH8.0 100mL
Dissolved in purified water and made up to 1 L.
Purification of DNA
Gel purification of restricted DNA was used as a method to obtain fragments of interest for 
subsequent cloning. DNA was separated as described above using a 0.7% TAB low melting point 
gel containing no ethidium bromide. The gel was stained in a 0.5pg/mL ethidium bromide solution 
for 30 mins, then destained for 30 mins in water before visualising the DNA under UV illumination. 
The band of interest was excised from the gel with a scalpel blade and placed in a pre-weighed 
microfuge tube. The DNA was purified using a Qiagen DNA Gel Extraction Kit according to the 
manufacturer's instructions followed by ethanol precipitation. The DNA was redissolved in a suitable 
volume of purified water.
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Polymerase chain reaction
The polymerase chain reaction (PCR) was used to amplify DNA sequences used in the generation 
of various plasmid constructs detailed later.
The primers were designed specifically to meet the needs of each amplification. Their melting 
temperatures were calculated using the formula; Tm(°C)=64.9+0.41(%GC)-€00/N
The PCR was setup in 0.5mL eppendorf tubes as follows:
T emplate DNA ~ 0.1 pmol
Forward primer (1 Opmol/L) 5pL
Reverse primer (1 Opmol/L) 5pL
x10 PCR buffer (Gibco BRL) 5pL
50 mmol/L MgCI2 1 5pL
10 mmol/L dNTPs 1 pL
Taq polymerase (Gibco BRL) 0.5pL
The volume was made up to 50pL with purified water and 50pL of mineral oil was placed on the top 
to prevent evaporation during the thermal cycling. The reactions were placed in a PTC-100 thermal 
cycler (MJ Research) and denatured for 5 minutes at 930C, followed by 30 cycles of 60 secs at 
93°C( 60 secs at Tm-5°C and 90 secs at 72°C.
The thermal cycle was modified for primers designed with a non-complementary 5' end. A lower 
annealing temperature corresponding to the Tm of the complementary region of the primers was 
used for 5 cycles, followed by 30 cycles at an annealing temperature suitable for the whole primer.
Purification of M13 phage particles
10mL of culture was spun at OOOOg for 10 mins and the phage containing supernatant transferred to 
a fresh tube. 200pL of 30%PEG/2.5M NaCI was added for every 1mL of supernatant, mixed well by 
inversion and incubated at room temperature for 15 mins. The precipitate was pelleted by 
centrifuging at 10,000g for 10 mins and the supernatant aspirated and discarded. The pellet was 
resuspended in 1mL of TE buffer, transferred to a microfuge tube and spun at 10,000 rpm in a MSE 
microfuge for 10 mins to pellet the cell debris. The supernatant was transferred to a fresh microfuge 
tube and the PEG precipitation repeated. The final phage pellet was resuspended in 100pL of TE 
buffer and stored at 4"C.
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Phage titration
Suitable plating bacteria were prepared by the method described in Sambrook et al. (1989). The 
phage suspension was 10-fold serially diluted in TE buffer. 1pL-1OpL of diluted phage was added to 
100pL of plating bacteria and incubated at room temperature for 5 mins to allow the phage to attach 
to the cells. The cells were then spread on to LB agar plates containing a suitable antibiotic 
complementary to the phage resistance marker and incubated overnight at 37°C.
Lambda phage was titrated by plaque counting. The phage suspension was 10-fbld serially diluted 
in SM buffer. 1pL-1OpL of diluted phage was added to 100pL of plating bacteria and incubated at 
37°C for 15 mins to allow the phage to attach to the cells. 3mL of melted NZY top agar was added 
to each sample and the agar immediately poured on to warm NZY plates. The top agar was allowed 
to set. The plates were inverted and incubated for 6-8 hours at 37°C for plaques to become visible.
the  titre (cfu/mL or pfu/mL) was determined by counting the number of colonies or plaques formed 
and using the formula;
Titre(cfu/mL or pfu/mL) = (number of colonies x dilution factor x 1000) / phage volume plated (pL)
SDS-PAGE
SDS-polyacrylamide electrophoresis was used to separate protein mixtures according to relative 
molecular weight to assess them qualitatively and semi-quantitatively. Samples were 
electrophoresed using a Mini-protean II apparatus (Bio-Rad) according to manufacturer's 
instructions, which are based on the method of Laemmli (1970). Briefly, samples were diluted in 
sample buffer and 5pL loaded into each lane of a 12% gel and electrophoresed at 150v until the 
tracker dye reached the bottom of the gel. The gel was removed from the glass plates and stained 
with Coomassie R-250 stain for 30mins, then destained with repeated changes of destain solution 
until the background was clear. They were then dried onto blotting paper using a vacuum gel drier 
set at 80°C for 2 hours.
Sample buffer Amount
Purified water 4.0mL
0.5M Tris-HCI, pH6.8 1.0mL
Glycerol 0.8mL /
10% (w/v) SDS 1.6mL
2-pmercaptoethanol 0.4mL
0.05% (w/v) Bromophenol blue 0.2mL
Samples were diluted at least 1:4 with sample buffer and heat at 95°C for 4 mins
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Running gel (12%) Amount
Purified water 3.35mL
1.5M Tris-HCI, pH8.8 2.5mL
10% (w/v) SDS 100pL
37.5:1 Acrylamide/Bis (30% stock) 4.0mL 
10% (w/v) Ammonium persulphate 50pL 
TEMED 5pL
Stacking gel (4%) Amount
Purified water 6.1mL
0.5M Tris-HCI, pH6.8 2.5mL
10% (w/v) SDS 100pL
37.5:1 Acrylamide/Bis (30% stock) 1.6mL 
10% (w/v) Ammonium persulphate 50pL 
TEMED 10pL
Electrode buffer (x5), pH8.3 Amount/Litre
Tris base 15g
Glycine 43.2g
SDS 3g
60mL x5 stock was diluted with 24OmL of purified water to make sufficient buffer for one 
electrophoresis run.
Stain Amount/Litre
Coomassie Brilliant Blue R250 2.5g
Methanol 450m L
Water 450m L
Glacial acetic acid 100mL
Destain
Methanol
Water
Glacial acetic acid
Amount/Litre
200mL
725mL
75mL
Western blotting
Samples from SDS-polyacrylamide gels were transferred onto nitrocellulose using a Trans-Blot 
apparatus (Bio-Rad) according to the manufacturer's instructions. Briefly, gels were laid onto wetted 
Whatman 3M filter paper and a sheet of Hybond-C nitrocellulose (Amersham) applied to the upper 
surface, followed by another sheet of 3M paper. This was sandwiched between two porous pads 
and submerged in transfer buffer in the Trans-Blot tank. The proteins were transferred overnight at 
0.1mA.
Transfer buffer (pH8.3)
Glycine 
Tris base 
SDS
Methanol
Amount/litre
2.9g
5.8g
0.37g
200mL
Final concentration
39mM 
48mM 
0.037% (w/v) 
20% (v/v)
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The nitrocellulose was remove from the gel and blocked by incubating in PBS containing 0.05% 
Tween 20 and 1% (w/v) dried milk powder for 1 hour at room temperature. The specific primary 
antibody was diluted in the same solution and the nitrocellulose incubated for 1 hour with gentle 
agitation. The primary antibody was aspirated and the nitrocellulose washed four times with PBS 
containing 0.05% Tween 20 by sequential buffer changes. The second antibody, a species specific 
anti-lg antibody labeled with horseradish peroxidase, was diluted 1:1000 in PBS containing 0.05% 
Tween 20 and 1% (w/v) dried milk powder and incubated with the nitrocellulose for 1 hour with 
gentle agitation. The nitrocellulose was washed four times as previously described. The blot was 
developed using the substrate 4-chloro-1-napthol in the form of the HRP Substrate Kit (Bio-Rad). It 
was made to working strength as described in the manufacturer's instructions, added to the 
nitrocellulose membrane and allowed to develop to the required colour intensity. The reaction was 
stopped by decanting the substrate and washing the membrane several times with purified water. 
The resulting banding patterns were analysed using GelCompai™ (Applied Maths, Kortrijk) 
electrophoresis analysis software where appropriate.
Serum panels
A panel of disease stage characterised serum specimens, consisting of 18 patients classified with 
early primary syphilis, 36 patients with late primary or secondary syphilis, 18 patients with latent 
syphilis, 20 patients with successfully treated infections, and 12 patients confirmed as biological 
false positives was obtained from Dr. S. I. Egglestone (Bristol Public Health Laboratory, UK). These 
specimens were classified by the supplier using a combination of clinical presentation and the 
results of VDRL, TPHA, and FTA-ABS results, which were supplied with the specimens.
A panel of 7 Lyme disease positive sera was obtained with testing data from a commercial supplier, 
Boston Biomedical (Boston, MA).
A panel of serum specimens consisting of 25 patients with well established infections or 
reinfections, characterised by high antibody titres and 76 non-selected serum specimens positive 
for syphilis from a genito urinary clinic were obtained from Dr. D. J. Merry (Institute of Medical and 
Veterinary Science, Adelaide, South Australia). These specimens were supplied with limited clinical 
data and serological testing results, and so were tested using the Captia® Syphilis-G test according 
to the manufacturer's instructions.
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Serum specimens from healthy blood donors and antenatal patients, with no history of syphilis, 
were obtained from North London Blood Transfusion Centre. Although some testing data was 
provided, the specimens were tested using the Captia® Syphilis-G test according to the 
manufacturer’s instructions.
Antisera
Rabbit antisera specific for T.pallidum was supplied from archived sources by Dr. J. A. Carney 
(Centocor UK Ltd) and Prof. C. W. Penn (University of Birmingham). Before use it was tested by 
western blotting against antigen derived from whole T.pallidum organisms to confirm the activity had 
not decayed on storage, and the claimed specificity was correct.
Cloning and expression of the major lipoproteins 
pET10
This construct was provided by Ms. A. Ivic and Prof. C. W. Penn, University of Birmingham. It 
consists of the whole tpnA4.5 gene inserted between the A/del/A/ofl sites in the multiple cloning site 
of the pET21 b vector.
pET17
This construct was provided by Ms. A. Ivic and Prof. C. W. Penn, University of Birmingham. It 
consists of the whole tpnM gene inserted between the A/del/A/ofl sites in the multiple cloning site of 
the pET21b vector.
pETSO
This construct was provided by Ms. A. Ivic and Prof. C. W. Penn, University of Birmingham. It 
consists of the whole tpn2A-2S gene inserted between the A/del/A/ofl sites in the multiple cloning site 
of the pET21 b vector.
pETSOREP
This construct was provided by Ms. A. Ivic and Prof. C. W. Penn, University of Birmingham. It 
consists of the tpn2A-2Q gene, excluding the upstream acétylation sequence, inserted between the 
Ndel/Notl sites in the multiple cloning site of the pET21b vector.
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pET60
This construct was provided by Ms. A. Ivic and Prof. C. W. Penn, University of Birmingham. It 
consists of the whole (pn15 gene inserted between the A/del/A/ofl sites in the multiple cloning site of 
the pET21b vector.
pET60REP
This construct was made by PCR amplification of /pn15, excluding the upstream acétylation 
sequence, using the primers 5* GTTGCTTGGGCATATGTCATTTAGTTC 3‘ and 5* 
GCGCGGCCGCCCTGCTAATAATGGCTTCC 3’. The PCR product was Ndel/Notl digested, gel 
purified and the DNA recovered using Qiagen Gel Extraction kit followed by ethanol precipitation. 
The DNA was ligated with suitably digested pET21b vector DNA (Novagen), transformed into 
competent XL-1 Blue E.coli cells and plated on to LB agar containing 100pg/mL ampicillin. 
Transformants were screened for the correct insert by restriction digestion and agarose 
electrophoresis. The vector/insert junctions were checked by DNA sequence analysis.
LIC47
This construct was made by PCR amplification of tpnAl, excluding the upstream acétylation 
sequence, using the primers 5’ GACGACGACAAGATGGGCTCGTCTCATCATGAG 3' and 5' 
GAGGAGAAGCCCGGTCACTGGGCCACTACC 3’ which also modify the ends of the amplified 
fragment to incorporate the LIC cloning sequences. The PCR product was purified using Qiagen 
PCR purification kit and ethanol precipitated. The DNA was treated with T4 DNA polymerase as 
described in the manufacturer's instructions and annealed with pre-treated pET32LIC vector DNA 
(Novagen). The sample was transformed into competent XL-1 Blue E.coli cells and plated on to LB 
agar containing 100pg/mL ampicillin. Transformants were screened for the correct insert by 
restriction digestion and agarose electrophoresis The vector/insert junctions were checked by DNA 
sequence analysis.
UC1S
This construct was made by PCR amplification of /jpnlS, excluding the upstream acétylation 
sequence, using the primers 5 GACGACGACAAGATGTGTTCATTTAGTTCT 3* and 5* 
GAGGAGAAGCCCGGTTTCTACCTGCTAATA 3’. These primers modify the ends of the amplified 
fragment to incorporate the LIC cloning sequences and introduce an amber stop codon. The PCR
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product was purified using Qiagen PCR purification kit and ethanol precipitated. The DNA was 
treated with T4 DNA polymerase as described in the manufacturer's instructions and annealed with 
pre-treated pET32LIC vector DNA (Novagen). The sample was transformed into competent XL- 
1Blue E.coli cells and plated on to LB agar containing 100pg/mL ampicillin. Transformants were 
screened for the correct insert by restriction digestion and agarose electrophoresis. The 
vector/insert junctions were checked by DNA sequence analysis.
Protein expression
The recombinant plasmid was transformed into BL21(DE3) E.coli cells and plated for single 
colonies on LB agar containing lOOpg/mL ampicillin. In a 250 mL conical flask, 50mL of LB broth 
containing 100pg/mL ampicillin was inoculated with a single colony and grown at 37°C in a shaker 
incubator until the Ag» of the culture reached 0.6. Samples were taken as uninduced controls for 
examination by SDS-PAGE. IPTG was added to a final concentration of 1mM and the culture grown 
for a further 2 hours. The flask was cooled on ice for 5 mins and then the cells were harvested by 
centrifugation at 6000g for 10 mins. The supernatant was discarded and the pellet resuspended in 
ice cold 50mM Tris, pH8.0 buffer containing 1mM PMSF.
Protein purification
The cell pellet was kept on ice throughout the procedure. It was sonicated at power level 4 for 10 
cycles of 30 seconds on followed by 30 seconds rest using an Ultrasonix sonicator fitted with a 
microtip probe. The disrupted pellet was centrifuged at 10,000g for 10 mins, the supernatant 
discarded and the pellet resuspended in 10mM Tris, pH8.0 containing 6M guanidine. HCI. It was 
then respun at 10,000g for 10 mins and the supernatant transferred to a clean tube. 5mL of 
equilibrated Talon metal affinity resin (Clontech) was added and mixed on a roller mixer for 20 
mins The resin was spun at 7Q0g for 5 mins and the supernatant aspirated. 50mL of 1QmM Tris, 
pHS.O containing 8M urea was added and the tube mixed on a roller mixer for 10 mins. The tube 
was centrifuged at 700g for 5 mins and the supernatant aspirated. This wash procedure was 
repeated three more times, then 5mL of 10mM Tris, pH8.0 containing 8M urea and 100mM 
imidazole was added and mixed on a roller mixer for 10 mins. The tube was centrifuged at 700g for 
10 mins and the supernatant, containing eluted recombinant protein, aspirated and transferred to a
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fresh tube. This elution procedure was repeated three more times. The pre and post induction 
samples, and the four elution samples were analysed by SDS-PAGE.
Preparation of affinity purified antisera 
Affinity column preparation
Purified recombinant TpN47, TpN44.5, TpN17 and TpN15 and a lysate from E.coli BL21(DE3) cells 
were dialysed into 0.2M NaHC03, 0.5M NaCI, pH8.3 and the protein concentration estimated using 
a Bradford dye binding assay (Bio-Rad) following manufacturer's recommendations. 10mg of each 
of the proteins was coupled to separate 1 mL NHS-HiTrap columns (Pharmacia) following the 
manufacturer's recommendations using FPLC®. The efficiency of coupling was monitored by 
measuring the A^o of the protein solution before and after coupling as recommended by the 
manufacturer's. The coupling efficiencies ranged between 78% and 92%.
Affinity purification of antisera
The five affinity columns were coupled together in series with the E.coli lysate column first and 
connected to an FPLC® system. A SOOmL pool of syphilis positive human sera was diluted with an 
equal volume of PBS, 0.2pm filtered and applied to the columns at 1 mL/min. The flow from the 
column was collected for reuse. The columns were washed with 25-30mL of PBS or until the A^o 
trace returned to baseline. The columns were separated and eluted individually with 5mL of 0.2M 
glycine/HCI, pH2.2 which was collected in O.SmL fractions. All protein containing fractions were 
pooled and 150pL of 1M Tris/HCI, pH9.1 was added per mL of protein containing solution.
A second purification of the serum pool was conducted as described above and the eluted protein 
pooled with that obtained from the first purification run.
Enzyme immunoassay (EIA)
Plate coating
The coating concentration was optimised for each material to be immobilised. Simple coatings of 
single proteins were optimised by coating curve analysis. A range of concentrations of the material 
were coated under various conditions, and tested for functional activity using the chosen EIA 
format. The coating concentration was selected on the basis of the best compromise of a series of
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criteria; concentration, total activity, background signal, and dose response. Coatings of protein 
mixtures, where interactions between components complicate the picture, were optimised using 
statistical experimental design software (ECHIP version 6.04) to formulate and perform response 
surface analysis of a multifactorial mixture design. The optimal coating was selected using similar 
criteria to those applied to simple single protein coatings. The material to be immobilised was 
diluted to the optimal coating concentration, usually between 1 and lOpg/mL, in 0.01 M carbonate 
buffer (pH9.6). It was added at 100pL per well to Maxisorp 96-well microplates (Nunc), covered to 
prevent evaporation and incubated for 18 hours at room temperature. The wells were washed three 
times with PBS containing 0.05% Tween 20, then filled with a 5% (w/v) lactose containing 1% (w/v) 
dried milk powder and allowed to stand for 5 minutes. The lactose/dried milk powder solution was 
aspirated and any residual solution removed by inversion onto adsorbent paper towels. The plates 
were dried for 2 hours in a 37°C warm air oven, sealed in a foil pouch with a desiccant sachet and 
stored at 4°C until required.
Assay procedure
Samples to be tested were diluted 1:21 in PBS, pH7.4 containing 0.05% Tween 20 and 1% dried 
milk powder. 100pL of diluted sample was added to each well, the plate was sealed to prevent 
evaporation and incubated at 37°C for 1 hour, The plate was washed five times with PBS containing 
0.05% Tween 20 and blotted dry on to adsorbent paper towels. Monoclonal anti-human 
IgG/horseradish peroxidase conjugate (Sigma I-2067) was diluted 1:15000 in PBS, pH7.4 
containing 0.05% Tween 20. 100pL of diluted conjugate was added to each well, the plate was 
sealed to prevent evaporation and incubated at 37°C for 1 hour. The plate was washed five times 
with PBS containing 0.05% Tween 20 and blotted dry on to adsorbent paper towels. Working 
strength substrate was prepared by adding 25pL of TMB chromogen to each 1mL of substrate 
solution. 100pL of working strength substrate solution was added to each well and incubated at 
room temperature for 30 mins. The enzyme reaction was stopped by adding 100pL of 0.25M H2SO4 
to each well, mixed and the adsorbance read at 450 nm using a Multiskan plate reader 
(Labsystems).
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Substrate solution
Glacial acetic acid 
Sodium acetate.3H20  
Disodium EDTA.2H20  
Sodium perborate.3H20  
Purified water 
Target pH 4.47
Amount
2.2g
1.8g
1.5g
0.74g
1000g
TMB chromogen
Dimethylsulphoxide (sg ~1.1) 
3,3'5,5'-tetramethylbenzidine 
Eosin B (spirit soluble)
Amount
110g
ig
0.02g
Synthetic peptide epitope mapping 
Peptide synthesis
The amino acid sequences of TpN47, TpN44.5, TpN17 and TpN15 were determined from the DNA 
sequences held on the Genebank database and used to design sets of overlapping peptides to 
cover each of the sequences. TpN47 was mapped using 101 14-mer peptides offset by 4 aa with 
an overlap of 8 aa covering the mature protein sequence from residue 21 through to residue 434 at 
the C-terminus. TpN44.5 was mapped using 79 14-mer peptides offset by 4 aa with an overlap of 8 
aa, except the last peptide which was offset by only 1 aa. The peptides covered the sequence from 
residue 23 to final residue, 345. TpN17 was mapped using 42 12-mer peptides offset by 3 aa with 
an overlap of 9 aa covering the sequence from residue 22 through to residue 176. TpN15 was 
mapped using 58 10-mer peptides offset by 2 aa with an overlap of 8 aa covering the sequence 
from residue 18 to the end at residue 141. These peptides along with control peptides, PLAQ 
(positive) and GLAQ (negative), were synthesized using commercially available epitope mapping 
system (Chiron Mimotopes Pty) according to the manufacturer's instructions. The completion of 
each successive amino acid coupling was confirmed by the presence of bromophenol blue in the 
reaction.
200pL/well of PBS containing 0.1% Tween20 and 2% (w/v) BSA was dispensed into a microplate. 
The pins were inserted into the plate and incubated for 1 hour at room temperature on a rotating 
platform (100rpm). The pins were removed and washed once in a bath of PBS for 10mins on a 
rotating platform (100rpm). The test antibody was diluted 1:1000 in PBS and 200pL/well dispensed 
into the wells of a microplate. The pins were inserted into the wells, sealed in a box to prevent 
evaporation and incubated overnight at room temperature on a rotating platform (100rpm). The pins
Testing
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were washed four times in a bath of PBS for 10 mins per wash using fresh PBS each time. 
Monoclonal anti-human IgG/horseradish peroxidase conjugate (Sigma I-2067) was diluted 1:5000 in 
PBS, pH7.4 containing 0.05% Tween 20 and 200pL/well dispensed into a microplate. The pins were 
inserted and incubated for 1 hour at room temperature on a rotating platform (100rpm), then 
washed four times as previously described. 150pL/well of working strength substrate was 
dispensed into the wells of a microplate and the pins inserted. The colour development reaction 
was allowed to proceed for 30 mins before being stopped by the addition of 150pL of 0.25M H2SO4. 
The well contents were mixed and their absorbances read at 450nm using a Multiskan plate reader 
(Labsystems).
Removal of antibody
The blocks of pins were immersed in PBS containing 1% (w/v) SDS and 0.1% (v/v) 2- 
pmercaptoethanol in a sonicator bath, preheated to 60°C, and sonicated for 10 mins. The pins were 
rinsed twice in purified water, preheated to 60°C, for 30 seconds. Then they were washed for 30 
minutes in a bath of purified water at an initial temperature of 60°C on a rotating platform. The pins 
were shaken dry and immersed in a bath of methanol, preheated to 60°C, for 15 seconds. The pins 
were air dried for at least 15 mins before being ready for another test. Alternatively, the pins were 
sealed in a foil bag with desiccant at 4°C until required.
PCR synthesized random gene fragment library 
Overview
The method below describes the construction of four separate random gene fragment libraries, one 
for each of the four major lipoproteins of T.pallidum, in the SurfZAP vector system (Stratagene). 
The SurfZAP vector encodes the N-terminal portion of the pelB leader sequence, upstream of the 
Notl restriction site. Therefore, the 5' end of the cloned inserts must include the remainder of the 
pelB DNA sequence located between the Notl site and the N-terminus of the fusion protein. The 3’ 
end of the DNA inserts were designed to be in-frame with the spacer-gene III sequence and 
included the Spel restriction site. Suitable inserts were prepared by a nested PCR method. DNA 
sequences corresponding to the tpnA7, tpnA4.5, tpnW and fpn15 genes were obtained by PCR 
amplification. This DNA was used as the template for an amplification reaction using primers with 
10 random bases at the 3’ end, which at a low annealing temperature allows for random priming.
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The DNA from this reaction was PCR amplified using primers complementary to just the 5* end of 
the original primers. The amplified DNA was ligated into the SurfZAP vector and converted into 
phage particles using helper phage. The recombinant phage particles display random polypeptide 
sequences as fusion proteins at the N-terminus of the cplll protein. This gene-targeted random 
epitope library was screened by affinity selection for recombinant phage which were specifically 
bound by the antibody of interest.
Library construction
Genomic DNA was isolated from T.pallidum subsp. pallidum (Nichols strain) using IsoQuick DNA 
extraction kit according to the manufacturer's instructions. The genomic DNA was used as the 
template in PCRs to obtain separate samples of tpn47, tpnAA.5, tpnM and (pn15 DNA. The primers 
used are shown below.
Primer Designation Sequence Tm
tpnA7 forward 47S 5' CGG AGGT GTAC ATAT G AAAGT GAAATACGC 3’ 62°C
tpnA7 reverse 47T 5’ ACACCCCTCTCGAGCTGGGCCACTA 3' 67°C
tpnAA.5 forward TmpA1 5* GCGC ATAT GAATGCT CATACGCTT GT GTAC 3’ 64°C
tpnAA.5 reverse TmpA2 5’ GCGCGGCCGCTCGAGAGGCTCCTTCTTCGT 3’ 74°C
tpn'l 7 forward SP8PROM 5' GCGCATATGAAAGGATCTGTCCGCGCG 3" 66°C
tpn17 reverse SP8TERM 5’ GGGGCGGCCGCTTTCTTTGI I I I ITTGAGC 3' 67°C
fpnl 5 forward 60P2 5’ GCGGC ACTCGG AGGT CATATGGTG 3' 65°C
tpn'l 5 reverse 60T 5’ GCGCGGCCGCCCTGCTAATAATGGCTTCC 3’ 71 °C
The reaction was run for 30 cycles of 93°C for 60 secs, 60°C for 60 secs and 72°C for 90 secs. The
PCR products were purified using Qiagen PCR purification kit according to the manufacturer's
instructions.
Generation of inserts
Each of the DNAs were used in separate PCRs to generate separate sets of random gene 
fragments. Sixteen PCRs were set up using the primers 5’ 
CTCGCTCGCCCATATGCGGCCGCAGGTCTCCTCCTCTTAGCAGCACAACCAGCAATGGCCXX 
XXXXXXXX 3" and 6’ GCCGGCCCGCCCAGCATCACTAGTXXXXXXXX 3’ where X represents a 
random base. The reactions were setup to the standard composition, except much more template 
was used in each reaction compared to a normal PCR. Template to primer ratios of 1:1, 1:2, 1:5 
and 1:10 were used. The reactions were run for five cycles of 93° for 60 secs, 20°C for 60 secs and 
72*C for 90 secs. The four reactions from each gene were pooled and purified using Qiagen PCR 
purification kit to remove unused primers and primer dimers. The purified DNA was used as the
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template for a second PCR using primers 5’ CTCGCTCGCCCATATGCGGCCGCA 3’ and 5* 
GCCGGCCCGCCCAGCATCACTAGT 3’. The reaction was cycled 93°C for 60 secs, 60°C for 60 
secs and 72°C for 90 secs for 35 cycles. The reaction was purified using Qiagen PCR purification 
kit.
Restriction digestion, ligation and packaging
The purified DNA was digested with an excess of A/ofl and Spel restriction enzymes and ligated 
with pretreated SurfZAP lambda arms (Stratagene) with positive and negative controls. The DNA 
from the ligation reaction was packaged directly using Gigapack II Plus packaging extract 
(Stratagene) and plaque titrated on NZY plates using XL1-Blue Eco//cells.
Characterisation of library
10 discrete plaques were randomly cored from a titration plate and eluted into 1mL of SM buffer. 
The suspension was spun at 10,000g for 10 mins in a microfuge to pellet any debris and 
resuspended in SM buffer. The phage stock was used as the template in a PCR designed to 
amplify across the cloning site of the vector. The upstream primer was (T3 promoter) 5’ 
ATTAACCCTCACTAAAGGGAA 3' and the downstream primer (T7 promoter) 5’ 
CCCTATAGTGAGTCGTATTA 3'. The components of the reaction were as previously described 
and the thermal cycle was 25 cycles of 93°C for 60 secs, 50°C for 60 secs and 72°C for 90 secs. A 
5pL aliquot of each reaction was electrophoresed through a 2.5% agarose gel containing 0.5pg/mL 
ethidium bromide and visualised under UV illumuination. A modification of this method was also 
used to determine the size of the inserts in a selection of colonies isolated after biopan enrichment 
of the library. The modification being that the template used was pSurfscript SK- plasmid DNA 
isolated by a miniprep method rather than lambda phage particles.
Amplification
The phage (10s pfu ) were mixed with 100pL of plating bacteria and incubated at 37°C for 20 mins. 
3mL of molten (50°C) NZY top agar was added and mixed. The agar was poured onto a warmed 
NZY agar plate and swirled to spread. It was allowed to cool before being inverted and incubated at 
37°C for 8 hours. 5mL of SM buffer was added to each plate and stored at 4°C for 2 hours with 
gentle agitation. The liquid was harvested and a further 1mL of SM buffer added and agitated for 15 
mins. The plates were inclined to allow the fluid to drain and as much SM buffer as possible to be
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harvested. The SM buffer was spun at 4000g for 10 mins and the supernatant aspirated into a 
sterile tube. DMSO was added to 7% (v/v) and stored at -80°C. The number of phage was 
estimated by plaque titration on NZY plates using XL1-Blue E.coli cells. This represents the 
amplified lambda libraries.
Mass excision and amplification
In a 50mL conical tube, SurfZAP bacteriophage and XL1-Blue were combined at a mutiplicity of 
infection of 1:10 lambda phage to cell ratio. ExAssist helper phage was added at a 1:1 helper phage 
to cell ratio. The mixture was incubated for 15 mins at 370C, then 20mL of LB broth was added and 
the tube incubated with gentle agitation for 3 hours at 37°C. The culture was placed in a water bath 
heated to 70°C for 20 mins to lyse the lambda phage particles and the XL1-Blue cells. The tube 
was centrifuged at 2500g for 10 mins to pellet the debris and the supernatant transferred to a fresh 
tube. The excised phagemid particles were stored at 4°C. The number of particles (cfu) excised 
was determined by titration on LB agar plates containing 100pg/mL ampicillin. The excised 
phagemids were amplified in SOLR E.coli cells to eliminate the ExAssist helper phage genome 
from the library. SOLR E.coli cells were mixed with the excised supernatant so that there was at 
least one cell per phagemid. The cells were incubated with the phagemids at 37°C for 15 mins. 
100mL of LB broth containing 100|jg/mL carbenicillin, 50pg/mL kanamycin and 1% (w/v) glucose 
was added and the culture incubated with shaking at 37°C until an Aeoo of 1.0 was reached. The 
culture was centrifuged at 1000g for 10 mins to pellet the cells. The cells were resuspended in 
10mM MgS04 and stored overnight at 4°C.
Conversion to phage particles
The SOLR E.coli cells were grown to an Aeoo of 0.2, centrifuged and 10® cells resuspended in 1mL 
of LB broth. 1010 VCSM13 helper phage were added and incubated at 37°C for 15 mins. 1OmL of 
LB broth containing lOOpg/mL carbenicillin and 50 pg/mL kanamycin was added and the culture 
grown at 37°C with gentle agitation until an Aeoo of 1.0 was reached. The culture was centrifuged at 
2500g for 10 mins and the supernatant transferred to a fresh tube. The phagemid particles were 
purified by two PEG precipitations and finally resuspended in 1mL of TE buffer. The titre was 
determined by titration on to LB agar plates containing ampicillin. This represents a library of
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phagemid particles expressing the cplll fusion protein on the surface and containing the 
recombinant cplll fusion protein DNA sequence.
Affinity selection of phage displayed peptides
Purified igG (various) was diluted to 10|jg/mL In 10mM sodium carbonate buffer, pHd.6 and 1 mi- 
dispensed in to a Maxisorp Immunotube (Nunc). The tube was capped and incubated at room 
temperature for 18 hours. It was washed three times with PBS containing 0.05% Tween 20 using a 
wash bottle. Excess wash fluid was removed using a disposable pipette. The tube was blocked by 
adding 1 mL of PBS containing 2% dried milk powder and incubated at room temperature for 1 hour. 
Approximately 1010 library phage were added to a microfuge tube containing 1mL of PBS 
supplemented with 2% dried milk powder, 0.1%(v/v) E.coli/phage lysate (Stratagene) and 1pg/mL 
purified human IgG. The phage was incubated at 37°C for 1 hour. The blocking solution was 
aspirated from the coated tube and replaced with the diluted phage solution, mixed and incubated 
at 37°C for 3 hours with agitation. The tube was filled with PBS containing 0.05% Tween 20 using a 
wash bottle and thoroughly aspirated using a disposable pipette. This wash procedure was 
repeated a total of ten times. The bound phage was eluted by adding 1 mL of 0.2M glycine/HCI 
buffer, pH2.2 for a maximum of 10 mins. The eluted phage were aspirated into a sterile universal, 
neutralised by adding 150pL of 1M Tris, pH9.1 and 200pL of XL1-Blue plating bacteria was added. 
An aliquot of the eluted phage was retained for quantitation. The universal was agitated for 15 mins 
at 37°C to allow the phage to attach to the cells before 9mL of LB broth containing 100pg/mL 
carbenicillin was added. The culture was incubated for 1 hour at 37°C. 1010 VCSM13 helper phage 
were added before incubating for 1 hour at 37°C. Kanamycin was added to a final concentration of 
50 pg/mL and the culture incubated overnight at 30°C. It was spun at 6000g for 10 mins and the 
phage purified from the supernatant by two PEG precipitations. The eluted phage and the purified 
phage were titrated with XL1-Blue cells on LB agar containing lOOpg/mL ampicillin.
The biopanning procedure described above was repeated twice more, each time using the phage 
from the previous round as the starting material. In each successive round of biopanning the 
stringency of the wash protocol was increased. The second round was washed 15 times with PBS 
containing 0.1% Tween 20 and the third round was washed 20 times with PBS containing 0.5% 
Tween 20.
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DNasel digested random gene fragment library 
Overview
DNA sequences corresponding to the tpnAl, tpnAA.5, (p/?17 and fpn15 genes were obtained by 
PCR amplification. The pooled DNA was randomly digested with DNasel to generate a population 
of DNA fragments of different sizes and sequences. After size fractionation, small DNA fragments 
(50bp - 350bp) were isolated and cloned into the phage expression vector fUSE2 to form an 
expression library displaying random polypeptide sequences as fusion proteins at the N-terminus of 
the phage gene III protein. The fUSE2 phage display expression vector (Parmley and Smith, 1988) 
was supplied by Dr. D. H. du Plessis, Onderstepoort Veterinary Institute, South Africa. This gene- 
targeted random epitope library was screened by affinity selection for recombinant phage which 
were specifically bound by the antibody of interest
Library construction
Genomic DNA was isolated from T.pallidum subsp. pallidum (Nichols strain) using IsoQuick DNA 
extraction kit according to the manufacturer's instructions. The genomic DNA was used as the 
template in PCRs to obtain separate samples of tpnA7, tpnAA.5, tpnM and (pn15 DNA. The primers 
used are shown below.
Primer Designation Sequence Tm
tpnAl forward 47S 5’ CGG AGGT GTAC ATAT G AAAGT GAAATACGC 3’ 62°C
tpnAl reverse 47T 5' ACACCCCTCTCGAGCTGGGCCACTA 3’ 67°C
tpnAA.5 forward TmpA1 5’ GCGCATAT GAATGCT CATACGCTT GT GTAC 3’ 64°C
tpnAA.5 reverse TmpA2 5’ GCGCGGCCGCTCGAGAGGCTCCTTCTTCGT 3" 74°C
tpnM forward SP8PROM 5’ GCGCATATGAAAGGATCTGTCCGCGCG 3’ 66°C
tpnM reverse SP8TERM 5’ GGGGCGGCCGCTTTCTTTG I ITTTTTGAGC 3' 67°C
fpnl 5 forward 60P2 5' GCGGCACTCGGAGGTCATATGGTG 3" 65°C
fpnl 5 reverse 60T 5' GCGCGGCCGCCCTGCTAATAATGGCTTCC 3’ 71 °C
The reaction was run for 30 cycles of 93°C for 60 secs, 60°C for 60 secs and 72°C for 90 secs. The
PCR products were purified using Qiagen PCR purification kit according to the manufacturer’s
instructions.
A sample of the purified PCR products was electrophoresed through a 0.7% agarose gel containing 
0.5pg/mL ethidium bromide, examined and quantitated under short wavelength UV illumination, The 
four DNA species were pooled in equimolar proportions. A trial DNasel digestion was performed to 
determine to optimal conditions required to produce fragment of the desired size. DNasel 
(Promega RNase-free, DNase 1000U/mL) was double diluted from 10U/mL to 0.3125U/mL in
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DNasel buffer (50mM Tris buffer, pH 7.6 containing 1mM MnCI2). 1pg of DNA was combined with 
1pL of x10 DNasel buffer, 1pL of 1mg/mL acetylated BSA and made up to 10pL with purified 
water. All tubes were chilled on ice. 3.5pL of each diluted DNasel was added to separate tubes, 
mixed and transferred a 15°C waterbath for exactly 10 mins. The digestion was stopped by adding 
2pL of stop solution (70% glycerol, 75mM EDTA, 0.3% bromophenol blue) to each tube. The 
contents of each tube was electrophoresed through a 2.5% agarose gel containing 0.5pg/mL 
ethidium bromide and visualised under UV illumination.
DNasel concentrations of 1.25U/mL and 2.5U/mL were selected to digest the bulk of the DNA. 
Reactions were set up each containing 30mg of pooled DNA dissolved in DNasel buffer. 30pL x10 
DNasel buffer, 30pL 1 mg/mL acetylated BSA and purified water to 300pL. All reactions were 
chilled on ice. 105pL of DNasel diluted in DNasel buffer was added and the reactions transferred 
to a 15°C waterbath for exactly 10 mins. The digestion was stopped by adding 30pL of 250mM 
EDTA. 1 mg of DNA was removed from each reaction and electrophoresed through a 2.5% agarose 
gel containing 0.5pg/mL ethidium bromide and visualised under UV illumination to determine if the 
scale-up digestion had performed as predicted. The two digestions were pooled and the DNA 
purified by phenol/chloroform extraction and recovered by ethanol precipitation.
The DNA was dissolved in water and combined in an eppendorf tube with 250U of T4 DNA 
polymerase (Gibco BRL), dNTPs to a final concentration of lOOpM each, DTT to a final 
concentration of 500pM and x5 T4 DNA polymerase buffer (Gibco BRL). The reaction was mixed 
and incubated in a 15°C waterbath for 15 mins. 10U of Klenow polymerase (large fragment) (NEB) 
was added and the reaction incubated for a further 15 mins at room temperature. The DNA was 
purified by phenol/chloroform extraction and recovered by ethanol precipitation. The DNA fragments 
were dissolved in water and combined into a ligation reaction with 200U of T4 DNA ligase 
(Stratagene), 40pg annealed 5’ phosphorylated Bgl\\ linker (NEB), x10 T4 ligase buffer 
(Stratagene), rATP (Stratagene) to a final concentration of 500pM and made up to 1mL with water. 
The reaction was incubated overnight at 4°C. The DNA was phenol/chloroform extracted and 
recovered by ethanol precipitation. It was combined into a restriction digestion with 800U of Bgl\\ 
(NEB), x10 NEB-3 buffer, acetylated BSA to a final concentration of 100|jg/mL, made up to 1mL 
with water and incubated at 37°C for 3 hours A further 200U of enzyme was added and‘ the
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reaction incubated for another hour. The DNA was phenol/chloroform extracted, recovered by 
ethanol precipitation and redissolved in water. •
Final size selection and removal of linkers
The DNA fragments were loaded onto a 60% Oligoprep gel (National Diagnostics) and separated 
using a Mini Protean II (Bio-Rad) vertical electrophoresis apparatus according to the manufacturer's 
recommendations. The gel was stained in 0.5pg/mL ethidium bromide for 30 mins and destained 
with water for 30 mins. Under UV illumination, the fragments were compared with a 50bp ladder 
(Gibco BRL) and those between 50bp and 350bp were excised using a scalpel blade. The DNA 
containing gel slice was macerated and solublised by adding 6 volumes of Oligoprep solubilising 
reagent. The DNA was purified from the resulting solution using Qiaex II kit (Qiagen) according to 
manufacturer's instructions and ethanol precipitation. The DNA was redissolved in water and 
quantitated by agarose gel electrophoresis and comparison with a DNA mass ladder (Gibco BRL).
Preparation offUSE2 vector
fUSE2 replicative form (RF) was transformed into TG1 cells and plated onto LB agar containing 
12.5pg/mL tetracycline. Transformants formed isolated colonies. A single colony was used to 
inoculate 50mL of LB broth containing 12.5pg/mL tetracycline. The culture was incubated overnight 
at 37°C in a shaker incubator. The culture was centrifuged at 6000g for 10 mins and the 
supernatant decanted. The fUSE2 RF was isolated using a Promega Wizard Midiprep kit according 
to the manufacturer's instructions. The fUSE2 RF DNA was Sg/ll digested for 3 hours at 37°C, then 
more enzyme was added and incubated for another hour. The digested DNA was 
phenol/chloroform extracted, recovered by ethanol precipitation and redissolved in water. The DNA 
was dephosphorylated using calf intestinal alkaline phosphatase (Gibco BRL) at 0.01U/pmol 5" 
protruding ends in a reaction containing x10 CIAP buffer (Gibco BRL) and made up to volume with 
water. The reaction was incubated for 30 mins at 37°C, another 0.001 U/pmol end of calf intestinal 
alkaline phosphatase was added and incubated for a further 30 mins. The reaction was stopped by 
adding 5pL of 250mM EDTA and incubating at 76°C for 10 mins. The reaction was purified using 
Qiagen PCR purification kit according to the manufacturer's instructions, ethanol precipitated and 
redissolved in water. An aliquot was tested by agarose gel electrophoresis for complete digestion 
and quantitated by comparison with a DNA mass ladder (Gibco BRL).
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Ligation, electroporation and harvesting the library
The average fragment size was taken as 200bp and used to calculate the amount of DNA required 
to give the desired vector : insert ratios. Ligation reactions were set up at using a Stratagene 
ligation kit according to manufacturer's recommendations. The reactions setup were, a no-ligase 
control, a no-insert control and ligations with vector : insert ratios of 1:2, 1:3, 1:4 and 1:5. The 
reactions were incubated at 4°C overnight. Each reaction was purified using a Qiagen spin column, 
ethanol precipitated and redissolved in 2pL of water. 50pL of MC1061 electro-competent Ecoli cells 
(Bio-Rad) was added to each sample, transferred to a 0.2cm electroporation cuvette (Bio-Rad) and 
electroporated at 12.5kV, 25pF, 200ft using a Gene Pulse electroporator and pulse controller (Bio- 
Rad). The time constants achieved were 6.3mses in each case. An aliquot of each electroporation 
was sequentially 10-fold diluted and each dilution plated onto LB plates containing 12.5pg/mL 
tetracycline to determine the yield of each electroporation. The remaining cells were added to 
250mL of LB broth containing 12.5pg/mL tetracycline and incubated overnight at 37°C. The culture 
was spun down at 6000g for 10mins. The supernatant was aspirated, reclarified by a further spin 
and the phage particles precipitated by the addition of 1/2 volume 30%(w/v)PEG/2.5M NaCI, mixed 
by inversion and allowed to stand at room temperature for 15 mins. The phage were pelleted by 
centrifuging at 10, 000g for 10 minutes and the supernatant carefully aspirated. The pellet was 
resuspended in lOmL of TE buffer and spun at lO.OOOrpm for 10 mins to pellet the residual cell 
debris. The supernatant was transferred to a fresh tube and the PEG precipitation repeated. The 
final pellet was resuspended in 2mL of TE buffer. This suspension represents the library of phage 
particles each carrying a displayed peptide. The final amplified library was titrated in TG1 cells on 
LB agar plates containing 12.5pg/mL tetracycline.
Characterisation of the library
10 discrete colonies were randomly selected from a titration plate, inoculated into 1OmL of LB broth 
containing 12.5 pg/mL tetracycline and incubated overnight at 37°C. The cultures were spun at 
6000g for 10 mins to pellet the cells. The supernatant was aspirated and discarded. The fUSE2 RF 
was isolated from the cells using a Wizard miniprep kit (Promega) according to the manufacturer's 
instructions. The purified DNA was used as the template in a PCR designed to amplify across the 
cloning site of the vector. The upstream primer was (cplll-S) 5’ GGTTGGTGCCTTCGTAGT 3’ and 
the downstream primer (cplll-T) 5’ CCATGTACCGTAACACTG 3’. The components of the reaction
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were as previously described and the thermal cycle was 25 cycles of 93°C for 60 secs, 45°C for 60 
secs and 72°C for 90 secs. A 5pL aliquot of each reaction was electrophoresed through a 2.5% 
agarose gel containing O.ôpg/mL ethidium bromide and visualised under UV illumuination. This 
method was also used to determine the size of the inserts in a selection of colonies after biopan 
enrichment of the library.
Affinity selection of phage displayed peptides
Purified IgG (various) was diluted to 10pg/mL in 10mM sodium carbonate buffer, pH9.6 and 1mL 
dispensed in to a Maxisorp Immunotube (Nunc). The tube was capped and incubated at room 
temperature for 18 hours. It was washed three times with PBS containing 0.05% Tween 20 using a 
wash bottle. Excess wash fluid was removed using a disposable pipette. The tube was blocked by 
adding 1 mL of PBS containing 2% dried milk powder and incubated at room temperature for 1 hour. 
Approximately 1010 library phage were added to a microfuge tube containing 1mL of PBS 
supplemented with 2% dried milk powder, 0.1%(v/v) E.coli/phage lysate (Stratagene) and 1pg/mL 
purified human IgG. The phage was incubated at 37eC for 1 hour. The blocking solution was 
aspirated from the coated tube and replaced with the diluted phage solution, mixed and incubated 
at 37°C for 3 hours with agitation. The tube was filled with PBS containing 0.05% Tween 20 using a 
wash bottle and thoroughly aspirated using a disposable pipette, This wash procedure was 
repeated a total of ten times. The bound phage was eluted by adding 1mL of 0.2M glycine/HCI 
buffer, pH2.2 for a maximum of 10 mins. The eluted phage were aspirated into a sterile universal, 
neutralised by adding 150pL of 1M Tris, pH9.1 and 2OOpL of TG1 plating bacteria was added. An 
aliquot of the eluted phage was retained for quantitation. The universal was agitated for 15 mins at 
37°C to allow the phage to attach to the cells before 1OmL of LB broth containing 12.5pg/mL 
tetracycline was added. The culture was agitated overnight at 37°C. It was spun at BOOOg for 10 
mins and the phage purified from the supernatant by two PEG precipitations. The eluted phage and 
the purified phage were titrated with TG1 cells on LB agar containing 12.5pg/mL tetracycline.
The biopanning procedure described above was repeated twice more, each time using the phage 
from the previous round as the starting material. In each successive round of biopanning the 
stringency of the wash protocol was increased. The second round was washed 15 times with PBS 
containing 0.1% Tween 20 and the third round was washed 20 times with PBS containing 0.5% 
Tween 20.
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Analysis of biopan enriched phage 
M13 immunoassay
Microplate wells were coated with either affinity purified antibodies specific for the major 
lipoproteins, and polyclonal anti-M13 antibody and purified normal human IgG. The antibodies to be 
immobilised were diluted to 5pg/mL in 0.01 M carbonate buffer, pH9.6 and added at 100pL per well 
to Maxisorp 96-well microplates (Nunc), covered to prevent evaporation and incubated for 18 hours 
at room temperature. The wells were washed three times with PBS containing 0.05% Tween 20, 
then filled with a solution of 2% (w/v) dried milk powder and allowed to stand for 15 minutes. The 
plates were aspirated and any residual solution removed by inversion onto adsorbent paper towels. 
The plates were used immediately.
1010 phage were added to 100pL PBS, pH7.4 containing 0.05% Tween 20, 2% dried milk powder 
and 1 pg/mL purified human IgG and allowed to stand for 1 hour. 100pL of the phage suspension 
was added to each well, the plate was sealed to prevent evaporation and incubated at 37°C for 2 
hours. The plate was washed five times with PBS containing 0.05% Tween 20 and blotted dry on to 
adsorbent paper towels. Monoclonal anti-M 13/horseradish peroxidase conjugate (Pharmacia 27- 
9421) was diluted 1:5000 in PBS, pH7.4 containing 0.05% Tween 20, 2% dried milk powder and 
Ipg/mL human IgG. 100pL of diluted conjugate was added to each well, the plate was sealed to 
prevent evaporation and incubated at 37°C for 2 hours. The plate was washed five times with PBS 
containing 0.05% Tween 20 and blotted dry on to adsorbent paper towels. Working strength 
substrate was prepared by adding 25pL of TMB chromogen to each 1ml_ of substrate solution. 
1OOpL of working strength substrate solution was added to each well and incubated at room 
temperature for 30 mins. The enzyme reaction was stopped by adding 100pL of 0.25M H2SO4 to 
each well, mixed and the adsorbance read at 450 nm using a Multiskan plate reader (Labsystems).
DNA sequencing
Plasmid or RF DNA was isolated using Wizard purification kits (Promega) and ethanol precipitated. 
The vector / insert junctions of plasmid constructs were sequenced with standard T7 promoter (S' 
TAATACGACTCACTATA 3') and T7 terminator (S' CCGCTGAGCAATAACTAGC 3’) primers. The 
pSurfscipt SK- plasmids were sequenced with a T3 promoter primer (S' 
ATTAACCCTCACTAAAGGGAA 3') and the fUSE2 RF DNA was sequences using the cplll-seq
Chapter 2
primer (S' CCCTCATAGTTAGCGTAACG 3'). DNA sequencing was performed by Alta Bioscience, 
University of Birmingham using an ABI Prism Model 377.
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Introduction
As previously discussed, the literature is unclear as to exactly which antigens are diagnostically 
significant. This is due to differences in nomenclature and techniques used by different researchers, 
which make the literature difficult to interpret. These initial experiments were performed to assist in 
the understanding of the literature and provide important first-hand observations of the research 
area. The results, in conjunction with the literature, should allow the diagnostically significant 
antigens to be identified for further study. The experiments also provide characterisation data on the 
antibody specificities present in each of the syphilitic serum specimens. This preparation provides 
useful baseline data for subsequent evaluations of recombinant proteins.
Results
The antibody response was investigated first by western blotting, using antigen from whole 
organisms separated on 10.5% SDS polyacrylamide gels and sera, diluted 1:100, from patients with 
different stages of syphilis. The resulting banding patterns were analysed using GelCompar™ 
(Applied Maths, Kortrijk) electrophoresis analysis software. Fig 1 shows that, early primary human 
sera react strongly and predominantly with polypeptides of 31, 35, 37 and 47 kDa. The most 
frequent response was to the 47 kDa polypeptide, virtually all sera reacting to a greater or lesser 
extent. Relatively few sera reacted, generally rather weakly, to polypeptides of 15 and 17 kDa. On 
the other hand late primary and secondary sera (Fig 2), while showing generally similar reactions as 
early primary to the higher molecular weight polypeptides, also show very strong reactions to a 44 
kDa polypeptide which are now apparent in a slightly higher proportion of sera. The pattern is 
generally similar in latent (Fig 3) and old treated syphilis (Fig 4), with possibly a higher incidence in 
the latent group of reactions to the 44 kDa antigen. In re-infection sera (Fig 5) the same set of 
reactions is seen, and in addition reactivity to a diffuse antigen of around 24 kDa is common. Serum 
specimens from eighty-eight non-selected normal blood donors, seven patients with Lyme disease 
and twelve serologically confirmed biological false positives were tested and found to be non 
reactive with any identifiable polypeptides of T.pallidum (results not shown). Table 2 summarises 
these data, and it is apparent that no single pattern of reactivities characterises a particular stage of 
disease. It is also clear that the three main categories of sera liable to give false positive results by 
other serological tests do not give any reactions to the polypeptides specified above.
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Figure 1. Western blot reaction patterns of serum specimens from 18 patients classified with 
early primary syphilis.
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Figure 2. Western blot reaction patterns of serum specimens from 36 patients classified with 
late primary syphilis or secondary syphilis.
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Figure 3. Western blot reaction patterns of serum specimens from 18 patients classified with 
latent syphilis.
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Figure 4. Western blot reaction patterns of serum specimens from 20 patients with successfully 
treated infections.
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Figure 5. Western blot reaction patterns of serum specimens from 25 patients with well 
established infections or reinfections, characterised by high antibody titres.
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Table 2. Summary of the frequency of the different western blot reaction patterns of the major 
lipoproteins.
Reaction pattern Disease stage of specimen
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+ + + - 3 2 1 2
+ + - - 5 1 2 2
+ - - - 8 1 0
+ - + - 1 1
+ - - + 1 0
+ - + + 8 5 4
+ + - + 1 1
- - - + 1
- - + + 1
- - - - 88 7 12
Totals 18 36 18 20 25 88 7 12
Discussion
Antibody responses to T.pallidum proteins have been extensively studied in patients and infected 
animals by radioimmunoprecipitation (Alderete and Baseman, 1981; Baseman and Hayes, 1980; 
Moskophidis and Muller, 1984; Thormburg et al., 1983) and western blotting (Baker-Zander et al., 
1985; Cockayne et al., 1989; Dettori et al., 1989; Hanff et al., 1982; Hanff et al., 1983; Lukehart et 
al., 1982; Lukehart et al., 1986; Norris and Sell, 1984; van Eijk et al., 1982; Wicher et al., 1989; 
Wicher et al., 1986). However it is difficult to interpret much of this work because of inconsistent 
nomenclature of the proteins between different researchers. The work described here duplicates 
some of these previous studies. The intention was to use the information to reinterpret these 
studies in relation to current nomenclature. Generally these studies show that the early immune 
response is to several distinct antigens of between 30 kDa and 38 kDa, and to a highly antigenic 
polypeptide of around 45-48 kDa. As the disease progresses, so the number of reactive proteins
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increases, with the most significant additional responses to proteins around 42 kDa, 12-14 kDa and 
14-16 kDa. From the results described here these are probably the flagellin proteins, and TpN47, 
TpN44.5, TpN17 and TpN15, respectively. The flagellin proteins elicit strong antibody responses at 
most stages of the disease. However, the FlaB flagellins closely resemble those of other bacteria, 
so they are unlikely to be pathogen specific and hence to be of diagnostic significance. FlaA 
appears only to be present in certain spirochaetes, but is highly conserved in those sequences 
studied (Parales and Greenberg, 1991, 1993). This suggests that FlaA could be a diagnostically 
significant antigen, but it also has the potential to exhibit crossreactivity with antibodies produced 
against related organisms. The results did not reveal any significant antigenic polypeptides other 
than the four lipoproteins already extensively cited in the literature. Their strength and spectrum of 
reaction make them prime candidates for use in diagnostic tests. However, as western blots 
preferentially detect polypeptides which are well expressed in the organism, the results do not 
preclude the possibility that a poorly expressed polypeptide could be an important diagnostic 
antigen. Recombinant proteins are useful tools to examine this possibility as they can be expressed 
at much higher levels than native proteins, therefore allowing the diagnostic significance of an 
antigen to be determined independently of its natural level of expression.
r-
The antigens of most interest as targets for the production of recombinant proteins are the strongly 
antigenic species; TpN47, TpN44.5, TpN17, and TpN15. Although TpN37 (FlaA) produces strong 
antibody responses, it is conserved in some spirochaetes, which does not make it a prime 
candidate for cloning. This limitation of TpN37 is further reinforced by the toxicity of the recombinant 
protein, experienced by researchers performing the initial cloning experiments, which led to 
difficulties in isolating and characterising the protein. This does not make FlaA an ideal initial target 
for cloning and expression, but it may be useful if the other recombinant proteins prove to be 
deficient in some way.
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Introduction
The main objective of these experiments was to clone the antigens identified in the previous 
experiments, and produce purified recombinant protein suitable for further serological studies. All 
the antigens described in this project have previously been cloned and sequenced by several 
researchers, as described in Chapter 1. The DNA sequences are readily available from Genebank 
or other similar databases, so the cloning experiments reported here are not new, but essential in 
order to provide recombinant protein for the subsequent work. The plasmid constructs provided for 
use in the experiments described here encoded the lipoproteins TpN44.5 and TpN17, and a 
previously poorly characterised lipoprotein, TpN24-28. TpN44.5 and TpN17 represent two of the 
major antigens identified from the previous experimental work. TpN24-28 was of interest because it 
appears as a diffuse, poorly reactive band in native antigen western blots due to its heterogeneous 
molecular weight. This property makes it difficult to observe and hence determine its diagnostic 
significance. The other prominent antigens identified in the previous experiments, TpN47 and 
TpN15, were cloned, expressed and purified as thioredoxin fusion proteins for further serological 
studies.
The use of recombinant proteins offers the opportunity to examine the antigenicity of the proteins 
independent of their natural levels of expression in the organism. Therefore, it is possible to identify 
weak responses not previously detected by the limited quantities of native antigen available in the 
organism.
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TpN24-28
Results
The constructs pET50 and pETSOREP, containing the genes encoding TpN24-28 and its modified 
form lacking the lipoprotein modification sequence, were provided by Ms. A. Ivic and Prof. C. W. 
Penn, University of Birmingham. They were expressed in E.coli BL21(DE3) cells and the results 
analysed by SDS polyacrylamide gel and western blot. Fig 6 and Fig 7 show the results of the 
expression of the pET50 and pETSOREP constructs, respectively. The recombinant proteins are not 
obvious in the pre and post induction coomassie stained gel tracks (Lane 1 and 2) against the 
background of E.coli proteins, but the western blots clearly demonstrate their presence after 
induction (Lane 2). There is no detectable expression of either product before induction as shown 
by Lane 1 of the western blots. Expression of pETSOREP produces a single distinct band, while 
pET50 produces two. Neither protein can be demonstrated in the culture media, even by western 
blot. After sonication of the harvested cells, the recombinant proteins are mostly found in the 
insoluble pelleted fraction, although a small quantity of material is released into the supernatant by 
sonication. Slightly more of the pETSOREP product is seen in the soluble fraction than with the 
pET50 product, but overall expression levels of the two constructs seem similar. Lane 6 shows the 
material recovered after purification, using metal affinity chromatography to consist of just the 
recombinant proteins with no observable contaminating material. This purified protein was used for 
subsequent studies. The two recombinant products seem similar in terms of antigenicity and 
expression levels, so as the pET50 product resembles the native protein most closely, this material 
was used for the further studies.
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Figure 6. Expression of pET50.
12% SDS polyacrylamide gel stained with coomassie blue and companion western blot developed with 
rabbit ant-T.pallidum antiserum. Lane M; pre-stained molecular weight markers ( Mr are indicated). Lane 1; 
E.coli lysate pre induction. Lane 2; E.coli lysate 2 hours post induction. Lane 3; Culture medium 2 hours 
post induction. Lane 4; post sonication supernatant. Lane 5; post sonication pellet. Lane 6; purified 
recombinant protein.
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Figure 7. Expression of pETSOREP.
12% SDS polyacrylamide gel stained with coomassie blue and companion western blot developed with 
rabbit ant-T.pallidum antiserum. Lane M; pre-stained molecular weight markers ( Mr are indicated). Lane 1; 
E.coli lysate pre induction. Lane 2; E.coli lysate 2 hours post induction. Lane 3; Culture medium 2 hours 
post induction. Lane 4; post sonication supernatant. Lane 5; post sonication pellet. Lane 6; purified 
recombinant protein.
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Discussion
The absence of the recombinant protein in the pre-induction samples is a result of the T7 promoter 
used in the pET vector series, which tightly controls expression of the cloned gene and minimises 
breakthrough expression of potentially toxic products. The pET50 construct carries the complete 
TpN24-28 gene sequence including the lipidation signal sequence and so should produce a fully 
lipid modified product. The presence of two polypeptides of different molecular weights suggests 
that processing of some kind is occurring. The finding that pETSOREP, which lacks the lipid
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modification signal sequence, produces a single protein species suggests that the most likely 
process occurring is lipid modification. However, the processing must be different from that which 
occurs naturally in T.pallidum as the product of pET50 does not show the heterogeneity in 
molecular weight seen in the native TpN24-28 protein. The majority of the recombinant protein is 
found in insoluble inclusion bodies within the cell and requires solubilisation with denaturing agents 
prior to purification. This insolubility probably results from a combination of the abnormally high level 
of expression of the recombinant proteins and the inability of E.coli to process the foreign material 
efficiently, which results in an accumulation of incorrectly folded protein. pETSOREP was 
constructed to see if removal of the lipidation sequence improved the solubility and expression 
levels of the protein by making the product easier for the E.coli cell to process and therefore 
minimise the amount of insoluble material produced. This strategy seems to have failed as both 
constructs produced relatively similar quantities of product and there is no noticeable improvement 
in the solubility of the pETSO REP unmodified product.
TpN44.5
Results
The construct pET10, containing the gene encoding TpN44.5 including the lipid modification 
sequence, was provided by Ms. A. Ivic and Prof. C. W. Penn, University of Birmingham. It was 
expressed in E.coli BL21(DE3) cells and the results analysed by SDS polyacrylamide gel and 
western blot (Fig 8). The recombinant products are visible in the coomassie stained, post induction 
sample (Lane 2) and absent prior to induction, which is confirmed by the western blot. The 
recombinant product appears as two major bands of closely related molecular weights and several 
other weaker bands at lower molecular weights, plus one band at a much higher molecular weight. 
No protein is detected in the culture medium (Lane 3) by coomassie staining, but western blotting 
reveals a single discrete band with a molecular weight similar to the lower of the two major bands in 
the post induction sample. After disruption of the cells by sonication, the recombinant products are 
partitioned fairly equally between the soluble (Lane 4) and insoluble fractions (Lane 5), with perhaps 
slightly more material present in a soluble form. Lane 6 shows that after purification using metal 
affinity chromatography the purified product contains approximately equal quantities of the two 
major polypeptide types with no other contaminating proteins detectable by coomassie staining.
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Figure 8. Expression of pET 10.
12% SDS polyacrylamide gel stained with coomassie blue and companion western blot developed with 
rabbit ar\[-T.pallidum antiserum. Lane M; pre-stained molecular weight markers ( Mr are indicated). Lane 1; 
E.coli lysate pre induction. Lane 2; E.coli lysate 2 hours post induction. Lane 3; Culture medium 2 hours 
post induction. Lane 4; post sonication supernatant. Lane 5; post sonication pellet. Lane 6; purified 
recombinant protein.
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Discussion
The pET10 construct contains the complete fpn44.5 gene including the lipidation signal sequence, 
so the expression product should be processed via the common acylation pathway. The presence 
of two polypeptide species suggests that some form of processing is occurring. The most likely 
explanation is that lipid modification is occurring, however the presence of large quantities of both 
species suggests that the process is far from complete. The level of expression seen is greater 
than that of the pET50/pET50REP constructs, which is probably related to how well the E.coli cells 
tolerate the foreign gene. The presence in the culture medium of a single protein band of a similar 
molecular weight to one of the two major expression products is an interesting finding. If it were due 
to being released from dead or damaged cells, then one would expect to find both of the major 
protein species occurring in similar relative proportions to those found in the post induction sample. 
The presence of only one of the species suggests that there maybe a selective process occurring, 
possibly an active export mechanism.
TpN17
Results
The construct pET17, containing the gene encoding TpN17 including the lipid modification 
sequence, was provided by Ms. A. Ivic and Prof. C. W. Penn, University of Birmingham. It was
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expressed in E.coli BL21(DE3) cells and the results analysed by SDS polyacrylamide gel and 
western blot (Fig 9). The results generally follow those previously described for the other constructs 
expressing lipoprotein sequences. Induction results in strong expression of the recombinant protein 
which can been seen in the coomassie stained post induction sample (Lane 2) as a large band that 
is not present prior to induction (Lane 1). This is confirmed by the western blot which shows the 
recombinant protein as a large, dark band with a much weaker lower molecular weight band below 
it. Lane 3 shows there is no detectable protein in the culture medium, even by western blot. After 
sonication of the harvested cells a large proportion of the recombinant protein is found in the 
soluble fraction (Lane 4). However, a significant fraction remains in an insoluble form (Lane 5). 
Lane 6 shows the recombinant protein after purification using metal affinity chromatography. The 
coomassie stained gel shows a weak band below the recombinant protein which is not detected in 
the western blot of the same sample.
Figure 9. Expression of pET 17
12% SDS polyacrylamide gel stained with coomassie blue and companion western blot developed with 
rabbit anl-T.pallidum antiserum. Lane M; pre-stained molecular weight markers ( Mr are indicated). Lane 1; 
E.coli lysate pre induction. Lane 2; E.coli lysate 2 hours post induction. Lane 3; Culture medium 2 hours 
post induction. Lane 4; post sonication supernatant. Lane 5; post sonication pellet. Lane 6; purified 
recombinant protein.
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Discussion
This construct codes for the complete tpnM  gene including the lipidation signal sequence, therefore 
it should produce a lipid modified product. It produces good levels of expression and the product 
seems more soluble than the other lipoproteins described above. The recombinant protein appears
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almost exclusively as a single entity, but there is some evidence of processing shown by the weak 
lower molecular weight band in the post induction sample. However, unlike the products of the other 
lipoprotein constructs, most of the pET17 product seems to occur as the higher molecular weight 
variant. The predominance of the higher molecular weight form and the superior expression levels 
may be due to better tolerance of the foreign gene by the E.coli cells resulting in more effective 
processing. The diffuse lower band seen in the purified protein sample that is not detected by 
western blot is unlikely to be unprocessed TpN17 due to its lack of reactivity with the antiserum. 
Two other possibilities are that it is either a contaminant protein or an artifact due to overloading of 
the gel track. No similar contaminant proteins have come through the purification method in the 
case of the other recombinant proteins, so this is unlikely to be the source. The most probable 
cause is smearing due to the high concentration of the protein loaded into that lane of the gel.
TpN15
Results
The construct pET60, containing the gene encoding TpN15 including the lipid modification 
sequence, was provided by Ms. A. Ivic and Prof. C. W. Penn, University of Birmingham. It was 
expressed in BL21(DE3) E.coli cells and the results analysed by SDS polyacrylamide gel and 
western blotting. Putative expression of the recombinant protein was only occasionally detected by 
western blotting after prolonged exposure to the blot development substrate. The bands were 
extremely faint which rendered them impossible to record by photography or scanning. The A6oo of 
the culture was found to decrease after induction (data not shown).
A construct, pETSOREP, was prepared which coded for the fpr?15 gene sequence except for the 
lipidation signal sequence. Sequencing of the vector / insert junctions confirmed the correct reading 
frame was maintained in the construct. It was expressed in BL21(DE3) E.coli cells exactly as the 
pET60 construct and the results were found to be identical.
Another construct, LIC15, was prepared which also coded for the tpn'\5 gene sequence without the 
lipidation signal sequence, but also resulting in a translational fusion to vector-coded thioredoxin. It 
was expressed in BL21(DE3) E.coli cells and the results analysed by SDS polyacrylamide gel and 
western blotting (Fig 10). After induction, the recombinant protein can be seen against the
108
Cloning of major lipoproteins of T.pallidum
background of E.coli proteins by coomassie staining (Lane 2). The western blot shows that the 
recombinant protein is slightly expressed before induction (Lane 1). Not surprisingly, no protein is 
detected in the culture medium. After sonication, most of the recombinant protein is found in the 
soluble fraction (Lane 4) with some remaining associated with the insoluble material (Lane 5). Lane 
6 shows that, after metal affinity chromatography, the purified material contains a single polypeptide 
band.
Figure 10. Expression of LIC15.
12% SDS polyacrylamide gel stained with coomassie blue and companion western blot developed with 
rabbit ani-T.pallidum antiserum. Lane M; pre-stained molecular weight markers ( Mr are indicated). Lane 1; 
E.coli lysate pre induction. Lane 2; E.coli lysate 2 hours post induction. Lane 3; Culture medium 2 hours 
post induction. Lane 4; post sonication supernatant. Lane 5; post sonication pellet. Lane 6; purified 
recombinant protein.
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Discussion
The pET60 construct codes for the complete tpn'\5 gene sequence including the lipidation signal 
sequence which means the product should be lipid modified by the common acylation pathway. The 
extremely poor expression and apparent cell lysis after induction suggests that the recombinant 
protein produced is poorly tolerated and possibly toxic to E.coli. A construct expressing the tpn'\5 
gene sequence without the lipidation signal sequence, pET60 REP, was constructed in an attempt 
to increase the tolerance of E.coli to the recombinant protein. The hypothesis was that an 
unmodified protein might be more easily processed and the lack of the lipid might hinder any 
functional activity the protein might have. As the outcome was virtually identical to the mature 
lipidated protein one can only conclude that if the lack of expression is due to toxicity then it is a 
function of the amino acid sequence and not dependent on the lipid content of the protein. This 
concept was taken further with the construction of LIC15. The sequence of tpn'\5 was cloned
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without the lipid modification sequence and expressed as a fusion with a vector encoded protein, 
thioredoxin. This should not only prevent any residual functional activity TpN15 may exhibit but also 
improve the solubility of the recombinant protein. Recombinant proteins which are normally 
produced in an insoluble form in the cytoplasm of E.coli have been shown to become more soluble 
when fused with thioredoxin (LaVallie et al., 1993). This strategy seems to be successful as it 
produces good expression of a recombinant protein. However, the presence of the recombinant 
protein prior to induction suggests that the control of the expression is not as tight as in the pET 
series of constructs. This is probably a function of the vector used rather than due to the cloned 
gene it contains. The presence of the fusion protein may interfere with the antigenicity of the TpN15 
polypeptide by altering the secondary structure of the protein thereby eliminating or masking key 
epitopes. The modification of the protein by fusion does not seem to affect the antigenicity as the 
recombinant product reacts strongly with the anti-T.pallidum antiserum tested. Whether or not the 
fusion enhances the solubility of the recombinant protein is difficult to judge. Although the majority 
of the recombinant can be recovered in the soluble fraction, the complete failure to generate a non­
fusion construct for comparison means no firm conclusions can be drawn. But the very fact that this 
construct expresses useful levels of protein, whereas the pET constructs produced nothing, 
suggests that the fusion is exerting a significant influence on the TpN15 sequence product.
TpN47
Results
The construct LIC47, containing the tpn47 gene without the lipidation signal sequence, but also 
resulting in translational fusion to vector-coded thioredoxin, was prepared and expressed in 
BL21(DE3) E c o //cells. The results were analysed by SDS polyacrylamide gel and western blot (Fig 
11). The most obvious point to note is the high levels of expression seen with this recombinant 
protein compared to most of the others described in this chapter. It can be clearly seen as a large 
band on the polyacrylamide gel after induction (Lane 2), which appears absent from the pre­
induction sample (Lane 1). However, the western blot reveals that a small amount of expression is 
actually occurring prior to induction. Most of the material separates to the insoluble fraction (Lane 5) 
and purifies to a single entity after metal affinity chromatography (Lane 6).
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Figure 11. Expression of LIC47.
12% SDS polyacrylamide gel stained with coomassie blue and companion western blot developed with 
rabbit ani-T.pallidum antiserum. Lane M; pre-stained molecular weight markers (Mr are indicated). Lane 1; 
E.coli lysate pre induction. Lane 2; E.coli lysate 2 hours post induction. Lane 3; Culture medium 2 hours 
post induction. Lane 4; post sonication supernatant. Lane 5; post sonication pellet. Lane 6; purified 
recombinant protein.
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Discussion
As no transformants were produced after numerous attempts to clone tpn47 into a pET21b, so the 
strategy used to clone tpn'IS was adopted and proved successful. The expression levels achieved 
by this construct greatly exceed those seen with the other constructs described in this chapter. 
Obviously, expression of the thioredoxin-TpN47 fusion protein is well tolerated by E.coli resulting in 
very high expression levels being seen after induction. Compared to the amount of protein 
produced after induction, the small amount seen prior to induction is minimal and may just be a 
product of the high expression levels achieved. The breadth of the bands on the gel and western 
blot is a result of the amount of protein present causing distortion of the gel track and not due to 
heterogeneity in the molecular weight. When smaller amounts of protein are electrophoresed the 
recombinant protein forms narrow discrete bands. The presence of the fusion protein does not 
appear to alter the antigenicity of the TpN47 portion of the recombinant protein as strong reactions 
are seen with the anti-T.pa/Mvm antiserum.
Summary
TpN44.5 and TpN17 were successfully expressed from the full lipoprotein sequences including the 
lipid modification sequence. The plasmids seem to be well tolerated by the E.coli cells and 
expression levels were adequate to produce reasonable quantities protein that was readily purified
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from inclusion bodies. There is evidence that the proteins are lipid-modified and seem to be 
antigenic judged by their reactions with anU-T.pallidum antiserum.
TpN24-28 was expressed from two constructs, as the full lipoprotein sequence and as the mature 
protein excluding the lipid modification sequence. The full lipoprotein seems to be processed by the 
E.coli cells, which is shown by the two bands on SDS-PAGE. This is further reinforced by the single 
band produced by the truncated gene, suggesting that removal of the lipid modification sequence 
prevents processing occurring. The plasmids are tolerated by the E.coli cells but expression levels 
are lower than those seen with the previous two constructs. The expression levels of the two 
TpN24-28 variants seem similar, so elimination of processing by the deletion of the lipid 
modification signal sequence does not enhance expression. The fully lipid-modified version was 
purified and used for the subsequent studies as it was thought most closely to resemble the native 
molecule.
TpN15 proved highly problematic to clone and express. Constructs expressing the gene, both with 
and without the lipid modification sequence, were poorly tolerated by the E.coli cells and probably 
toxic. Induction of the gene resulted in a decrease in the number of cells in the culture and poor 
expression of the recombinant protein. TpN15 was finally successfully cloned and expressed as the 
mature protein sequence, minus the lipid modification sequence, fused to vector-coded thioredoxin. 
This plasmid was well tolerated by the E.coli, resulting in high expression of the recombinant protein 
which was easily purified by metal affinity chromatography. The fusion protein did not appear to 
affect the antigenicity of the recombinant protein as judged by its reaction with anti-T.pallidum  
antiserum.
The TpN47 was successfully cloned and expressed using an identical strategy to that used for 
TpN15. The construct was very well tolerated by the E.coli cells and resulted in exceptionally high 
levels of expression. The recombinant protein was purified using metal affinity chromatography and 
its antigenicity appeared to be unaffected by the presence of the fusion protein, judged by its 
reaction with ar\i\-T.pallidum antiserum.
All the purified proteins were stored frozen and used for further serological studies.
1 1 2
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Introduction
TpN24-28 is a previously poorly characterised lipoprotein that shows molecular weight 
heterogeneity by SDS-PAGE. This produces a diffuse, weakly reactive band in native antigen 
western blots. An antibody response directed towards it is only observed in a proportion of patients 
with well established infections. This could be due to its diffuse nature making observation difficult, 
or to the protein being poorly immunogenic. The objective of this experiment was to evaluate the 
frequency and strength of the response to TpN24-28 using recombinant protein. The recombinant 
TpN24-28 can be tested at higher concentrations than is possible using native antigen and 
therefore should determine its true antigenicity independent of natural levels of expression. The 
testing was performed by western blot, even though the material was purified, because it offers a 
qualitative evaluation that is independent of purity. Reactions to TpN24-28 can be easily 
distinguished from those directed towards contaminating proteins in the antigen preparation. 
Recombinant TpN44.5 and TpN17 were used for comparison as antibody responses are commonly 
seen to these proteins, especially in established infections.
Results
The reactivity of syphilitic and non-syphilitic serum specimens with the recombinant TpN24-28 was 
investigated by western blotting. TpN44.5 and TpN17 were also tested for comparison and to act as 
controls. All gels are 12% acrylamide covering molecular weights from >200 kDa to <10 kDa, and 
are shown with high molecular weight to the right. Fig 12 shows that all 38 serum specimens from 
patients with syphilis are clearly reactive with TpN44.5 and all 20 normal antenatal specimens are 
non-reactive. A similar picture is seen in Fig 13 which shows the reactivity of the same specimens 
to TpN17. Again, all syphilitic sera are clearly reactive and the normal specimens are non-reactive 
with TpN17. A different picture is seen in Fig 14 where the same specimens are tested against 
TpN24-28. All the normal antenatal specimens are non-reactive with TpN24-28 and only 13 of the 
38 syphilitic serum specimens are strongly reactive, two are weak and a further one very faint. 
There are additional reactivities seen at higher molecular weights, to the right of the figures, which 
are present in a large number of specimens both syphilitic and non-syphilitic.
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Figure 12. Reactivity of recombinant TpN44.5 with syphilitic and non-syphilitic serum specimens.
Western blot reaction patterns of serum specimens of 38 serologically reactive patients with established 
syphilis infections, 20 non-selected antenatal patients negative for syphilis, and two controls. The positive 
and negative controls are a high titre syphilitic serum and a pool of sera from non-reactive blood donors.
Figure 13. Reactivity of recombinant TpN 17 with syphilitic and non-syphilitic serum specimens.
Western blot reaction patterns of serum specimens of 38 serologically reactive patients with established 
syphilis infections, 20 non-selected antenatal patients negative for syphilis, and two controls. The positive 
and negative controls are a high titre syphilitic serum and a pool of sera from non-reactive blood donors.
115
Chapter 5
Figure 14. Reactivity of recombinant TpN24-28 with syphilitic and non-syphilitic serum specimens.
Western blot reaction patterns of serum specimens of 38 serologically reactive patients with established 
syphilis infections, 20 non-selected antenatal patients negative for syphilis, and two controls. The positive 
and negative controls are a high titre syphilitic serum and a pool of sera from non-reactive blood donors.
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Discussion
Western blot results are affected by the amount of each antigen present in the cell and they tend to 
favour the detection of antibodies against abundant proteins. TpN24-28 is thought to be pathogen 
specific, but produces a diffuse weak reaction in western blots due to the variation in molecular 
weight and low level of expression in the organism. Putative reactivity to TpN24-28 can be seen in 
some specimens from patients with well established disease in the western blot studies described 
in Chapter 3. The infrequency of the response may be due to the low level of expression and the 
heterogeneous nature of the antigen making detection difficult, or the response to TpN24-28 may 
develop late in the disease. It is difficult to assess the diagnostic significance of this antigen using 
whole treponemes. However, recombinant proteins can be expressed at a much higher level and so 
are not limited in this way. The product of pET50 was used for this study as it should be lipid 
modified and therefore is the material most closely resembling native TpN24-28.
Although the material was purified, western blotting was still used as it provides qualitative 
information about the nature of the reactions, thereby allowing the differentiation between true 
reactivity and reactions with contaminating proteins. It is clear from the data that in contrast to the
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reactions with TpN44.5 and TpN 17, reactivity to TpN24-28 is far more erratic. A large number of the 
specimens tested showed reactions with high molecular weight species that were most probably 
E.coli proteins not removed by the purification process. If a quantitative method, such as enzyme 
immunoassay, had been used these reactions could lead to the conclusion that TpN24-28 was 
more reactive than it actually is. TpN24-28 was non reactive with all the normal antenatal 
specimens which, although a rather limited evaluation, hints at the specific nature of the protein. 
The lack of reactivity with all the syphilitic specimens means that it would not be diagnostically 
significant by itself, but it could be useful in conjunction with other proteins. However, as all the 
specimens that reacted with TpN24-28 also reacted strongly with TpN44.5 and TpN 17, its inclusion 
in a mixture would be unlikely to add any extra reactivity. For this reason TpN24-28 was not 
investigated further during this study. The attention was therefore focused on the four disease 
specific lipoproteins that were thought to show strong reactivity in most stages of the disease, 
TpN47, TpN44.5, TpN17 and TpN15.
Summary
This preliminary evaluation suggests that TpN24-28 seems to be pathogen specific as judged by 
the lack of response with any of the antenatal specimens tested. In order to confirm this many more 
specimens from patients with no history of syphilis would have to be tested, as well as specimens 
from potentially cross reactive sources. However, the sporadic nature of the antibody response to it, 
compared to the other lipoproteins tested, means that it is not reactive frequently enough to provide 
any additional antigenicity over more universally reactive antigens. Therefore, TpN24-28 was not 
investigated further during the study reported here.
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Introduction
The antibody responses to the recombinant proteins of a range syphilitic serum specimens were 
evaluated by western blotting. This particular technique was applied because it allows a qualitative 
assessment of the responses which is not reliant on the purity of the antigen preparations. The 
technique is also fairly robust and potentially highly sensitive, mainly due to the large quantities of 
antigen that can be immobilised on the nitrocellulose membrane. The objective was to determine 
the frequency and strength of the antibody responses to the recombinant proteins at all stages of 
the disease, and compare the results with the responses of the same sera to native antigen. This 
would allow comparison of the specificity of the recombinant proteins with native antigen to be 
made and might highlight any effects of the fusion proteins on antigenicity. The results also 
provided baseline data for comparison with any subsequent experimental results, and if necessary 
allow resolution of any discrepancies.
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Results
The four recombinant proteins, TpN47, TpN44.5, TpN17 and TpN15, were tested by western 
blotting against a range of serum specimens from patients with different stages of syphilis infection. 
All gels were 12% acrylamide and covered molecular weights from >200 kDa to <10 kDa, and are 
shown with high molecular weight to the right.
T p N 47
All the early primary (Fig 15), late primary / secondary (Fig 16) and latent syphilis specimens (Fig 
17) were reactive. Generally, the reactions were strong and clear, with only the occasional weaker 
reaction. Fig 18 shows that all, except one, of the specimens from successfully treated cases were 
also reactive.
Figure 15. Reactivity of recombinant TpN47 in early primary syphilis.
Western blot reaction patterns of serum specimens from 18 patients classified with early primary syphilis 
tested against recombinant TpN47.
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Figure 16. Reactivity of recombinant TpN47 in late primary / secondary syphilis.
Western blot reaction patterns of serum specimens from 36 patients classified with late primary syphilis or 
secondary syphilis tested against recombinant TpN47.
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Figure 17. Reactivity of recombinant TpN47 in latent syphilis.
Western blot reaction patterns of serum specimens from 18 patients classified with latent syphilis tested 
against recombinant TpN47.
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Figure 18. Reactivity of recombinant TpN47 in successfully treated cases.
Western blot reaction patterns of serum specimens from 20 patients with successfully treated infections 
tested against recombinant TpN47.
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Tp N 44 .5
Generally, the reactions with TpN44.5 are weaker and more variable in strength than is seen with 
TpN47. Fig 19 shows that most of the early primary specimens react weakly, however only three 
specimens are actually completely non-reactive. A similar picture can be seen in Fig 20 with the late 
primary / secondary specimens where the reactions are predominantly fairly weak, but with a 
greater proportion clearly reactive, and only two specimens completely non-reactive. The latent 
syphilis specimens (Fig 21) divide fairly evenly with nine reacting strongly and seven weakly. The 
remaining two specimens are non-reactive. Most of the treated cases (Fig 22) are strongly reactive 
with only one specimen non-reactive.
Figure 19. Reactivity of recombinant TpN44.5 in early primary syphilis.
Western blot reaction patterns of serum specimens from 18 patients classified with early primary syphilis 
tested against recombinant TpN44.5.
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Figure 20. Reactivity of recombinant TpN44.5 in late primary / secondary syphilis.
Western blot reaction patterns of serum specimens from 36 patients classified with late primary syphilis or 
secondary syphilis tested against recombinant TpN44.5.
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Figure 21. Reactivity of recombinant TpN44.5 in latent syphilis.
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Western blot reaction patterns of serum specimens from 18 patients classified with latent syphilis tested 
against recombinant TpN44.5.
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Figure 22. Reactivity of recombinant TpN44.5 in successfully treated cases.
Western blot reaction patterns of serum specimens from 20 patients with successfully reacted infections 
tested against recombinant TpN44.5.
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T p N 17
The reactions with TpN17 are more consistent in strength than those seen with the previously 
described proteins and the overall picture is different. Fig 23 shows that the early primary 
specimens are generally non-reactive, with only six specimens giving weak responses. The late 
primary / secondary specimens (Fig 24) show the opposite picture, where most are clearly reactive 
with very few weak responses and two non-reactive specimens. This picture continues for the 
specimens from patients with latent syphilis (Fig 25) and the successfully treated cases (Fig 26) 
which are mostly reactive, showing little variation in reaction strength, and only three and two non­
reactive specimens, respectively.
Figure 23. Reactivity of recombinant TpN17 in early primary syphilis.
Western blot reaction patterns of serum specimens from 18 patients classified with early primary syphilis 
tested against recombinant TpN17.
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Figure 24. Reactivity of recombinant TpN 17 in late primary / secondary syphilis.
Western blot reaction patterns of serum specimens from 36 patients classified with late primary syphilis or 
secondary syphilis tested against recombinant TpN17.
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Figure 25.
Figure 26.
Reactivity of recombinant TpN 17 in latent syphilis.
Western blot reaction patterns of serum specimens from 18 patients classified with latent syphilis tested 
against recombinant TpN17.
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Reactivity of recombinant TpN 17 in successfully treated cases.
Western blot reaction patterns of serum specimens from 20 patients with successfully treated infections 
tested against recombinant TpN17.
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T p N 15
The overall pattern of reactions with TpN 15 are similar to those seen with TpN 17, little reactivity 
with early primary specimens and generally strong, consistent reactions with the other categories of 
specimens. Fig 27 shows that most of the early primary specimens are non-reactive with only seven 
reactive, and then only relatively weakly. The late primary / secondary specimens (Fig 28) show the 
reverse situation where all, except five, are clearly reactive. Fig 29 shows that only three of the 
specimens from patients with latent syphilis are non-reactive and the rest show strong reactivity. 
This is repeated for the specimens from treated cases (Fig 30), where four are non-reactive and the 
rest clearly reactive.
Figure 27. Reactivity of recombinant TpN 15 in early primary syphilis.
Western blot reaction patterns of serum specimens from 18 patients classified with early primary syphilis 
tested against recombinant TpN15.
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Figure 28. Reactivity of recombinant TpN15 in late primary / secondary syphilis.
Western blot reaction patterns of serum specimens from 36 patients classified with late primary syphilis or 
secondary syphilis tested against recombinant TpN15.
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Figure 29.
Figure 30.
Reactivity of recombinant TpN 15 in latent syphilis.
Western blot reaction patterns of serum specimens from 18 patients classified with latent syphilis tested 
against recombinant TpN15.
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Reactivity of recombinant TpN15 in successfully treated cases.
Western blot reaction patterns of serum specimens from 20 patients with successfully treated infections 
tested against recombinant TpN15.
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Discussion
The serum specimens used here were also used in the whole-organism western blots described in 
Chapter 3. Generally, the recombinants show an increased frequency and strength of reaction 
compared to the native antigen western blots. This may simply be due to the increased amount of 
the protein present in the blots producing greater sensitivity and to the broader bands aiding 
visualisation of the results. However, the underlying pattern of reactivity remains the same as that 
seen in the native antigen blots. The similarity in the frequency of the responses suggests that the 
recombinant proteins exhibit broadly similar antigenicity to that of the native antigens. Similarly, the 
presence of the fusion proteins does not significantly affect the frequency of the responses, and 
therefore probably exerts only limited effects on the antigenicity of the recombinant proteins. In early 
primary disease the reactivity is primarily directed toward TpN47 with significant, but weaker 
reaction with TpN44.5, and little reactivity to TpN15 and TpN17. In the other stages of the disease, 
all four antigens are frequently reactive. However, no single antigen reacted with all of the 
specimens tested and no reaction patterns were specific for a particular disease stage. This 
outcome confirms that the conclusions from the native antigen blots hold true and are not affected 
significantly by differences in the expression of the proteins in the native organism. It also shows 
TpN47 to be an important antigen for the diagnosis of syphilis, particularly in early primary infection, 
but although it is the antigen that most frequently elicits an antibody response, it alone is not 
adequate to detect all cases of syphilis. Therefore, an effective diagnostic test for detection of 
syphilis would probably require more than one antigen.
Summary
Generally, the recombinant proteins exhibit similar patterns of reactivity to the native antigens, and 
the fusion proteins do not significantly affect their antigenicity. The frequency and strength of the 
responses observed means that all four recombinant proteins are good candidates, individually and 
in combination, for the development of an enzyme immunoassay for the serodiagnosis of syphilis.
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Introduction
The objective was to develop an enzyme immunoassay using recombinant proteins to improve the 
serodiagnosis of syphilis. It was essential that the method provided adequate sensitivity at all stages 
of the disease, especially in early primary infections. Enzyme immunoassay offers several 
advantages over other techniques. It is a quantitative method which is suitable for testing large 
numbers of specimens. An enzyme immunoassay based on antigen derived from whole organisms 
has proved to be highly sensitive and specific, suitable for screening, and even possibly as a 
confirmatory test (Young et al., 1992). This assay, Captia® Syphilis-G, was shown to perform at 
least as well as the more widely accepted testing protocol utilising a combination of VDRL and 
TPHA methods. This is the main reason for using it for comparative purposes in the series of 
experiments described here. The results are depicted as antibody indices, which allow comparison 
of results between testing occasions, and are calculated by dividing the absorbance of the test 
specimen by the absorbance of a cut-off standard. So, values less than one represent non-reactive 
specimens and values greater than one are considered to be reactive, and therefore to contain 
antibodies to T.pallidum.
The use of antigen derived from natural sources imposes certain limitations on assay performance. 
The antigenic composition is limited to that found in the organism, so this may affect the sensitivity 
of the assay due to the concentrations of some antigens being sub-optimal. Alternatively, it may 
cause cross reactions due to the presence of antigens also expressed by other organisms. Assays 
based on recombinant proteins can avoid these problems, because the antigen composition and 
concentrations used can be optimally tailored to suit the application. The result is commonly seen 
as improvements in sensitivity and specificity of the recombinant assay over the native antigen 
based assay. Recombinant proteins have the advantage that they can be produced in relatively 
large quantities by in vitro cell culture, which is more economical than producing antigen from in 
vivo culture in animals. The quality of the antigen produced is more consistent and free from the 
seasonal variations seen in material from animal sources. Clearly, recombinant proteins have many 
advantages over native antigen preparations, which is probably why there is a steady increase in 
their use in all areas of serodiagnosis.
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Results
T p N 47
The optimal coating of the recombinant TpN47 was determined by coating curve analysis to be 
1pg/mL. The resulting enzyme immunoassay showed the expected sigmoidal dose response curve 
with a positive specimen serially diluted with negative serum (data not shown). The coated wells 
were tested in triplicate with a range of serum specimens from a variety of different conditions . Fig 
31 shows the absorbances of a group of serum specimens from patients with different stages of 
syphilis, 88 normal blood donors, and potential cross reactive samples consisting of seven patients 
with Lyme disease and twelve serologically confirmed biological false positives. For clarity, the 
normal negative specimens are shown as a “box and whisker” graphic rather than as individual 
values. The box extends from the 25th percentile to the 75th percentile with a horizontal line at the 
median, and the whiskers extend down to the smallest value and up to the largest. This shows the 
negatives to form a tight group with low absorbance values. The potentially cross reactive 
specimens all give absorbance values within the range of the negative population. The disease 
stage sera show a wide range of absorbances from values similar to the highest of the negative 
population up to the maximum response of the assay. The only significantly different distribution is 
the reinfection specimens, which all give high absorbances clearly separated from the negative 
population. Fig 32 shows a comparison of the absorbances of 76 non-selected syphilis positives 
obtained from a genito-urinary clinic (black) and the 88 normal blood donors (red) with their results 
in a commercially available enzyme immunoassay. The most obvious and notable result seen is the 
almost random scatter of plotted results. Some specimens that are positive in the commercial 
assay produce absorbance values within the range of the negative population. There are also some 
specimens that the commercial assay categorises as negative that produce absorbances much 
higher than the negative population.
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Figure 31. Mean absorbances of various specimen types in an enzyme immunoassay using
TpN47 coated wells.
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Figure 32. Comparison of an enzyme immunoassay using TpN47 coated wells with a 
commercially available EIA for syphilis.
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Tp N 44 .5
The optimal coating of the recombinant TpN44.5 was found to be 1 pg/mL by coating curve analysis. 
The resulting enzyme immunoassay showed the expected sigmoidal dose response curve with a 
positive specimen serially diluted with negative serum (data not shown). The serum specimens 
described previously were tested in triplicate and the results are presented in the same format as 
the previous section. Fig 33 shows the generally similar results to those seen with TpN47. The 
negative specimens show a tight grouping with low absorbances and the cross reactive specimens 
give broadly similar absorbances. The syphilitic sera show a wide range of absorbance values, with 
a high number giving absorbances similar to those of the negative specimens. Again, the 
reinfection specimens produce high absorbances which are widely separated from the negative 
population. The result of the comparison with the commercial enzyme immunoassay is shown in Fig 
34, and shows a generally similar impression to the results previously described for TpN47. The 
plotted results produce a wide scatter, with some specimens that are positive in the commercial 
assay producing absorbance values similar to the negative specimens. There are also some 
specimens categorised as negative by the commercial assay that produce absorbances higher than 
the negative population.
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Figure 33. Mean absorbances of various specimen types in an enzyme immunoassay using
TpN44.5 coated wells.
3 . 5 -
3.0-
•  •
E 2.5-
c
om
3 -  2 .0 - 
0) o c to
f  1-5-O
V)
S ,o-
• » e • e
0.5-
0 .0 -
Negative Primary Secondary Latent Old treated Reinfection Lyme
Specimen type
BFP
Figure 34. Comparison of an enzyme immunoassay using TpN44.5 coated wells with a 
commercially available EIA for syphilis.
0 0.5 1 1.5 2 2.5 3
C a p t ia  S y p h i l is -G  a n t ib o d y  in d e x  ( A 4 5 0 /c u t -o f f  A 4 5 0 )
140
Enzyme immunoassay using recombinant proteins
T p N 17
The optimal coating concentration for the recombinant TpN 17 was determined by coating curve 
analysis. The wells were coated at 1pg/mL and showed the expected sigmoidal dose response 
curve with a positive specimen serially diluted with negative serum (data not shown). The serum 
specimens previously described were tested in triplicate and the results presented in the same 
format as the previous sections. Fig 35 shows generally similar results to those seen with TpN47 
and TpN44.5, but differs in some respects. The results are similar in respect to the absorbances 
seen with the negative specimens and the specimens from patients with secondary, latent, treated 
and recurrent infections. Also, the potentially cross reactive samples again show absorbances 
within the negative range. The difference is seen in the results of the specimens from patients with 
early primary disease which show generally much lower absorbances than were seen when they 
were tested with TpN47 and TpN44.5. Fig 36 depicts the result of the comparison with the 
commercial enzyme immunoassay, and shows a generally similar pattern to the results previously 
described. The plotted results produce a wide scatter, with some specimens that are positive in the 
commercial assay producing absorbance values similar to the negative specimens. There are also 
some specimens categorised as negative by the commercial assay that produce absorbances 
higher than the negative population.
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Figure 35. Mean absorbances of various specimen types in an enzyme immunoassay using
TpN 17 coated wells.
3.5
•••
••
: • ••
•• •
. •
••••
•• • •••• • •
. • *
e •• •
: * _ ••• :' •• • *.
•A •
• :• •ee. .
.  •• •: • •• • •
se\
•• • • ••• .
•v • •=q ••• •i*
3.0
E 2.5-
c
om
S  2.0-
<tio
c(0
■e 1-5- o(I)
5 , 0 .
0.5-
0 .0 -
Negative Primary Secondary Latent Old treated Reinfection Lyme
Specimen type
BFP
Figure 36. Comparison of an enzyme immunoassay using TpN 17 coated wells with a 
commercially available EIA for syphilis.
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T p N 15
Coating curve analysis was used to determine the optimal coating concentration for the 
recombinant TpN 15. The coated wells were coated at Ipg/m L and showed the expected sigmoidal 
dose response curve with a positive specimen serially diluted with negative serum (data not shown). 
The serum specimens previously described were tested in triplicate and the results presented in the 
same format as the previous sections. Fig 37 shows the results to be generally similar to those 
seen with TpN 17. The negative specimens produce low absorbances in a narrow range. The early 
primary specimens give generally lower absorbances than the other syphilitic sera and several 
produce results within the range of negative values. The other syphilitic sera produce a range of 
absorbances covering the full range of the assay, except the reinfection samples which showed 
predominantly high absorbances. Again, the specimens from patients with Lyme disease and the 
biological false positive samples produced results within the range of the negative specimens. Fig 
38 depicts the result of the comparison with the commercial enzyme immunoassay, and shows a 
slightly different pattern to the distribution of results to those previously described. The plotted 
results still produce a scatter, but it tends to be mostly directed towards specimens that are positive 
in the commercial assay producing absorbance values similar to the negative specimens. However, 
there are two specimens categorised as negative by the commercial assay that produce 
absorbances higher than the negative population.
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Figure 37. Mean absorbances of various specimen types in an enzyme immunoassay using
TpN 15 coated wells.
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Figure 38. Comparison of an enzyme immunoassay using TpN 15 coated wells with a 
commercially available EIA for syphilis.
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Combined coating
The coating concentrations within the mixture of each of the recombinant proteins was determined 
using ECHIP experimental design software to formulate an experiment using a Mixture design. 
Response surface analysis showed there to be distinct interactions between the components of the 
mixture, but a broad plateau in the response covered the central region of the experimental space. 
The four recombinants were coated at equal concentrations with a total coating concentration of 
1pg/mL, i.e. four recombinants each at 0.25pg/mL. The resulting enzyme immunoassay showed the 
expected sigmoidal dose response curve with a positive specimen serially diluted with negative 
serum (data not shown). The coated wells were tested in triplicate with a range of serum specimens 
and the results are presented in the same format as the previous sections. Fig 39 shows that the 
negative specimens and the potential cross reactive samples produce lower, more tightly grouped 
absorbances than was seen with any of the recombinant proteins coated singly. The syphilitic 
specimens show a range of absorbances, but now the lowest absorbances are significantly higher 
than the most reactive negative specimens. Fig 40 depicts the result of the comparison with the 
commercial enzyme immunoassay, and shows a slightly different pattern to the distribution of 
results to those previously described. The plotted results produce a much tighter grouping through 
the center diagonal of the graph. There are some specimens categorised as negative by the 
commercial enzyme immunoassay that produce results significantly greater than the negative 
population. There are no specimens giving antibody indices greater than one in the commercial 
assay that produce absorbances even close to the negative range.
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Figure 39. Mean absorbances of various specimen types in an enzyme immunoassay using wells
coated with an optimal combination of all four recombinants.
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Figure 40. Comparison of an enzyme immunoassay, using wells coated with an optimal 
combination of all four recombinants, with a commercially available EIA for syphilis.
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Discussion
Generally, the assays produced by the recombinant proteins coated singly each give a compact 
negative distribution which suggests good specificity. The lack of reactivity with the samples from 
patients with Lyme disease and the biological false positive specimens also indicates the specific 
nature of the responses. They produce good responses with most of the positive specimens, but all 
to a greater or lesser extent fail to adequately discriminate some of the lower responding 
specimens from the negative population. This picture is characteristic of assays that lack sensitivity, 
thereby falsely categorising a proportion of the specimens as negative. The combined coating 
produces an assay with an even more compact distribution to the negative specimens than any of 
the single antigen coatings achieved. There is also an increase in the reactivity of the lowest 
reacting positive specimens relative to the negative population. These findings suggest the 
combined coating produces an assay that is more sensitive than any of the individual antigen 
assays, and is probably more specific as well. These two effects combine to produce greater 
separation between the lowest reacting specimens and the most reactive negative specimens. This 
means that the combined coating produces an assay with the necessary discrimination to 
differentiate reliably between positive and negative specimens. This outcome shows the limitations 
associated with using single antigens and clearly demonstrates the benefits of using a combined 
coating for the detection of antibodies to T.pallidum.
The evaluation above indicates the superiority of using a combination of four antigens, but it does 
not give any information on how these results relate to the current serological testing practices, i.e. 
quantitative data on the performance relative to other immunoassays. The results were compared 
with those of a leading commercially available immunoassay, Captia® Syphilis-G, based on wells 
coated with antigen derived from whole T.pallidum. It has been extensively evaluated and shown to 
be extremely sensitive and specific (Lefevre et al., 1990; Young et al., 1989; Young et al., 1992; 
Ross et al., 1991; Backhouse and Hudson, 1995; Hooper et al., 1994; Nayar and Compas, 1993). It 
has been recommended for screening and is used by many blood centres for routine testing. It has 
also been suggested that it may be suitable for confirmatory testing in place of FTA-ABS for positive 
results identified by other methods. These many evaluations mean that the performance 
characteristics of the assay are well known and documented, so it provides a good assay for 
comparative purposes. The results with the specimens from the genito-urinary clinic, when tested in
147
Chapter 7
the single antigen enzyme immunoassays, basically reiterated the findings of the disease stage- 
characterised specimens. The absorbances of the positive specimens were widely spread with 
many overlapping the negative population. Additionally, they show poor correlation with the Captia® 
Syphilis-G antibody index producing a scatter of results when plotted. The overlap of the positive 
specimens with the negative population is probably simply due to poor sensitivity of the assay, but 
the scattering of the results seen suggests an additional phenomenon is present. A simple lack of 
sensitivity would be manifested as a scatter of results around a line of equivalence with good 
correlation, but with a low slope. Specimens with strong responses in the Captia® Syphilis-G assay 
would produce much lower absorbances in the recombinant antigen assay, but all the specimens 
would maintain their relationships to each other. In the scattering of the results observed here some 
strong Captia® Syphilis-G positives are poorly reactive in the recombinant immunoassay, yet others 
of a similar reactivity are strongly reactive. This suggests that each of the individual recombinant 
proteins fails to detect significant antibody responses in some specimens that are detected by the 
whole treponeme based assay. The antibody responses of the specimens to each of the 
recombinant proteins are not directly proportional to their total anti-T.pallidum  activity. This means 
that any assay based on a single recombinant protein would tend to show poor sensitivity and give 
more false negative results than the commercial immunoassay. Some of the scattering of the 
results seen here is caused by a proportion of the specimens being detected more effectively by the 
recombinant proteins than by native antigen. This is probably due to the increase in the amount of 
antigen present when recombinant proteins are used to coat the solid phase, thus increasing 
sensitivity to that particular antigen.
When the specimens were tested against a combined coating of the four recombinants, the data 
generally replicated the findings previously seen. The range of absorbances of the negative 
specimens was reduced, producing a much tighter distribution, and the absorbances of the positive 
specimens were generally increased. Some of the specimens just below the Captia® Syphilis-G cut­
off were now shown to be distinctly more reactive than the negative population. These specimens 
probably contain low levels of syphilis antibodies and were falsely categorised as non reactive, 
suggesting that the combined coating produces an assay with greater sensitivity than the 
commercial immunoassay. Another noticeable effect was the improved correlation between the 
recombinant immunoassay absorbance and the Captia® Syphilis-G antibody index, shown by a
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reduction in the spread of the positive results. This suggests that the antibodies detected by the 
combined coating are a proportionate sample of those detected by the whole cell assay and no 
significant reactivities are left undetected. The combined coating of the four recombinant proteins 
performs well and produces an assay with a tight negative distribution and a good dose response. 
The assay discriminated well between positive and negative specimens, and is potentially more 
sensitive than the commercial immunoassay used for comparison.
Studies have shown antigenic cross-reactivity between T.pallidum and the non pathogenic Reiter’s 
spirochaete, T.phagedenis (Pedersen et al., 1980. Pedersen et al., 1981. Lukehart et al., 1982. 
Wos and Wicher, 1986. Baker-Zander and Lukehart, 1984). This cross reactivity has been widely 
exploited in syphilis serology in the use of T.phagedenis as the antigen source in the Reiter protein 
complement fixation test. It has also been used as a sorbent in the FTA-ABS test to remove cross 
reacting antibodies. T.phagedenis has been shown to encode and express a homologue of 
TpN44.5 (Yelton et al., 1991). This suggests the possibility that the use of TpN44.5 as an antigen 
might produce unwanted cross reactions. However, an enzyme immunoassay based on TpN44.5 
has been shown to be highly specific and sensitive, and comparable in performance to TPHA 
(Ijsselmuiden et al., 1989a). The only limitation of the test was a slight lack of sensitivity in early 
primary disease, which is a ubiquitous problem in syphilis serology. There was no evidence of cross 
reactivity in this study, so cross reactions may be more of a theoretical problem than a reality. 
Reviewing the data obtained for individual sera in this study shows that no specimen is reactive 
solely with TpN44.5, so omitting it from the combined coating may not be detrimental to the assay 
performance. This suggestion is supported by a recent publication (Young et al., 1998) evaluating a 
new commercial immunoassay based on a combined coating of recombinant TpN47, TpN17 and 
TpN 15. This study shows the assay to have superior sensitivity to Captia® Syphilis-G, particularly 
with early primary infections and patients with HIV co-infection. Perhaps elimination of TpN44.5 
from the antigen coating may not have any detrimental effects on overall assay sensitivity.
In conclusion, a combined coating of the four recombinant proteins has been shown to be suitable 
for the serological diagnosis of syphilis, but a coating of TpN47, TpN17 and TpN15 may be equally 
effective and should be investigated. The role of TpN44.5 should be investigated further to 
determine if its inclusion is detrimental or bestows any benefits on the assay performance.
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Summary
The enzyme immunoassays using each of the recombinant antigens individually lack sensitivity and 
the scattering of the results suggests that they each miss key antibody responses that are detected 
by the assay based on antigen derived from whole organisms. The combination of all four 
recombinant antigens produces an assay with better sensitivity than the native antigen assay. This 
is shown by the significant separation of the most reactive negative specimens from the least 
reactive syphilitic specimen. Additionally, there is much better correlation between the absorbances 
of the syphilitic specimens and their antibody indices in the native antigen assay. This suggests that 
all the significant antibody specificities are detected by the combination of the four recombinant 
proteins. The enzyme immunoassay developed here has the potential to perform well in a clinical 
situation, but requires additional testing to confirm its specificity and allow a cut-off to be 
determined.
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Introduction
Although recombinant proteins have many advantages over antigen derived from animal sources, 
they are still quite time consuming to produce and purify. There is also the problem of residual 
E.coli proteins, which are a potential cause of false positive results. This is exaggerated when 
several recombinant proteins are required to provide the necessary antigenicity. If the antigenic 
sequences within the proteins were identified, then perhaps a single synthetic recombinant protein 
could be constructed that consisted of a concatenation of these sequences. This would 
considerably reduce the complexity of the assay design. Depending on the number and strength of 
the antigenic sequences, an alternative strategy might be to produce synthetic peptides that 
represent the antigenic sequences of the proteins. Synthetic peptides can be produced to high 
levels of purity on an industrial scale, and are relatively inexpensive diagnostic reagents due to the 
low coating concentrations required.
The initial objective was to identify the antigenic sequences that the antibody responses were 
directed towards, using a synthetic peptide epitope mapping technique. Synthetic peptide epitope 
mapping is a simple way to define the linear or sequential epitopes within a protein sequence. 
However, due to restricted lengths of the peptides the technique fails to identify non-sequential or 
conformational types of epitope. The technique uses a set of overlapping peptides of a defined 
length, each offset from the previous peptide by a chosen number of residues, which are 
homologous to the amino acid sequence of the native protein. The peptide length and offset chosen 
are usually a compromise between the cost of the synthesis and the resolution of the experiment 
required. The use of short peptides with large overlaps and small offsets provides the highest 
resolution, but can be prohibitively expensive. For longer protein sequences, where cost of 
synthesis is a major consideration, a larger offset of 2 or 4 residues can be used. This reduces the 
number of peptides required, but also reduces the resolution of the experiment. However, this can 
be compensated for, to some extent, by using longer peptides, which reduces the chances of 
bisecting epitopes. TpN47 and TpN44.5 were mapped using a set of 14-mer peptides each offset 
from the previous one by four residues. TpN17 was mapped with 12-mer peptides offset by three 
residues, and TpN15 with 10-mer peptides offset by two residues. This technique is based on the 
simultaneous synthesis of large numbers of peptides using standard Fmoc chemistry. Synthesis of 
the peptides on derivatised pins was accomplished by repetitive cycles of Fmoc-deprotection,
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washing and amino acid coupling, adding one amino acid residue per cycle. After completion of 
synthesis of the desired peptides, the final Fmoc-protecting group was removed and the terminal 
amino group capped by acétylation. The side-chain protecting groups were removed by 
trifluoroacetic acid treatment. The success of the experiment depends on the correct synthesis of 
the peptides, and to ensure this various controls were incorporated during the synthesis procedure. 
Bromophenol blue stains the free amino groups blue, and was added to the coupling mixture to 
monitor the addition of each amino acid to the peptide. Successful coupling through the deprotected 
amino groups causes bleaching of the colour due to their reaction and elimination. Therefore, after 
each round of coupling the pins should become colourless, confirming successful attachment of the 
next amino acid in the chain. The peptide PLAQ reacts specifically with a control monoclonal 
antibody supplied with the derivatised pins, and the tetrapeptide GLAQ fails to react. These two 
control peptides were synthesised on each block of pins, in parallel with the test peptides. After 
synthesis, the reactions of the control peptides with the monoclonal antibody were compared to the 
reactions of identical peptides synthesised and supplied by the manufacturer. Comparable reactivity 
to the manufacturer-supplied peptides indicates successful synthesis has been achieved. The 
overlapping peptide sets were tested with specific antisera using an enzyme immunoassay 
procedure to identify antigenic regions and locate epitopes within the protein.
Results
The absorbances of the control peptides, synthesised in parallel to the test peptides, closely 
matched those of control peptides supplied by the manufacturer. All the test peptides produced low 
absorbances, less than 0.1, when tested directly with the monoclonal anti-human IgG/HRP 
conjugate. Repetition of this test after every five specimens tested produced similar low 
absorbances with all peptides. The testing of the peptides was further controlled by periodically 
testing the same syphilitic serum specimen. Fig 41 shows a graph of the absorbances from the first 
(test A) and last (test B) of these tests plotted against each other. The absorbances correlate well in 
terms of relative reactivities and absolute absorbance values, resulting in a narrow scatter of points 
around the x= y line. This is confirmed by regression analysis of the data which produces an R2 
value of 0.98 and a slope of 0.99.
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Figure 41. Effect of multiple cycles of testing and regeneration on peptide activity.
Absorbance of the peptides tested with a syphilitic serum at the beginning of the study (test A) compared 
with the same specimen retested at the completion of the testing programme (test B).
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The peptides were tested with serum specimens from 18 normal blood donors, 22 patients with 
syphilis, and a pool of syphilitic serum before and after affinity purification. A cut-off value (mean + 3 
SD of the 100 least reactive peptides) was applied to the data to identify the most significant 
reactivities. Peptides above the cut-off are identified in red and those below in blue. All serum 
specimens from normal blood donors generally gave absorbances of less than 0.1 with all peptides. 
A typical set of results are shown in Figure 42. When the peptides were tested with serum 
specimens from patients with syphilis some peptides showed more reactivity than was typically 
seen with a negative specimen and there was a range of absorbances across the peptides 
producing reactive regions interspersed with less reactive sequences. The overall reactivity of each 
serum specimen varied greatly. Fig 43 shows the epitope scans from a weakly reacting specimen 
where the range of responses across the peptides is relatively small. Fig 44 shows the other end of 
the spectrum of the responses seen where there is a large difference in absorbance between the 
most reactive and least reactive peptides. This type of response produces clearly defined reactive 
regions separated by several non reactive peptides.
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Figure 42. Epitope scans produced by a serum specimen from a normal blood donor.
A; Absorbances of the set of 14-mer overlapping peptides covering TpN47. B; Absorbances of the set of 
14-mer overlapping peptides covering TpN44.5. C; Absorbances of the set of 12-mer overlapping peptides 
covering TpN17. D; Absorbances of the set of 10-mer peptides covering TpN15.
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Figure 43. Epitope scans produced by a weakly reacting serum specimen from a patient with 
syphilis.
A; Absorbances of the set of 14-mer overlapping peptides covering TpN47. B; Absorbances of the set of 
14-mer overlapping peptides covering TpN44.5. C; Absorbances of the set of 12-mer overlapping peptides 
covering TpN17. D; Absorbances of the set of 10-mer peptides covering TpN15.
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Figure 44. Epitope scans produced by a strongly reacting serum specimen from a patient with 
syphilis.
A; Absorbances of the set of 14-mer overlapping peptides covering TpN47. B; Absorbances of the set of 
14-mer overlapping peptides covering TpN44.5. C; Absorbances of the set of 12-mer overlapping peptides 
covering TpN17. D; Absorbances of the set of 10-mer peptides covering TpN15.
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Affinity purified antibody preparations specific for each of the recombinant proteins were prepared 
from a pool of syphilitic serum specimens. The affinity purified antibodies produced dramatically 
different epitope scans to those of the original serum pool from which they were derived. Fig 45 
compares the epitope scans of TpN47 before and after affinity purification. Compared to the original 
material, the affinity purified antibodies show a large increase in the response of the reactive 
peptides and, proportionately, a much smaller increase in the absorbances of the least reactive 
peptides. This produces much more clearly defined reactive regions than is seen with the original 
serum pool. A similar overall picture is seen in the epitope scans of the other antigens using the 
appropriately purified antibody preparation. The results of TpN44.5 are shown in Fig 46, those of 
TpN17 in Fig 47, while Fig 48 features the scans of TpN15. It is interesting to note the similarity of 
results produced by the affinity purified antibody preparations to those of the most reactive 
individual sera tested as shown in Fig 44.
Figure 45. Epitope scans of TpN47 using a syphilitic serum pool before and after affinity 
purification.
Absorbances of the set of 14-mer peptides covering the sequence of TpN47. The dark red and dark blue 
bars represents the syphilitic serum pool and the light red and light blue represents it after affinity 
purification. Red bars represent peptides greater than the cut-off value.
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Figure 46. Epitope scans of TpN44.5 using a syphilitic serum pool before and after affinity 
purification.
Absorbances of the set of 14-mer peptides covering the sequence of TpN44.5. The dark red and dark blue 
bars represents the syphilitic serum pool and the light red and light blue represents it after affinity 
purification. Red bars represent peptides greater than the cut-off value.
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Figure 47. Epitope scans of TpN17 using a syphilitic serum pool before and after affinity 
purification.
Absorbances of the set of 12-mer peptides covering the sequence of TpN17. The dark red and dark blue 
bars represents the syphilitic serum pool and the light red and light blue represents it after affinity 
purification. Red bars represent peptides greater than the cut-off value.
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Figure 48. Epitope scans of TpN15 using a syphilitic serum pool before and after affinity 
purification.
Absorbances of the set of 10-mer peptides covering the sequence of TpN15. The dark red and dark blue 
bars represents the syphilitic serum pool and the light red and light blue represents it after affinity 
purification. Red bars represent peptides greater than the cut-off value.
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Dramatic variations in the responses to individual peptides among the various serum specimens 
was noted. The epitope scans produced a complicated picture of multiple reactivities across the 
protein with no obvious consensus. In an attempt to analyse the results, frequency profiles were 
constructed based on the number of sera reacting with each peptide and also based on the total 
absorbance for each peptide. Neither approach proved useful in interpreting the epitope scans. The 
most successful approach was to plot the reactive regions of each serum epitope scan, which were 
defined as a sequence of at least two consecutive reactive peptides. In order to identify consensus 
reactive sequences, plots were constructed of all the reactve regions identified by the various 
syphilitic sera. Fig 49 summarises the data for the peptides covering TpN47. Fig 50, Fig 51, and Fig 
52 show similar data summaries for TpN44.5, TpN17, and TpN15, respectively. Significant 
immunoreactive regions could be identified that were reactive with the majority of sera tested. 
TpN47 shows such six such regions spanning amino acid start positions, A; 21-33, B; 69-85, C; 
165-185, D; 261-277, E; 293-361 and F; 409-421. TpN44.5 and TpN17 each show two such regions 
spanning amino acid start positions, A; 171-195 and B; 219-263, and A; 79-91 and B; 139-145, 
respectively. TpN15 shows four regions spanning amino acid start positions A; 20-28, B; 52-56, C; 
72-76 and D; 112-132.
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Figure 49. Summary of the reactive regions of TpN47.
Sequences of two or more reactive peptides in the epitope scans of 22 serum specimens from patients with 
syphilis (black), a syphilitic serum pool (blue) and an affinity purified anti-TpN47 antibody preparation (red).
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Figure 50. Summary of the reactive regions of TpN44.5.
Sequences of two or more reactive peptides in the epitope scans of 22 serum specimens from patients with 
syphilis (black), a syphilitic serum pool (blue) and an affinity purified anti-TpN44.5 antibody preparation 
(red).
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Figure 51. Summary of the reactive regions of TpN17.
Sequences of two or more reactive peptides in the epitope scans of 22 serum specimens from patients with 
syphilis (black), a syphilitic serum pool (blue) and an affinity purified anti-TpN17 antibody preparation (red).
25
20
14212210282624222
A mino terminal  residue n u m b e r
Figure 52. Summary of the reactive regions of TpN 15.
Sequences of two or more reactive peptides in the epitope scans of 22 serum specimens from patients with 
syphilis (black), a syphilitic serum pool (blue) and an affinity purified anti-TpN15 antibody preparation (red).
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Discussion
The results of synthetic peptide epitope mapping experiments very much depend on the accurate 
synthesis of the peptides. This was monitored by the presence of bromophenol blue in the reaction 
mixture to detect any un reacted amino groups. After each round of the synthesis process the 
absence of bromophenol blue staining of the pins indicated that the amino acid had been 
successfully added to the sequence. No staining was detected after any of the coupling steps, 
therefore the peptides were assumed to be correctly synthesised, and should correspond to the 
sequences of the experimental plan. The synthesis procedure was also controlled using functional 
activity. Control peptides (PLAQ and GLAQ) were synthesised in parallel with the test peptides. The 
reactivity of in-process control peptides, with a specific monoclonal antibody, compared well to that 
of similar peptides supplied by the manufacturer, suggesting the sequences were not only 
synthesised correctly, but also functionally active. The nature of the peptide synthesis and the 
format used necessitated a sequential testing programme. Therefore, it was necessary to confirm 
the successful regeneration of the peptides and determine the consistency of the testing program, if 
comparative analysis was to be performed. Periodic testing of the peptides after regeneration with 
conjugate only, failed to detect residual antibody on any occasion. Therefore, the regeneration 
procedure effectively and reliably removed all traces of bound antibodies between testing runs. The 
repeated cycles of testing and regeneration could lead to deterioration of the peptides. The virtually 
identical results of the same serum specimen tested at the beginning and end of the testing 
programme suggests that there was no detectable loss of activity of the peptides over the course of 
the experiment. The similarity of the absorbances demonstrates not only the lack of deterioration, 
but also the reproducibility of the testing protocol making comparison of the results of different sera 
possible.
Even though there was considerable variation in the response to individual peptides and weak 
reactions were relatively common, an overall consensus of the reactive regions was found which 
suggests the process is fairly robust. The weak nature of some responses is probably due to the 
low specific activity of polyclonal human sera because only a small proportion of the IgG present will 
be disease specific. Affinity purification will not only purify out the specific antibodies, but has the 
tendency to favour the selection of high affinity variants. This has the effect of increasing the 
specific activity of the sample and also eliminating weak or non-specific reactivities. These effects
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are shown clearly by the affinity purified antibody preparations in the strength and specificity of their 
reactions with the peptides. The responses were dramatically different from the weak indistinct 
results of the raw serum pool from which the affinity purified antibodies were derived. They 
produced much stronger responses with more clearly defined sequences of peptides, and low 
background reactions. The immunoreactive regions identified by the affinity purified antibodies 
agree with the consensus reactivities of the other specimens. They also define some regions only 
detected by a minority of specimens. The use of affinity purification in epitope mapping studies is an 
innovative approach and seems particularly applicable to situations where only weak, indistinct 
serological reactions are present.
The literature contains a huge number of reports of epitope mapping studies of a large number of 
antigens from a range of different microorganisms. Review of the extensive literature in this field 
reveals only three reports describing epitope mapping studies of polypeptides of T.pallidum, and no 
studies of closely related organisms. The major lipoproteins of T.pallidum have no known function 
and no homologues have been identified in other organisms, so comparisons with the results of 
similar studies on related proteins are not possible. This means that the analogous literature 
available for discussion is relatively restricted.
Baughn et al. (1996a) have comprehensively investigated the B-cell determinants of TpN47 using 
syphilitic rabbit sera and IgM fractions of human sera. These investigators also found that there 
were dramatic variations in the response with individual peptides. By constructing plots based on 
the numbers of sera reacting with each peptide they identified a series of ten immunoreactive 
regions, none of which agree with the regions identified in this study. In fact the two sets of results 
seem mutually exclusive of each other, the reactive regions of Baughn et al. coinciding virtually 
exactly with the non-reactive sequences identified here. This is difficult to reconcile solely on the 
basis of differences in the peptide length and overlap used as the peptides used by Baughn et al. 
were similar to those used in this study. However, the nature of the sera tested may have some 
influence on the results obtained. The rabbit antisera used by Baughn et al. will not only have a 
much higher specific activity than immune human sera used in the present study, but the immune 
response might be directed towards a different set of species-specific epitopes, accounting for the 
different results seen in the two studies. Similarly, the results obtained by Baughn et al. using 
human IgM specimens may indicate that the IgM response is directed towards fundamentally
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different epitopes to the IgG response examined in this study. No studies could be found in the 
literature that investigated whether the IgM and IgG antibody responses are directed towards 
different epitopes. Further testing of the peptide with IgM fractions and hyperimmunised rabbit 
antisera would be required to determine if the differences between the results reported by Baughn 
et al. and those described in the present study are due to differences in the peptides used, or due to 
the type of specimen tested.
In another study, Baughn et al. (1996b) have epitope-mapped TpN15 using immunised rabbit 
serum and identified seven discrete regions of reactivity: I, 10-17; II, 20-27; III, 49-60; IV, 69-79; V, 
84-92; VI, 107-113; VII, 115-128. The region I identified by Baughn et al. occurs completely within 
the signal sequence of the protein. The set of peptides used in the present study did not include the 
signal sequence, and so no conclusions can be drawn concerning region I. Regions A, B, and C 
identified in the study reported here matched regions II, III, and VI, respectively, to within a few 
amino acids one way or the other. Region D can be considered to match regions VI and VII, which 
are virtually contiguous producing a larger region covering residues 107-128. Region V matches a 
sequence that is only detected by the affinity purified antibody and not by any of the individual 
specimens tested. The hyperimmunised rabbit serum used by these researchers will be much more 
avid, and of a higher titre than immune serum from a patient with syphilis, and possess many of the 
characteristics of an affinity purified preparation. Region V is only detected by antibodies produced 
after artificially enhanced immunisation or purified to increase their potency, which suggests that 
this region is probably weakly immunogenic. Generally, these two studies agree quite closely on 
which sequences within TpN 15 are immunoreactive, even though they use different antibody 
sources.
The antigenic structure of TpN44.5 has recently been investigated (Antoni et al., 1996) using an 
alternative approach. A series of ten overlapping peptides, 35-40 amino acids long covering the 
entire sequence were synthesised. They were coated on to microplates and tested by enzyme 
immunoassay against serum specimens from patients with syphilis. These researchers found the 
most reactive peptide to be the one covering the N-terminal portion of the sequence between 
residue numbers 23-60. They found a second region of lesser reactivity at the C-terminal end of the 
protein between residues 250-345. This contrasts with the results found here where the main 
reactivity is in a central region of the protein between amino acids 171 and 263. The likely cause of
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this discrepancy is in the differences in the experimental protocols used. The enzyme immunoassay 
method requires the peptides to be bound to the microplate wells. This brings with it problems of 
differential binding that will affect the level of response in the assay. So, a weak reaction might not 
be due to low reactivity with a peptide but actually due to poor binding of the peptide to the plastic 
surface. This highlights another limitation of the enzyme immunoassay procedure, the need to use 
relatively long peptides to allow them to be bound to plastic. Short peptides bind very poorly to 
polystyrene surfaces. The strategy used by Antoni et al. (1996) selected the size of the peptides, 
the position of the junctions between peptides, and their overlaps on the basis of a hydrophobicity 
plot. This could impose a predetermined outcome to the experiment due to the position of the 
junctions between the chosen peptides. However, this approach does have some advantages. 
Using large fragments of the protein could mean that conformational epitopes are present that 
would be absent when small peptides are used. This could account for the differences in the 
reactions observed by Antoni et al. compared to those seen in the study reported here, and could 
mean that a significant antibody response to TpN44.5 is directed towards a conformational epitope 
contained within the first 38 amino acids of the mature protein sequence. This epitope would not be 
identified using the small peptides featured in the present study as they exhibit little or no secondary 
structure. Clearly the strategy used can profoundly affect the results generated.
A huge literature of epitope mapping studies exists, examining the antigens of a wide range of 
viruses, bacteria and other microorganisms, as well those of cell constituent proteins and enzymes. 
However, there is a preponderance of reports describing the epitopes of viral capsid proteins, and 
the target epitopes of monoclonal antibodies. There are relatively few reports on bacterial 
membrane proteins and none at all on other lipoproteins, so it is difficult to place the work reported 
here in context. In the studies examined, a commonly reported pattern of reaction is to see several 
reactive regions across a protein each containing multiple epitopes (Bolwell et al., 1989.; 
Middeldorp and Melsen, 1988.; Okahaski et al., 1993.; Strynadka et al., 1988.; Zhong et al., 1990.). 
This is a similar general pattern to that seen in the study reported here.
A report (Geysen et al., 1988), by some of the inventors of solid-phase peptide epitope mapping 
and the holders of key patents, suggests that it is not uncommon when using human sera for 
multiple weak reactivities to be reported and the poor signal to background ratios are not improved 
by increasing the concentration of the test sera. Their interpretation of this type of data is that the
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serum lacks a major population of antibodies directed to a linear epitope of the antigen. Many or all 
of the small peaks present are believed to be due to segments of discontinuous determinants. This 
conclusion is drawn from the similarity of the signals to those obtained when testing a monoclonal 
antibody known to recognise a discontinuous epitope. Further they suggest, based on unpublished 
epitope mapping studies with monoclonal antibodies, that approximately 5-10% of all antibodies 
directed to native antigens bind to linear epitopes (Geysen et al., 1987). This suggests that a large 
proportion of the antibody responses seen in the study reported here are possibly directed towards 
discontinuous epitopes and so are poorly defined by small synthetic peptides.
In view of the large literature it is surprising how few of the sequences identified by epitope mapping 
studies have been used to develop successful diagnostic tests. Volkmer-Engbert et al. (1994) and 
Wout et al. (1993) are two examples of epitope mapping studies that produced successful peptide- 
based antigens for the diagnosis of HIV and EBV infections, respectively. It is of note that they are 
both diagnostically significant viral outer envelope proteins and show a distinctly different reaction 
pattern to the many of the other studies, and also the study reported here. These proteins show 
only a few reactive regions with most of the reactivity confined to a single relatively short sequence. 
This pattern of antigenicity allows a relatively short sequence to capture most of the antibody 
response and so lends itself to the use of synthetic peptide-based antigen. However, when the 
antibody response is directed to determinants spread across the whole protein sequence, as in the 
study reported here, a large number of peptides would be required to capture enough antibody to 
be diagnostically effective. This makes the use of synthetic peptides impractical and lends itself to 
the use of recombinant proteins. It is for this reason, and the success of the recombinant protein 
approach, that the sequences identified here were not investigated any further.
Summary
Epitope mapping with overlapping synthetic peptides is an efficient way to identify the linear 
antigenic determinants defined by a particular serum or monoclonal antibody. However, a large 
proportion of the total epitopes present, the discontinuous or conformational epitopes, are 
inaccessible by this method. The antibody responses were not found to be directed towards clearly 
defined sequences of linear epitopes in a background of low responses, as is seen in the previously 
cited examples of diagnostically effective peptides. The technique identified multiple responses
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across the entire sequence of the proteins, however some consensus antigenic sequences were 
identified. This overall complex picture suggests that a high proportion of the diagnostically 
significant antibody response is probably directed to discontinuous conformational epitopes.
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Introduction
Filamentous bacteriophages such as M13, fl, and fd have three to five copies of the capsid protein 
III (cplll) located at one end of the phage particle. This protein is essential for proper phage 
assembly and for adsorption to the F pilus of male strains of E.coli. When small DNA fragments are 
inserted between the leader sequence and the mature coding sequence of the gene coding for 
cplll, the progeny phage carry the corresponding protein sequence as an N-terminal fusion with the 
cplll protein (Parmley and Smith, 1988). Such fusions do not affect the function of the cplll protein, 
so the phage are able to propagate normally. In the technique known as phage display, a library of 
different peptides or proteins are displayed on the surface of the phage particles. Phage expressing 
particular motifs, such as antibody binding properties, can be enriched in the population using a 
form of affinity selection known as biopanning. The library is first incubated with a target molecule 
bound to a solid-phase, then the unbound phage are washed away. The bound phage are eluted 
from the solid-phase by acidification and amplified, thus increasing the number of phage carrying 
binding motifs in the population. The enriched population is then biopanned again against a fresh 
solid phase coated with the target material. Usually, three to four rounds of this enrichment process 
are completed before the primary structure of the binding motifs are deduced by nucleotide 
sequencing of individual clones.
Phage display can be utilised to locate antigenic epitopes. Fragments of DNA that encode portions 
of the protein antigen are fused to the gene encoding capsid protein III. Phage can then be tested 
with the antibody to determine which displayed fragments react with the antibody. This has been 
done successfully for the HIV gag gene (Tsunetsugu-Yokota et al., 1991) and more recently for the 
outer capsid protein VP5 of the bluetongue virus (Wang et al., 1995). This is the basic concept 
explored in the work described in the study reported here. The simplest form of display, as utilised 
in the fUSE2 vector used in this study, is achieved by insertion of the DNA fragments directly into 
the gene coding for the cplll protein, this means that all copies of cplll carry the resulting fusion. 
Some sequences, usually large proteins like antibody fragments, are poorly displayed using this 
type of display because of interference with the function of cplll by the presence of the large fusion 
protein. This has been overcome using a different type of vector system. The DNA fragments are 
clone into a phagemid vector. When bacterial cells harbouring these phagemids are infected with 
M13 helper phage, which carry a full complement of capsid-encoding genes but are defective in
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replication, the secreted phage particles carry the phagemid genome and a mixture of wild-type and 
fusion cpllls. The presence of wild-type cplll ensures the phage particles can adequately interact 
with the F pilus and propagate normally. This type of display is exemplified by the Surf ZAP vector 
system used in the study reported here.
In the work described here, the objective was to produce random gene fragment phage display 
libraries which expressed sequences of the four lipoprotein antigens of T.pallidum, TpN47, 
TpN44.5, TpN17, and TpN15. In accomplishing this objective two different vector systems and two 
different methods of preparing the gene fragments were employed. Random gene fragments were 
prepared by a nested PCR technique using a primer pair which rebuilt the portion of the cplll leader 
sequence missing from the vector and terminated in a series of random bases. The rationale was 
that the random bases of the primers would anneal at arbitrary points along the gene creating the 
random fragments. Then a second set of primer complementary to the 5’ ends of the first primer 
pair would be used, after removal of excess primers from the first reaction, to amplify the reaction 
products of the first PCR. These DNA fragments were cloned into the Surf ZAP vector system to 
produce a set of phagemid libraries. The second method used was simpler and involved producing 
DNA fragments of the lipoprotein genes by digestion with DNase 1. Following size selection and 
modification of the fragment termini, they were cloned into the BglW site of the fUSE2 vector, thus 
producing a library of phage particles displaying random fragments of the lipoprotein antigens. 
These libraries were biopanned with antibodies specific for T.pallidum and the binding motifs of 
individual clones identified by nucleotide sequencing.
Epitope mapping by phage display was employed because it has the potential to supply 
complementary information to that of the previous studies using synthetic peptides. Synthetic 
peptides epitope mapping studies are limited to identifying linear or sequential epitopes due to the 
restricted size of the peptides used. Phage display can express a larger range of sizes of protein 
fragments, therefore it allows an array of different motifs to be displayed from short linear epitopes 
to longer sequences with the potential to express significant conformational structure. The objective 
of the phage display work described here was to identify antigenic sequences within the lipoprotein 
antigens of T.pallidum preferentially bound by specific antibodies regardless of size. The type of 
fragments selected by the biopanning procedure would give valuable information on the nature of 
the antibody response to T.pallidum. If predominantly short sequences were selected this would
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suggest that the significant antibody responses were principally directed towards linear epitopes. 
However, if long sequences were selected then conformational epitopes represent the most 
significant targets of the antibody response. Alternatively, long sequences might contain multiple 
epitopes allowing multipoint attachment of the protein, thereby enhancing retention by the solid- 
phase. Finally, any sequences identified would be of great interest as antigens for use in serological 
tests.
Results
PCR synthesised random gene fra
Random gene fragments were generated by a nested PCR technique, using random primers to 
amplify segments of the target genes, which were then cloned into the Surf ZAP phage display 
vector system (Stratagene). Separate gene fragment libraries were constructed for TpN47, 
TpN44.5, TpN17 and TpN15. Table 3 shows the sizes of the primary libraries before amplification, 
estimated by lambda plaque titration. After amplification each library consisted of a total of 1011 pfu 
per library, at a concentration of 2x109 pfu per mL.
Table 3. Number of phage successfully packaged for each of the primary libraries.
Target
gene
Library
designation
Total number 
of
pfu packaged
Number of pfu in 
primary library
tpnA7 SZ47 8.2x10^ 8.1x105
tpnAA.5 SZ44 3.7x105 3.6x105
tpnM SZ17 3.4x105 3.3x105
tpn'\5 SZ15 4.1x105 X o
No insert control - 1x104 -
10 random plaques were randomly selected from each of the primary libraries and the size of their
inserts determined by PCR amplifying across the cloning site using standard T3 and T7 promoter 
primers. Fig 53 shows the results of the plaques selected from the SZ47 library. The theoretical size 
of the amplified DNA from the vector only is 882bp. The randomly selected plaques produced
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amplified DNA segments with a range of sizes and all larger than the vector only controls. Similar 
amplifications of randomly selected plaques from the other three libraries also showed a range of 
insert sizes, all larger than the vector only controls (data not shown).
Figure 53. Characterisation of SZ47 library complexity.
PCR amplified inserts of 10 random plaques from the SZ47 primary library separated on a 2.5% agarose 
gel. Lane M; 1kb DNA ladder (bp are indicated). Lane C; SurfZAP vector only. Lane 1-10; 10 random 
plaques.
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The four libraries were biopanned against a solid phase coated with purified IgG from a pool of 
serum from patients with high titre syphilis antibodies. The number of phage recovered from the 
solid phase was estimated after each round of biopanning by phage titring. There was no increase 
in the number of phage eluted from the solid phase in successive rounds of biopanning. Random 
clones arbitrarily selected from the enriched libraries failed to produce a signal when tested in the 
M13 immunoassay.
In another attempt at biopan enrichment, the four libraries were biopanned against solid-phases 
coated with affinity purified antibody of the same specificity as the library. After each successive 
round of biopanning there was an increase in the number of phage recovered from the solid 
phases. After three rounds, individual colonies were randomly selected from each of the enriched 
libraries and the inserts analysed by PCR, M13 immunoassay and DNA sequencing.
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PCR screening
The insert contained in each clone was PCR amplified using T3 and T7 promoter primers that 
anneal to sequences in the vector flanking the cloning site. Fig 54 shows the amplified inserts in the 
clones selected from the SZ47 and SZ44 separated by agarose gel electrophoresis. The size of the 
inserts were estimated by interpolation against the DNA standards. The SZ47 library clones 
produced a range of insert sizes: clones 1, 3, 5, 6, 7 and 8 contain an insert 45 bp long, clones 2 
and 9 contain a 90 bp insert, while clone 10 contains a much larger insert approximately 222 bp 
long. Clones 4 and 11 give bands of the same size as the vector only control, so probably contain 
no inserts. The clones selected from the SZ44 library produces two types of inserts. Clones 12, 15, 
18 and 20 produce bands of the same size as the vector only control, therefore probably contain no 
inserts, and clones 13, 14, 16, 17, 19, 21 and 22 contain a 342 bp insert.
Figure 54. Insert sizes of colonies from biopan enriched SZ47 and SZ44 libraries.
PCR amplified inserts of randomly selected SZ47 and SZ44 colonies separated on a 2.5% agarose gel. 
Lane M; 1kb DNA ladder (bp are indicated). Lane C; fUSE2 vector only. Lane W; No DNA PCR control. 
Lane 1-11; 11 randomly selected SZ47 colonies after enrichment by biopanning with affinity purified anti- 
TpN47 antibodies. Lane 12-22; 11 randomly selected SZ44 colonies after enrichment by biopanning with 
affinity purified anti-TpN44.5 antibodies.
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Fig 55 shows the amplified inserts of clones selected from the SZ17 and SZ15 libraries. Again, the 
size of the inserts were estimated by interpolation against the DNA standards. The SZ17 library 
produced a range of insert sizes. Clones 2, 8, and 11 contained an insert approximately 393 bp 
long. Clones 1 and 3 contain no insert. The insert in clone 5 is approximately 84 bp long and the
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insert in clone 6 is 45 bp long. Clones 4, 7, 9 and 10 appear to contain a 33 bp insert. The clones 
selected from the enriched SZ15 library all contain an insert approximately 255 bp long.
Figure 55. Insert sizes of colonies from biopan enriched SZ17 and SZ15 libraries.
PCR amplified inserts of randomly selected SZ17 and SZ15 colonies separated on a 2.5% agarose gel. 
Lane M; 1kb DNA ladder (bp are indicated). Lane C; fUSE2 vector only. Lane W; No DNA PCR control. 
Lane 1-11; 11 randomly selected SZ17 colonies after enrichment by biopanning with affinity purified anti- 
TpN17 antibodies. Lane 12-22; 11 randomly selected SZ15 colonies after enrichment by biopanning with 
affinity purified anti-TpN15 antibodies.
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M13 immunoassay
Recombinant phage particles were prepared from the clones analysed by PCR and tested in an 
M13 immunoassay. Fig 56 shows the absorbances of the 11 clones, previously tested by PCR, 
selected from the enriched SZ47 library. All the clones produce a strong signal with the anti-M13 
coated wells, but low absorbances with the test wells coated with anti-TpN47 and control wells 
coated with human IgG. The VCSM13 helper phage produced the expected response with the anti- 
MIS coated well and the diluent control gives low absorbances with all wells. Fig 57 and Fig 58 
show the results of the clones selected from the SZ44 and SZ17 libraries, respectively. They show 
a similar pattern of reactions to those already described for the SZ47 clones, strong responses with 
the anti-M13 coated wells and little response to the affinity purified antibody coated wells and 
normal IgG control wells. The results of the clones from the SZ15 library show a different pattern of 
reactions. All samples show a strong response to the anti-M13 coated wells and a weaker response
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to the anti-TpN15 coated wells that is distinctly greater than that seen with the normal IgG coated 
wells. Again, the VCSM13 and diluent controls give the expected responses.
Figure 56. M13 immunoassay results of clones selected from enriched SZ47 library.
Absorbances of 11 randomly selected SZ47 clones after enrichment by three rounds of biopanning against 
affinity purified anti-TpN47 antibodies.
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Figure 57. M13 immunoassay results of clones selected from enriched SZ44 library.
Absorbances of 11 randomly selected SZ44 clones after enrichment by three rounds of biopanning against 
affinity purified anti-TpN44.5 antibodies.
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Figure 58. M13 immunoassay results of clones selected from enriched SZ17 library.
Absorbances of 11 randomly selected SZ17 clones after enrichment by three rounds of biopanning against 
affinity purified anti-TpN17 antibodies.
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Figure 59. M13 immunoassay results of clones selected from enriched SZ15 library.
Absorbances of 11 randomly selected SZ15 clones after enrichment by three rounds of biopanning against 
affinity purified anti-TpN15 antibodies.
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DNA sequences
Several clones were sequenced to identify the inserted DNA sequences. Clones 2, 5 and 10 from 
the SZ47 library, clones 21 and 22 from the SZ44 library, and clones 2, 5, 6, and 7 from the SZ17 
library were sequenced. The sequences were compared with the known database sequences of the 
T.pallidum lipoproteins. None of the inserts showed homology with the T.pallidum lipoproteins at 
either a nucleotide or amino acid level.
Clones 12 and 19 from the SZ15 library were sequenced and both found to contain the same 255 
bp insert. This insert was found to have homology to a sequence within the TpN15 lipoprotein of 
T.pallidum between residue 121 and 375. Fig 60 shows the alignment of the DNA sequence of the 
insert (black) with the known database sequence of that region of tpnîS  (blue) and highlights the 
discrepant nucleotides in red. The deduced amino acid sequences associated with the DNA 
sequences are also shown for comparison.
Figure 60. DNA sequence of clone 12 from the enriched SZ15 library.
5'A T A A A G A A G G G C G G T T T A A G T C C C A G G AC G CT GA C TA C CA T CG GG TC A TG T AT G CA T CC T CG G G 3'
5 - A T A A A G A A G G G C G G T T T A A G T C C C A GG A CG C TG A CT A CC A TC G G GT C AT G TA T GC A TC C TC G GG  3 '
5'C A T A G G T C C T G A A A A G G C C T T CA GA G AG C TC G CC G AT G CT T TG CT TG A AA A GG G TA A TC C CG A G 3'
5'C A T A G G T C C T G A A A A G G C C T T C A G AG A GC TC G CC G AT G CT T TG CT TG A AA A GG G TA A TC C CG A G 3
5'A T G G T G G A T G T G G T C A C C G G T G C A AC TG T TT C TT C CC A GA T GT TC AG G AG G TT G GG T CG T GC G  3 
5'A T G G T G G A T G T G G T C A C C G G T G C A A C T G T T TC T TC C CA G AT G T TC A GG AG G T TG GA T CA G GC T  3'
DNA and deduced amino acid sequences of the insert of clone 12 biopanned from the SZ15 library using 
affinity purified anti-TpN15 antibodies. Database sequence is shown in blue and the insert sequence in 
black, with non homologous residues in red. The amino acid sequence is deduced from the DNA sequence.
5'A A G G A C T T T C T C G A G G T T A C T T T T GA TG G TG G CA A GA T GG T GC AG GT G GT T TA C GA T TA T CA G C 3 
5'A T T G A T G T T C T C G A G G T T A C T T T T G A T G GT G GC A A G A T G G T G C A G G T G G T T T A C GATTATCAGO 3
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DNasel digested random gene fragment library
A single random gene fragment library was constructed by digesting the four major lipoprotein 
genes with DNase I, and cloning the resulting fragments into fUSE2 phage display vector. The 
number of recombinant phage produced under different ligation conditions was estimated by phage 
titring and the results are shown in Table 4. Electroporation of the replicative form (RF) DNA 
produced the large number of transformants expected. The ligation reactions at different 
vector:insert ratios all produced similar numbers of transformants, but less than uncut RF DNA 
produced. These reactions produced significantly more transformants than when no insert was 
present in the reaction. The four reactions containing the recombinant phage were pooled giving a 
primary library of around 106 phage, which was amplified to give a stock of 1012 cfu/mL.
Table 4. Number of recombinant phage produced under different ligation conditions.
Ligation reaction No. of phage / pg DNA
RF DNA 2x107
Vectorlnsert ratio = 1:0 1x10"
Vectorlnsert ratio = 1:2 0.8x105
Vectorlnsert ratio =1 :3 2.3x105
Vectorlnsert ratio = 1:4 1.8x105
Vectorlnsert ratio =1 :5 5.1x105
MC1061 E.coli cells only none detected
The library was characterised by PCR amplifying across the cloned insert using primers (cplll-S, 
cplll-T) that annealed to vector encoded sequences. 10 random colonies were selected, the RF 
DNA isolated and used as template for the PCR. The amplified DNA was separated by 
electrophoresis on a 2.5% agarose gel which is shown in Fig 61. Amplification across the cloning 
site theoretically produces a fragment of 496 bp, which is confirmed by the DNA in lane C. All ten of 
the clones selected contained an insert of various sizes, which covered the range of sizes (50 - 350 
bp) in the original DNasel digestion.
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Figure 61. Characterisation of fUSE2 library.
Amplified inserts of 10 random plaques from the fUSE2 primary library separated on a 2.5% agarose gel. 
Lane M; 1kb DNA ladder (bp are indicated). Lane C; fUSE2 vector only. Lane 1-10; 10 random colonies.
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The four libraries were biopanned against a solid phase coated with purified IgG from a pool of 
serum from patients with high titre syphilis antibodies.
The library was biopanned against a solid phase coated with purified IgG from a pool of serum from 
patients with high titre syphilis antibodies. The number of phage recovered from the solid phase 
was estimated after each round of biopanning by colony titring. There was no increase in the 
number of phage eluted from the solid phase in successive rounds of biopanning. Randomly 
selected clones from the enriched libraries failed to produce a signal when tested in the M13 
immunoassay.
The library was biopanned against four different solid-phases. The solid phases were prepared by 
separately coating affinity purified antibodies to TpN47, TpN44.5, TpN17 and TpN15. After each 
successive round of biopanning there was an increase in the number of phage recovered from the 
solid phases. After three rounds, individual colonies were arbitrarily selected from each of the 
enriched libraries and the inserts were characterised by PCR amplification, M13 immunoassay, and 
DNA sequencing.
PCR screening
12 colonies were randomly selected after biopan enrichment, RF DNA isolated and the insert PCR 
amplified as previously described. Fig 62 shows the DNA separated on a 2.5% agarose gel. The 
sizes of the inserts were estimated by interpolation against the DNA standards. Eleven of the twelve
.T v, 'L.;* if
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from the library biopanned with anti-TpN47 contain a 141 bp insert, except clone 8 that contains no 
insert. The inserts from the library biopan enriched against anti-TpN44.5 show two types of insert. 
Clones 18 and 24 contain an insert approximately 153 bp long and the rest have a smaller 87 bp 
insert.
Figure 62. fUSE2 insert sizes after enrichment with anti-TpN47 or anti-TpN44.5 antibodies.
PCR amplified inserts of randomly selected fUSE2 colonies separated on a 2.5% agarose gel. Lane M; 1kb 
DNA ladder (bp are indicated). Lane C; fUSE2 vector only. Lane W; No DNA PCR control. Lane 1-12; 12 
random colonies selected after enrichment by biopanning with affinity purified anti-TpN47 antibodies. Lane 
13-24; 12 random colonies selected after enrichment by biopanning with affinity purified anti-TpN44.5 
antibodies.
W  M  1 2 3 4  5 6 C  7 8 9 10 11 12 M  13 1 4 1 5  16 17  18 C  19 20  21 2 2  23  2 4  M
Figure 63. fUSE2 insert sizes after enrichment with anti-TpN 17 or anti-TpN 15 antibodies.
PCR amplified inserts of randomly selected fUSE2 colonies separated on a 2.5% agarose gel. Lane M; 1kb 
DNA ladder (bp are indicated). Lane C; fUSE2 vector only. Lane W; No DNA PCR control. Lane 1-12; 12 
random colonies selected after enrichment by biopanning with affinity purified anti-TpN17 antibodies. Lane 
13-24; 12 random colonies selected after enrichment by biopanning with affinity purified anti-TpN15 
antibodies.
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Fig 63 shows the results of similar amplifications of the insert in clones selected from libraries 
enriched against anti-TpN17 and anti-TpN15 solid phases. Nine out of the twelve phage picked 
from the library biopanned against anti-TpN17 have a 123 bp insert. The remaining three clones 
isolated, 1, 4, and 6, contain no insert. Eleven of the twelve phage isolated from the library 
biopanned with anti-TpN15 have no insert. Only clone 21 contains an insert which seems to be 78 
bp long.
M13 immunoassay
Samples of each of the recombinant phage particles were tested in an M13 immunoassay. All 
phage samples produced a strong response with the anti-M13 antibody coated wells and gave low 
absorbances with the negative control wells coated with normal human IgG. All assays gave the 
expected results with the VCSM13 helper phage and diluent controls. Fig 64 shows the 
absorbances of the phage selected after enrichment against affinity purified anti-TpN47. Eleven of 
the twelve clones gave a response with the affinity purified antibody coated wells, only clone 8 
shows a response of a similar level to that seen with the negative control wells. Fig 65 shows the 
results for the clones selected after biopanning with affinity purified anti-TpN44.5 antibodies. All 
phage samples show a good response with the affinity purified antibody coated wells, although 
there is some variation in the level of the responses. Fig 66 shows the results of the clones selected 
after enrichment against the affinity purified anti-TpN17. Clones 1, 4, and 6 give low absorbances 
similar to those of the negative controls, while the other nine clones produce a good response with 
the affinity purified antibody coated wells. Fig 67 shows the results of the clones selected after 
biopanning against affinity purified anti-TpN15. All 12 clones produce responses similar to those of 
the negative control wells, although there is a strong response with the anti-M13 coated wells.
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Figure 64. M13 immunoassay results of anti-TpN47 enriched fUSE2 clones.
Absorbances of 12 randomly selected fUSE2 clones from the third round of biopanning against an affinity 
purified anti-TpN47 antibody coated solid phase.
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Figure 65. M13 immunoassay results of anti-TpN44.5 enriched fUSE2 clones.
Absorbances of 12 randomly selected fUSE2 clones from the third round of biopanning against an affinity 
purified anti-TpN44.5 antibody coated solid phase.
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Figure 66. M13 immunoassay results of anti-TpN17 enriched fUSE2 clones.
Absorbances of 12 randomly selected fUSE2 clones from the third round of biopanning against an affinity 
purified anti-TpN17 antibody coated solid phase.
¥ / Anti-M13
H u Z r7 —
O Ü [  
S a m p le  ID
Figure 67. M13 immunoassay results of anti-TpN15 enriched fUSE2 clones.
Absorbances of 12 randomly selected fUSE2 clones from the third round of biopanning against an affinity 
purified anti-TpN15 antibody coated solid phase.
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DNA sequencing
Several clones from each enriched library were sequenced to identify the inserted DNA sequences. 
The clones selected from the fUSE2 library biopanned against anti-TpN47 showed a single size of 
insert, so clones 4 and 7 were sequenced and found to contain the same 141 bp insert. This insert 
was found to have sequence homology to the tpnA7 gene of T.pallidum between base pairs 748 
and 888, which corresponds to residues 250 and 296 of the amino acid sequence. Figure 68 shows 
the alignment of the DNA sequence with the database sequence, and also shows the deduced 
amino acid sequences for comparison. The database sequence is shown in blue and the insert 
sequence in black, with non homologous residues highlighted in red.
Figure 68. DNA sequence of clone 4 from the anti-TpN47 enriched fUSE2 library.
DNA and deduced amino acid sequences of the insert of clone 4 biopanned from the fUSE2 library using 
affinity purified anti-TpN47 antibodies. Database sequence is shown in blue and the insert sequence in 
black, with non homologous residues in red. The amino acid sequence is deduced from the DNA sequence.
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The clones selected from the fUSE2 library biopanned against anti-TpN44.5 showed two sizes of 
insert, so two of each were sequenced for comparison. Clones 17 and 23 were sequenced and 
found to contain the same 87 bp insert, while clones 18 and 24 were found to share the same 153 
bp insert. Sequence comparisons using GCG showed the 87 bp insert to have homology with a 
portion of the tpn44.5 gene between base pairs 901 and 987. The larger insert was shown to have 
homology with the sequence between base pairs 430 and 582. Fig 68 shows the alignment of the
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DNA sequences of the inserts with the database sequences. It also shows the deduced amino acid 
sequences of the inserts for comparison. The database sequence is shown in blue and the insert 
sequence in black, with non homologous residues highlighted in red.
Figure 69. DNA sequence of clone 17 and 24 from the anti-TpN44.5 enriched fUSE2 library.
DNA and deduced amino acid sequences of the inserts of clones 17 and 24 biopanned from the fUSE2 
library using affinity purified anti-TpN44.5 antibodies. Database sequence is shown in blue and the insert 
sequence in black, with non homologous residues in red. The amino acid sequence is deduced from the 
DNA sequence.
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The clones selected from the fUSE2 library biopanned against anti-TpN17 all showed the same size 
insert, so two clones were sequenced. Clones 2 and 10 were found to contain the same 123 bp 
insert. This insert was found to have homology with the sequence of the tpnM  gene of T.pallidum 
between base pairs 298 and 420. Figure 70 shows the DNA and deduced amino acid sequences of
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the insert aligned with the database sequences for comparison. The database sequence is shown 
in blue and the insert sequence in black, with non homologous residues highlighted in red.
Figure 70. DNA sequence of clone 10 from the anti-T pN 17 enriched fUSE2 library.
DNA and deduced amino acid sequences of the insert of clone 10 biopanned from the fUSE2 library using 
affinity purified anti-TpN17 antibodies. Database sequence is shown in blue and the insert sequence in 
black, with non homologous residues in red. The amino acid sequence is deduced from the DNA sequence.
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The clones selected from the fUSE2 library biopanned against affinity purified anti-TpN15 were 
previously shown to contain no insert, apart from clone 21 which did contain an inserted sequence. 
This clone was sequenced (data not shown) and confirmed to contain a 78 bp insert, but 
comparisons using GCG failed to find any homology with the sequence of the tpn'\5 gene at either 
the nucleotide or amino acid level.
Discussion
Synthetic peptide epitope mapping is a powerful tool for identifying simple linear epitopes, but is of 
limited use in defining conformational epitopes that require a degree of secondary structure for their 
expression. Phage display epitope mapping is a technique that can theoretically overcome this 
limitation by expressing larger protein fragments or even whole proteins on the surface of a 
bacteriophage.
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The objective was to express fragments of the lipoproteins on the surface of bacteriophage M13 
and enrich for binding motifs by biopanning with various anti-treponemal antibodies. The library 
must contain a reasonable representation of all the possible gene fragments for it to give an 
accurate picture of the reactive sequences present in the protein under study. The number of 
fragments of a certain size a gene can be split into can be calculated using the 
formula: (gene length-fragment size)+1. The total number of fragments possible is the sum of all 
those fragment lengths that are multiples of three, up to the length of the gene. Fragment lengths 
that are not multiples of three will cause a frame shift in the gene III sequence and will not be 
propagated. Not all fragments will represent the native sequence due to frame shifts allowing 
sequences in the two other reading frames to be expressed. For the purpose of the SurfZAP library 
constructions, TpN47 is 1302 base pairs long and can be split into 282317 unique clonable 
fragments. Similarly, TpN44.5, TpN17 and TpN15 can be split into 178365, 36426 and 29751 
unique clonable fragments, respectively. It must be noted that the fragments can be cloned in both 
orientations, therefore doubling the number of possible fragments. The number of independent 
recombinants required in the library must be greater than these values, because sampling variation 
will lead to the inclusion of some sequences several times, and the exclusion of other sequences in 
a library of this size. Clarke and Carbon (1976) derived a formula that relates the probability (P) of 
including any DNA sequence in a random library of (N) independent recombinants, where n is the 
number of possible DNA sequences:
Therefore, for the SZ47 random gene fragment library, to achieve a 95% probability (P = 0.95) of 
including any particular fragment, the primary library must contain 1.7 x 106 independent 
recombinants:
N = l 4 z l l
ln ( l -0.95)
282317x2
= 1.7x10*
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If the same calculation is performed for the other libraries, the SZ44 would require 1.1x106 
independent recombinants, the SZ17 library would require 2.2x105, and the SZ15 library would 
require 1.8x105 independent recombinants to have a 95% probability of containing any given 
sequence. Comparing these values to the actual numbers of unique phage generated in the primary 
libraries shows the SZ47 and SZ44 libraries to contain approximately half the required numbers of 
unique phage, while the SZ17 and SZ15 libraries contain more than enough phage to represent all 
possible fragments. The fUSE2 library was constructed to contain a restricted range of fragment 
sizes, from 51 to 351 base pairs long, but cover all four major lipoprotein genes. The reasoning 
described above applies equally well to this library, so a similar calculation shows there to be 
245228 unique fragments which can be cloned in two orientations. This would require 1.5x106 
independent recombinants to have a 95% probability of representing all possible fragments within 
the library. The fUSE2 primary library contained around 1x106 unique clones and so is fairly close to 
the size required to contain all possible fragments. The diversity of the libraries was also shown by 
the range of insert sizes seen by PCR amplification. However, not all the clones will contain useful 
native sequences due to frame shifts and compound ligations. The real diversity of the libraries will 
be much lower than the theoretical value, but even small libraries have been shown to produce 
meaningful results (Wang et a i, 1995).
The SurfZAP libraries were biopanned against purified IgG from a pool of serum from patients with 
high titre syphilis antibodies. The failure to achieve enrichment of the libraries and detect any 
binding clones by M13 immunoassay was probably due to the low specific activity of the immune 
human antibodies used for biopanning. In immune human sera the proportion of the total IgG that is 
disease specific is extremely small compared to even hyperimmunised animal serum. Most of the 
IgG is non-specific and results in the biopanning solid phase having a relatively poor binding 
capacity and a tendency for non-specific interactions. A large number of the binding phage will be 
bound non-specifically, resulting in poor enrichment of specific binding phage over background 
binding. Affinity purified antibodies were used to increase the specific activity of the solid phase 
used to biopan the phage display libraries and improve the enrichment of specific binders over 
background binding.
Even after enrichment with their appropriate affinity purified antibody, the SurfZAP libraries, SZ47, 
SZ44 and SZ17, failed to show any binding clones and the inserts all proved to be unrelated to the
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lipoproteins. Only the SurfZAP library, SZ15, produced a clone that was reactive in the M13 
immunoassay and contained a DNA sequence homologous to a region of the tpn'IS gene between 
bases 121 and 375. The fUSE2 library, after biopanning with affinity purified antibodies specific for 
each of the lipoproteins produced binding phage homologous with regions of TpN47, TpN44.5 and 
TpN17. No binding phage were detected after enrichment with affinity purified anti-TpN15 antibody. 
The DNA inserts were shown to be homologous with regions between bases 748-888 of TpN47, 
bases 298-420 of TpN17. Two sequences were isolated from TpN44.5 homologous with the 
sequence between bases 430-582, and bases 901-987. Comparison of the sequences isolated 
from the phage display libraries with the reactive regions identified in the synthetic peptide epitope 
mapping studies shows a degree of concordance. The 255 bp SZ15 sequence covers a significant 
proportion of the TpN15 lipoprotein. Therefore, it is not surprising that it binds well to the solid 
phase as it contains most of the protein sequence and all but one of the reactive regions identified 
in the synthetic peptide epitope mapping studies. The sequences isolated from the fUSE2 library 
were shorter than the SZ15 insert, relative to the overall size of the parent protein. The enriched 
TpN47 sequence covered the region D, an intervening sequence plus the start of region E from the 
synthetic peptide studies. The TpN17 sequence that was isolated covered region A plus a 
contiguous sequence of amino acids that were non reactive in the synthetic peptide studies. The 
first of the two TpN44.5 sequences covered region A identified using synthetic peptides, and the 
second sequence corresponded to a region close to the C-terminus of the protein identified by only 
a few serum specimens and the affinity purified antibody.
Generally, the phage display technique isolated sequences that are antigenic, which is shown by 
their specific reactivity in the M13 immunoassay. They also broadly correspond to some of the 
sequences previously identified in the synthetic peptide epitope mapping studies. However, it is of 
note that the regions identified are all relatively long sequences compared to the reactive regions 
identified using the synthetic peptides. In phage display systems the inserted sequence is 
expressed as a gene III fusion and so has a tendency to interfere with cell attachment and hence 
propagation. Therefore, in the absence of any selection pressure on the phage population there 
would be a tendency for native phage or phage with small inserts to be preferentially propagated 
because their inserts have less effect on the function of the gene III protein. The preferential 
propagation of large gene III fusions in the presence of antibody means they must have significant
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selection advantages over other phenotypes. Single epitopes could be expressed by very small 
gene III fusions. The absence of this type of fusion in the enriched libraries suggests that the most 
critical part of the antibody response is not described by simple linear epitopes. The propagation of 
large fusions suggests that either multiple epitopes or conformational epitopes form a significant 
portion of the antibody binding activity.
The biopanning experiments with the fUSE2 library show that the affinity purified antibodies are 
perfectly capable of enriching for binding motifs, so the failure to identify sequences from the SZ47, 
SZ44 and SZ17 libraries is surprising. The most likely reason is that the SurfZAP libraries were not 
as complex as the characterisation and phage titre data suggested. The failure to produce binding 
phage from three of the libraries, and the fourth producing a virtually full length clone, suggests that 
the library construction may not have been completely successful. The construction method, using 
a nested PCR technique and random primers, is rather complex and likely to produce a high 
proportion of non-specific phage containing irrelevant sequences. The size of the primary libraries 
and diversity of insert size may not represent different fragments of the lipoprotein genes, but 
nonsense sequences from primer-primer annealing. The libraries may be more like random peptide 
libraries rather than random gene fragment libraries. The fUSE2 library was constructed in a much 
simpler manner by fragmenting and cloning the genes themselves. Any recombinant phage 
produced should contain an insert at least derived from the target DNA. Although there is still scope 
to produce non-specific phage due to frame shifts and multiple inserts, this method should be more 
reliable. When the fUSE2 library was biopanned with several different specificity antibodies it 
produced sequences related to the source of the antibody, suggesting the library initially contained 
multiple phage phenotypes. However, to produce a single binding clone in each case was an 
unexpected result. It was initially thought that an antibody would select many different sequences, 
some related and sharing common sequences, across the protein.
Many researchers have investigated the factors affecting the efficiency of the phage display system. 
The library enrichment process has been examined using model systems to calculate the relative 
enrichment of various clones over non-binders (McCafferty et al., 1990; Brietling et al., 1991; Bass 
et al., 1990; Barbas et al., 1991). The general findings are that the number of phage binding and the 
enrichment of specific clones over background increases with affinity across the range. The 
enrichment of binding clones over non-binders can be as much as 40,000 fold or greater in a single
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round of biopanning. Whereas the enrichment of high affinity over low affinity clones is more 
modest, a 4-fold increase in a 10 nM clone over a 320 nM clone. However, after three rounds of 
biopanning even the higher affinity clone would show a 64-fold increase over the low affinity clone. 
So, selecting 10-12 random clones from the enriched library is likely to yield repeated isolates of the 
same phage type.
The expectation that enrichment of the random gene fragment libraries would result in a range of 
different clones being selected, rather than just one, is probably unlikely. An alternative explanation 
might be that the libraries do not have the necessary complexity to express the full range of 
possible motifs. Only extensive sequencing of the primary library would answer this question. 
Alternatively, it could be a result of the biopanning protocol, which used a short binding time and a 
stringent wash protocol to remove unbound phage. This would have the tendency to select for high 
affinity clones by limiting the time available for binding, therefore favouring clones with high 
association rates. The original objective was to identify all the reactive regions within the protein and 
gain some idea of their relative potency by their representation in the enriched library. To 
accomplish this the biopanning protocol would have to allow a range of binding clones of different 
affinities to be selected. If the binding time were lengthened to allow the reaction to come closer to 
equilibrium and the wash protocol made less stringent, perhaps the range of specificities recovered 
would be increased. Most biopanning protocols are designed to facilitate the recovery of rare binder 
from the library, whereas in this study most of the clones should show some reactivity to the solid 
phase. A different strategy would be required to maximise the number of distinct binding clones 
recovered. Examination of the library after the first round of binding would probably provide a better 
idea of the range of binding clones present, rather than after several rounds of biopanning when the 
library may just represent the best binder. Perhaps phage display is unsuitable for providing this 
sort of qualitative information because the selection pressures produced by a few rounds of 
biopanning are so high that it will only really ever find the best binder in the library.
Epitope mapping using this approach requires a good understanding of the true complexity of the 
library under study. The diversity can only be assessed by extensive sequencing of the primary 
library to determine the range of inserts present. Gene targeted random epitope libraries are only of 
use for a single experiment which makes extensive sequencing of the library impractical. However, 
random peptide phage display libraries can be used for selection against many different targets and
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so sequencing a selection of the primary library becomes a better investment of time. Also, with 
each subsequent experiment using the same primary library and the identification of new binding 
motifs, so confidence in the complexity of the library grows. This suggests that random peptide 
libraries might be a more appropriate approach from the point of confidence in diversity, but they do 
have other limitations. The best primary libraries are restricted to around 1010 individual clones, 
which limits them to only confidently displaying all combinations of seven amino acids. Libraries of 
longer sequences will be incomplete. This means that random peptide libraries are only suitable for 
identifying simple linear epitopes. They will fail in situations where significant antibody responses 
are directed towards conformational epitopes.
Without a detailed knowledge of the diversity of the libraries constructed here it is difficult to draw 
any firm conclusions as to the significance of the binding motifs identified. If the libraries genuinely 
possess a good representation of all possible binding clones, then it could be argued that the 
binding clones recovered represent immunodominant regions within the proteins. However, if the 
libraries lack diversity then these binding clones simply represent the most reactive regions 
represented in the libraries. Which ever interpretation is true, it is interesting to note that the binding 
clones all represent relatively large segments of the protein sequence. This suggests that simple 
linear epitopes are not the most significant antigenic determinants, and conformational epitopes 
probably represent the most significant binding motifs present. Since these long sequences almost 
certainly contain multiple epitopes, including some linear epitopes, this might enhance retention by 
the solid-phase by allowing multipoint attachment of the protein. So, the long sequences might be 
those with the highest affinity for the solid phase through a combination of interactions.
Phage display is a powerful means of selecting rare specific binders in a library from non binders or 
low affinity binding clones. Therefore, it has been very successful in determining the target 
sequence of monoclonal antibodies and in isolating single chain antibodies of a desired specificity. 
It has efficiently identified the highest affinity clones within the libraries specific for the anti- 
T.pallidum antisera. It is perhaps less well suited to mapping the spectrum of antibody epitopes 
within a protein.
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Summary
The work described here provides useful information in two areas: the effectiveness and application 
of the phage display technique itself, and the sequences of the antigenic determinants within the 
lipoproteins of T.pallidum. The construction of the libraries is central to the success of the 
technique. The method used to construct the SurfZAP libraries was found to be too complicated to 
give confidence in the relevancy of library contents. The simpler technique used to construct the 
fUSE2 library produced greater confidence that the library contained relevant sequences. Phage 
display proved an effective technique for identifying high affinity binding motifs within the libraries, 
but it does not give any information on the range of epitopes present within the proteins. However, it 
provides a more complete picture than synthetic peptide epitope mapping as it is not restricted to 
linear epitopes representing only 10% of the response. The technique identified several long protein 
sequences that represented high affinity binding motifs, preferentially retained by the solid phase. It 
is difficult to deduce the exact nature of the epitopes responsible for their retention by the solid 
phase, but several possibilities exist. They might contain significant conformational epitopes, or a 
mixture of epitope types which produce high affinity binding through multipoint attachment to the 
solid phase. Clearly, the sequences identified have potential as antigens for use in diagnostic tests, 
but require further investigation.
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Conclusions
The antigens most universally reactive over the range of disease stages tested were, TpN47, 
TpN44.5, TpN17, and TpN15, which confirmed the literature and provided a sound platform for the 
subsequent work. The most significant conclusion drawn, and one not completely apparent from the 
literature, was the importance of TpN47 during early infections, being the only relevant specificity 
present in some patient's specimens. Additionally, there are no obvious patterns of antibody 
responses that are indicative of particular disease stages. These four antigens became the principal 
candidates for the production of recombinant proteins.
The production of recombinant proteins proved more problematic than expected in some cases. 
The full lipoprotein sequences of TpN44.5, TpN17, and TpN24-28, were well tolerated by the E.coli 
cells and expressed in moderate levels. Their expression produced different molecular weight 
forms of each recombinant protein which suggested putative processing, probably by lipid- 
modification, of these recombinant proteins was occurring. This processing was eliminated by 
deletion of the lipid-modification signal sequence. The full lipoprotein sequences of TpN15 and 
TpN47 proved difficult to clone, possibly due to toxicity of the recombinant proteins. They were 
finally successfully cloned as the mature protein sequences, minus their lipid-modification 
sequences, fused to vector-coded thioredoxin. These constructs were well tolerated and produced 
high levels of expression. The recombinant proteins were purified and all seemed to be antigenic as 
judged by their reactions with anW-T.pallidum antisera.
The antigenicity of the recombinant proteins was evaluated to identify any differences between their 
antigenicity and that of the native antigens tested earlier. TpN24-28, a minor antigen that appears 
as a diffuse band on SDS-PAGE, was found to be disease specific, but does not react with 
sufficient numbers of patient specimens to be a significant diagnostic antigen The antibody 
responses to the other recombinant proteins, TpN47, TpN44.5, TpN17, and TpN15, showed an 
overall pattern similar to those seen with the comparable native antigens, suggesting that their 
antigenicity was similar to the native antigens. The frequency and strength of the responses 
suggested that all four recombinant proteins were good candidates, individually or in combination, 
for the development of an enzyme immunoassay for the serodiagnosis of syphilis. However, none 
of these antigens were universally reactive with all serologically confirmed cases of syphilis, so an
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enzyme immunoassay for the detection of all stages of syphilis infection would probably require 
more than one antigen.
During the development of an enzyme immunoassay it was found that assays using single 
recombinant antigens lacked sensitivity, and the nature of the spread of the results suggested that 
they each missed key antibody responses that were detected by antigen from whole organisms. A 
combination of the four recombinant proteins produced an enzyme immunoassay with superior 
performance to that achieved by each of the recombinant antigens used individually. This was 
manifested as a greater difference between the absorbances of the positive and negative 
specimens, and a tighter correlation with the results of the native antigen based assay. It also 
showed better performance than the assay based on antigen derived from whole organisms that 
was used for companson. Therefore, effective serodiagnosis was shown to require the use of a 
combination of four antigens to provide adequate sensitivity. The recombinant antigen-based 
enzyme immunoassay developed here has the potential to provide an alternative to assays based 
on antigen derived from in vivo cultured of whole organisms.
The sequences within the antigens responsible for their antigenicity was investigated using 
overlapping synthetic peptides complementary to the native amino acid sequence. The antibody 
responses were not found to be directed towards clearly defined sequences of linear epitopes within 
a background of low responses. A complicated picture of multiple responses across the entire 
sequence of the proteins was seen, however some relatively long consensus antigenic sequences 
were identified. This picture suggested that a high proportion of the diagnostically significant 
antibody responses were probably directed to discontinuous epitopes. Therefore, it is was thought 
unlikely that short synthetic peptides would be reactive enough to bind sufficient antibody to provide 
adequate serodiagnosis.
The antigenic sequences within the proteins were further investigated using phage display to 
examine a much wider variety of potential antibody binding motifs. Phage display proved an 
effective technique for identifying high affinity binding motifs, and recognised several long protein 
sequences within each antigen. The preferential selection of long protein sequences strongly 
suggests that simple linear epitopes do not represent the most significant binding motifs. A 
oignificont proportion of the antibody reoponoc io probably directed towardo discontinuous opitopos. 
A conclusion that is supported by the evidence drawn from the earlier synthetic peptide work. The
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binding observed might not be due to conformational epitopes, but could be a result of a mixture of 
epitope types which produce high affinity binding through multipoint attachment to the solid phase.
In conclusion, the antigonio activity of these proteins is net confined to discrete areas, but is spread 
across the whole protein. It is quite probable that a significant proportion of the antigenicity resides 
in conformational epitopes, which requires longer protein sequences for expression. Therefore, 
synthetic peptide antigens would be unsuitable as antigens for serodiagnosis. A combination of 
recombinant proteins remains the best means of providing the antigenicity required for adequate 
serodiagnosis of syphilis at this point
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Future work
The recombinant antigen-based enzyme immunoassay shows potential, but the preliminary 
evaluations performed here only confirm the feasibility of the design; more comprehensive testing 
would be required to fully validate the design. The solid phase was optimised using a single pool of 
syphilitic serum, so the coating concentrations should be further refined to ensure the best 
compromise of sensitivity at all stages of the disease. Testing with a wider variety of specimens 
would better evaluate the sensitivity and specificity, particularly potentially cross reactive specimens, 
and difficult specimens such as those from patients co-infected with HIV. This testing should also 
consider the concerns over the inclusion of TpN44.5 in the antigen mixture. It should be determined 
if the inclusion of TpN44.5 does cause false positive reactions, or if its omission would be 
detrimental to assay performance. Once the assay design was finalised, the remaining tasks would 
be to determine a cut-off value, and ensure the reproducibility and robustness of the assay.
The synthetic peptide and phage display epitope mapping studies identified antigenic sequences 
that should be investigated further to determine if they are suitable as diagnostic antigens, either 
singly or in combination. This would be best pursued by constructing a range of artificial 
recombinant proteins from the sequences and using them to test the diagnostic efficacy of the 
polypeptides produced. Further testing of the SurfZAP libraries is unlikely to yield much extra 
information because they are too incomplete, but there would be benefits from biopanning the 
fUSE2 library against other syphilitic antibody preparations. Comparison of any sequences selected 
with those previously isolated might reveal more information on the nature of the antigenicity of 
these antigens. It would also improve confidence in the complexity of the library and the validity of 
any conclusions drawn.
A simple synthetic antigen would offer many potential benefits. It would significantly reduce the 
costs of syphilis testing compared to current treponemal tests using native antigen, and also allow 
simple assay designs, more suitable for use in developing areas, to be adopted. This may promote 
the introduction of screening and treatment programmes in the poorer areas of the world where 
syphilis is still a significant problem, closely associated with the spread of HIV.
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